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Abstract 
 
Introduction: The circulating renin-angiotensin system (RAS) was originally described as a 
key  endocrine  regulator  of  intravascular  homeostasis;  however,  the  existence  of  a  local 
(tissue) RAS has become increasingly reported in a variety of tissues including liver. RAS 
components  have  now  also  been  detected  in  rat  heart,  brain  and  smooth  muscle  cell 
mitochondria  as  well  as  within  intramitochondrial  dense  bodies  of  rat  adrenal  tissue. 
Further, reduced RAS levels have been associated with improved endurance performance 
and  fatigue  resistance  in  human  skeletal  muscle,  suggesting  that  low  RAS  activity  is 
associated  with  metabolic  efficiency,  potentially  via  RAS  action  upon,  or  within, 
mitochondria.  However,  such  investigation  has  often  relied  heavily  upon  qualitative 
techniques  (e.g.  Western  blotting,  immunofluorescence  and  electron  microscopy),  which 
contain  inherent  limitations  in  that  they  completely  rely  upon  the  limited  specificity  of 
antibodies to demonstrate the existence of intra-mitochondrial RAS components. 
Methods: The presence of RAS components within the mitochondria of rat hepatic tissue 
and liver cell-lines was investigated via sub-fractionation of rat liver tissue and cell-lines, 
followed by Western blotting, as well as via immunofluorescence and confocal microscopy, 
and electron microscopy. The mitochondrial effects of stimulating or antagonizing hepatic 
RAS  were  assessed  via  functional  fluorescence  microscopy  (for  assessment  of  NADH, 
calcium and mitochondrial membrane potential) and measurement of oxygen consumption 
within live cells of a liver cell-line. 
Results:  Western  blotting,  immunofluorescence  and  electron  microscopy  suggested  the 
presence of RAS components within mitochondria; however, there was a lack of results 
consistency between techniques and the staining patterns were largely non-specific. Western 
blotting  further  demonstrated  the  presence  of  a  prominent  55  kDa  band,  when 
immunostaining  a  mitochondrial  fraction  with  (angiotensin-converting  enzyme)  ACE  C-
terminal antibody (usual size 180 kDa). This was further explored via isolation of the 55 
kDa molecule and mass spectrometry to yield results consistent with non-specific staining 
only.  Addition  of  RAS  agonists  or  antagonists  to  live  liver  cell-lines  demonstrated  no 
consistent results, except at supra-physiological levels, where RAS antagonists improved 
oxygen consumption.  
Conclusions: Such data suggest that the previous descriptions of RAS components within Hepatic Mitochondrial Renin-Angiotensin Systems 
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mitochondria are likely to be secondary to methodological flaws, particularly the reliance 
upon single antibodies, which have subsequently been shown to have poor specificity. Thus, 
the effect of ang II on liver mitochondria is unlikely to be direct and any such action is 
likely to occur via one of several intracellular pathways, regulation of gene expression or 
mitochondrial biogenesis.  
   Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      8	 ﾠ
Contents 
 
Introduction                      10 
I1. Renin-Angiotensin Systems ........................................................................................................................... 11 
I2. A Metabolic Role for RAS ............................................................................................................................. 27 
I3. RAS & Mitochondria ..................................................................................................................................... 30 
I4. Summary & Rationale ................................................................................................................................... 54 
	 ﾠ
	 ﾠ
Aims & Study Plan                    56 
 
 
Methods                      60 
M1. Materials ....................................................................................................................................................... 61 
M2. Cell-Lines & Tissues .................................................................................................................................... 65 
M3. Cellular Sub-Fractionation & Mitochondrial Isolation............................................................................ 68 
M4. Western Blotting  ........................................................................................................................................... 73 
M5. Immunofluorescence .................................................................................................................................... 76 
M6. Functional Fluorescence Microscopy ......................................................................................................... 79 
M7. Immunogold Labeling & Electron Microscopy  ......................................................................................... 81 
M8. Immunoprecipitation ................................................................................................................................... 83 
M9. Mass Spectrometry  ....................................................................................................................................... 85 
M10. Oxygen Consumption ................................................................................................................................ 90 
	 ﾠ
	 ﾠ
Results 1: Presence of RAS Components In Hepatic Mitochondria      91 
R1.1 Introduction ................................................................................................................................................. 93 
R1.2 Methods ........................................................................................................................................................ 94 
R1.3 Results .......................................................................................................................................................... 96 
R1.6 Discussion  ................................................................................................................................................... 122 
	 ﾠ
	 ﾠ
	 ﾠ
	 ﾠHepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      9	 ﾠ
Results 2: Is There A Mitochondrial Specific Form Of ACE?               124 
R2.1 Introduction ............................................................................................................................................... 127 
R2.2 Methods ...................................................................................................................................................... 129 
R2.3 Results ........................................................................................................................................................ 130 
R2.5 Discussion  ................................................................................................................................................... 134 
	 ﾠ
	 ﾠ
Results 3: Functional analysis Of A Hepatic Mitochondrial RAS             135 
R3.1 Introduction ............................................................................................................................................... 138 
R3.2 Methods ...................................................................................................................................................... 140 
R3.3 Results ........................................................................................................................................................ 144 
R3.4 Discussion  ................................................................................................................................................... 160 
	 ﾠ
	 ﾠ
Discussion                             164 
D1. Conclusions .................................................................................................................................................. 165 
D2. Hepatocellular RAS .................................................................................................................................... 170 
	 ﾠ
	 ﾠ
References                             172 
 
 
 
Appendices                             212 
  
 
 
 
 
 Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      10	 ﾠ
 
 
INTRODUCTION 
 
   Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      11	 ﾠ
I1. Renin-Angiotensin Systems 
I1. a. Circulating Renin-Angiotensin Systems 
The  circulating  (endocrine  or  systemic)  renin-angiotensin  system  (RAS)  was  originally 
described  as  a  key  regulator  of  intravascular  homeostasis,  controlling  extracellular  fluid 
volume, blood pressure and absorption of electrolytes (Peach, 1977, Reid et al., 1978) (see 
Figure I1). In response to decreased afferent arteriolar pressure, decreased filtered sodium 
load  in  the  nephron  ultra-filtrate  (from  low  plasma  sodium  concentrations  or  decreased 
glomerular  filtration)  or  sympathetic  nervous  stimulation,  the  renal  juxtaglomerular 
apparatus releases renin (Hackenthal et al., 1990). This aspartyl protease cleaves a leucine-
leucine peptide bond in the hepatically-derived α2 globulin angiotensinogen to yield the 
non-pressor  decapaptide  angiotensin  I  (ang  I)  (Menard,  1993).  Angiotensin-converting-
enzyme  (ACE)  is  a  peptidyl  dipeptidase  which  hydrolyses  ang  I  to  yield  the  pressor 
octapeptide  angiotensin  II  (ang  II)  (Caldwell  et  al.,  1976),  whose  effects  are  mediated 
through 2 specific human receptors (AT1R and AT2R) (Timmermans and Smith, 1994).  The 
endocrine  roles  of  the  AT2  receptor  are  less  well  defined  (de  Gasparo  et  al.,  2000, 
Matsusaka and Ichikawa, 1997) than that of the AT1R which, stimulated by ang II, mediates 
a hypertensive response through primary vasoconstriction and the release of aldosterone, the 
latter  promoting  sodium  and  water  resorption  from  the  distal  convoluted  tubule  and 
collecting ducts (Matsusaka and Ichikawa, 1997). ACE is also a potent kininase, reducing 
the activity of bradykinin at its BK1 and BK2 receptors, capable of stimulating a variety of 
inflammatory and vascular responses, and ACE may also have similar regulatory actions 
upon other RAS components (Leeb-Lundberg et al., 2005, Campbell et al., 1994, Brown et 
al.,  1998,  Murphey  et  al.,  2000,  Margolius,  1996).  Increasing  circulating  ACE  activity 
therefore drives hypertensive responses (increased AT1R receptor activation) and diminishes 
hypotensive responses (reduced vasodilation via BK2 receptor activation). In these ways, 
circulating RAS plays a crucial role in the regulation of human blood pressure and salt and 
water balance (Kem and Brown, 1990). 
 Hepatic Mitochondrial Renin-Angiotensin Systems 
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Figure  I1.  The  traditional  concept  of  a  circulating,  endocrine  renin-angiotensin  system, 
leading  to  hypertensive  responses  via  angiotensin  II  action  at  the  AT1R  (BP-  Blood 
pressure; H20- Water; ACE- Angiotensin converting enzyme; Ang- Angiotensin). 
 
 
I1. b. Local Renin Angiotensin Systems: The RAS Concept Expanded 
In  the  mid  1980s,  imunohistochemical  techniques  demonstrated  that  proteins  of  the 
traditional RAS were present within cells and organs outside of that expected as part of its 
systemic, endocrine actions (Re, 1984). Such RAS presence has been termed ‘local RAS’ 
and have now been identified in tissues as diverse as the heart (Danser et al., 1995), kidney 
(Reams, 1992), vasculature (Paul et al., 2006), adipose tissue (Fowler et al., 2009), liver 
(Paizis et al., 2002), nervous tissue/brain (Reams, 1992), adrenals (van Kats et al., 2005), 
gonads/reproductive system (Leung and Sernia, 2003), the gastrointestinal system (Wong et 
al., 2007) and the pancreas (Lau et al., 2004, Paul et al., 2006). Local RAS play roles in 
signaling between different cell types (paracrine), cells of the same type (autocrine), or 
within a cell (intracrine role) (Rohrwasser et al., 1999). Such systems may be ‘complete’, 
where all RAS components are synthesised de novo, or ‘depleted’, being dependent for their Hepatic Mitochondrial Renin-Angiotensin Systems 
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function on the uptake of some critical RAS components from the circulation (Campbell and 
Habener, 1986, Deschepper et al., 1986, Dzau, 1989). Such tissue RAS play myriad roles, 
including  the  regulation  of  cell  growth,  differentiation,  apoptosis,  and  proliferation; 
metabolism and generation of reactive oxygen species and free radicals; tissue inflammation 
and fibrosis; local haemodynamics; and hormonal secretion (Leung and Ip, 2006, Ganong, 
1995, Leung et al., 1999, Speth et al., 1999, Regulska et al., Paul et al., 2006, Hitomi et al., 
2007, Touyz, 2005).  
 
Local  RAS  demonstrate  significantly  more  complexity  than  the  traditional,  circulating 
system,  and  include  an  alternative  RAS  pathway  (ACE2-Ang(1-7)-Mas  axis)  for  the 
cleavage of ang I (see Figure I2). ACE2, the principal processing enzyme of the alternative 
RAS pathway, is capable of cleaving the terminal leucine from ang I to generate ang II (1-9) 
(Donoghue et al., 2000), but it has 400-fold greater affinity for ang II itself (Vickers et al., 
2002), from which it cleaves the terminal phenylalanine residue to synthesise ang (1-7), an 
angiotensin  I  heptapeptide  (Tipnis  et  al.,  2000,  Turner  et  al.,  2002).  ACE2  has  been 
identified in diverse rodent tissues including lung, adipose tissue (Gembardt et al., 2005), 
liver (Paizis et al., 2002), brain (Xia and Lazartigues, 2008) and pancreas (Tikellis et al., 
2008),  with  confirmation  in  human  heart,  kidney,  testis  and  small  and  large  intestine 
(Donoghue et al., 2000, Tipnis et al., 2000), suggesting ubiquitous expression. Ang (1-7), 
the primary product of ACE2 action on ang II acts through the Mas receptor (Santos et al., 
2003) and therefore has separate effects to the vasoconstrictor, pro-inflammatory and pro-
oxidant effects mediated via ang II action on the AT1 receptor. Mas receptor activation, by 
contrast, produces vasodilation via activation of bradykinin and nitric oxide (possibly via 
the Akt pathway (Sampaio et al., 2007, Toblli et al., 2008), prostaglandin release (Almeida 
et  al.,  2000),  norepinephrine  inhibition  (Gironacci  et  al.,  2004)  and  attenuation  of 
inflammation  and  fibrosis  via  TGF  and  MIF  (macrophage  migration  inhibitory  factor) 
inhibition (Zhong et al., 2008, Grobe et al., 2007). ACE2 therefore negatively regulates the 
RAS  and  acts  as  an  endogenous  ACE  inhibitor  through  alterations  in  formation  of 
angiotensin II and angiotensin (1-7), thereby counter-balancing ACE action (see Figure I3). 
The alternative RAS pathway may act independently or in conjunction with ACE in the 
regulation  of  the  local  RAS,  and  may  therefore  be  important  in  novel  pathways  of 
angiotensin metabolism and multiple pathogenic processes. Hepatic Mitochondrial Renin-Angiotensin Systems 
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Within local RAS, a variety of ang I-processing enzymes exist in addition to ACE and 
ACE2,  including  chymase,  chymotrypsin,  tonin,  aminopeptidase  A,  B  and  N, 
prolylendopeptidase,  and  neutral  endopeptidase.  Their  actions  yield  a  range  of  other 
biologically-active  compounds.  However,  some  of  these  enzymes  will  only  become 
biologically active in pathological or abnormal conditions and the physiological relevance 
of such alternate ang-processing enzymes therefore requires further elucidation (Fyhrquist 
and Saijonmaa, 2008). Angiotensin II is degraded to ang III (heptapeptide angiotensin 2-8) 
by  vascular  and  erythrocyte  angiotensinases,  and  subsequently  to  hexapeptide  ang  IV 
(hexapeptide angiotensin 3-8), both of which have qualitatively similar circulatory effects to 
that of ang II, with ang III also acting via the AT1R and ang IV having its own specific 
functional receptor (Fyhrquist and Saijonmaa, 2008). 
 
Figure I2. Local renin angiotensin systems: an expanded concept involving an alternative 
RAS processing pathway, via action of ACE2 (Ang- Angiotensin; AT1R- Angiotensin II 
type  1  Receptor;  AT2R-  Angiotensin  II  type  2  Receptor;  MasR-  Mas  Receptor;  ACE- 
Angiotensin converting Enzyme; ACE2- Angiotensin Converting Enzyme 2). 
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Figure I3. The various roles of the classical (endocrine) and alternative (novel) local renin-
angiotensin systems are largely antagonistic (Ang- Angiotensin; AT1R- Angiotensin II type 
1  Receptor;  MasR-  Mas  Receptor;  ACE-  Angiotensin  converting  Enzyme;  ACE2- 
Angiotensin Converting Enzyme 2). 
 
 
I1. c. RAS Components 
 
I1. c. i. Renin 
Renin  is  a  highly-specific  endopeptidase,  secreted  by  granular  cells  of  the  renal 
juxtagomerular apparatus, whose primary endocrine function is to increase blood pressure 
and to this end renin hydrolyzes angiotensinogen to ang I. It is synthesized from renin 
precursor,  a  406-amino  acid  peptide,  which  undergoes  sequential  proteolytic  cleavage 
within the Golgi apparatus to an active, mature 340 amino acid (37 kDa) form (Imai et al., 
1983, Pratt et al., 1983). Prorenin is glycosylated to various degrees, with higher levels of 
glycosylation  affecting  its  cellular  secretion  and  internalisation,  via  the  mannose-6-
phosphate receptor (Kumar et al., 2007). As part of the local RAS, renin can be synthesized 
intracellularly or taken up from the circulation, or both (e.g. cardiac myocytes) (Kumar et 
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al., 2007) and internalisation of non-glycosylated prorenin, via as yet unidentified receptors, 
is  accompanied  by  similar  increases  in  ang  I  and  ang  II,  suggesting  intracellular  RAS 
synthesis (Kumar et al., 2007).	 ﾠ
 
During condensation and packaging of the renin granules, a dipeptide near the carboxyl 
terminus is excised, converting renin into a two chain molecule combined by a disulphide 
bridge, which has less enzymatic activity than the single chain form (Pratt et al., 1983). 
Minor differences in amino acid composition, via variations in cleavage positions during 
processing, mean that multiple isoelectric forms of prorenin, one- and two-chain renin have 
been observed, with both one- and two-chain renin being secreted; whereas, prorenin is 
usually not (Pratt et al., 1983). The renin gene comprises 12 kb of DNA and contains 8 
introns, producing multiple forms of mRNA to encode different renin isoforms (Hobart et 
al., 1984).	 ﾠ
 
I1. c. ii. ACE 
Angiotensin-converting enzyme (ACE) is a zinc-dependent dipeptidyl carboxypeptidase that 
belongs  to  the  M2  family  of  zinc  metallopeptidases  and  catalyses  the  hydrolysis  of 
dipeptides  from  the  carboxyl  terminus  of  a  wide  variety  of  oligopeptides.  The  most 
celebrated physiological substrate for ACE is angiotensin I, which is converted into the 
potent vasopressor angiotensin II by removal of the C-terminal His-Leu; and the vasodilator 
bradykinin,  which  is  inactivated  by  cleavage  of  the  penultimate  Pro-Phe  bond.  Other 
substrates of ACE include gonadotropin-releasing hormone (GnRH) or luteinising hormone-
releasing  hormone  (LH-RH);  substance  P;  b-neoendorphin1–9;  and  neurotensin,  but  the 
significance of these reactions in vivo remains uncertain. 
 
An  assessment  of  ACE’s  three-dimensional  structure  demonstrates  that  it  is  largely 
composed of alpha-helices, but also incorporates a zinc ion and two chloride ions. Thus, it 
bears little resemblance to carboxypeptidase A except in the presence of an active zinc-
binding motif. This similarity extends to the active site, which consists of a deep, narrow 
channel  that  divides  the  molecule  into  two  subdomains.  At  the  superior  aspect  of  the Hepatic Mitochondrial Renin-Angiotensin Systems 
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molecule is an amino-terminal, which allows only small peptide substrates (2530 amino 
acids) access to the active site cleft, thus accounting for the inability of ACE to hydrolyse 
large, folded substrates.  
 
ACE is expressed in two main forms derived from a single gene by alternative splicing. 
Both  forms  are  type-1  membrane  proteins  (i.e.  N-terminal  regions  are  located  extra-
cellularly)  but  differ  in  their  tissue  expression  and  structure.  The  larger  somatic  ACE 
(sACE;  195kDa)  is  a  ubiquitous,  membrane-bound  protein  with  two  metalloproteinase 
domains  (N-  and  C-terminal),  each  containing  a  canonical  zinc-binding  sequence  motif 
(HExxH;  His-Glu-x-x-His);  and  although  both  domains  have  protease  activity  (both  are 
blocked by ACE-inhibitors) and are capable of converting ang I to ang II, the C-terminal 
domain  is  more  important  for  blood  pressure  regulation.  The  smaller,  secreted,  testis-
specific form of ACE (tACE; 90kDa) is composed of 27 helices (20 alpha-helices and seven 
310-helices) and contains only the C-terminal metalloproteinase domain, together with the 
hydrophobic membrane-anchoring domain and a small N-terminal region that has multiple 
O-linked oligosaccharides; all of which packages into an ellipsoid shape with a central core 
channel (Sturrock et al., 2004). Both sACE and tACE are expressed on the cell surface, 
from where the biologically-active domains are released into the circulation by a cleavage-
secretion process regulated by a small region in the C-terminal domain; and both forms 
convert inactive ang I to active ang II, as well as inactivating bradykinin (Chattopadhyay et 
al., 2008, Pang et al., 2001). 
 
However, further, novel isoforms of ACE are also known to exist, with largely unknown 
functions and uncharacterized structures and synthetic pathways. Both 60 kDa and 130 kDa 
secretory isoforms exists, and an N-domain form also exists within urine in both 65 kDa and 
90 kDa isoforms (Fernandes et al., 2008, Ronchi et al., 2005, Ronchi et al., 2007, Camargo 
de Andrade et al., 2006). Further, although ACE exists primarily as a membrane-bound 
form, a soluble form is present in plasma, amniotic fluid and other bodily fluids and is 
derived  from  the  membrane-bound  form  by  a  post-translational  proteolytic 
cleavage/shedding mechanism (Kumar et al., 2007).  
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I1. c. iii. ACE2 
ACE2 (or ACE H) is an 805-amino acid protein initially isolated from a failing human heart 
ventricle and lymphoma cDNA libraries (Donoghue et al., 2000, Tipnis et al., 2000) and 
later confirmed as the receptor for the SARS coronavirus (Li et al., 2003), which shares 42% 
sequence  homology  with  ACE  (Donoghue  et  al.,  2000),  and  which  retains  its  catalytic 
domains (Donoghue et al., 2000, Tipnis et al., 2000).  However, unlike ACE, and unique 
among  mammalian  carboxypeptidases,  ACE2  contains  a  single  HEXXH  zinc-binding 
domain resulting in monocarboxypeptidase activity, although it does conserve other critical 
residues typical of ACE (Tipnis et al., 2000). ACE2 functions as a carboxypeptidase when 
acting upon ang I and II (Turner et al., 2002) and exists in both membrane-bound and 
soluble  (generated  by  proteolytic  cleavage  of  the  ectodomain  by  tumour  necrosis  factor 
convertase, ADAM17 (Lambert et al., 2005)) forms (Donoghue et al., 2000), but neither 
hydrolyses  or  is  inhibited  by  bradykinin,  and  is  not  sensitive  to  ACE-inhibitors  despite 
sharing ACE’s catalytic domain (Tipnis et al., 2000). 
 
I1. c. iv. Angiotensins 
Angiotensinogen (AGT) is a 452 amino acid α-2-globulin, of the serine protease inhibitor 
family (serpins), which is synthesised locally and then secreted extracellularly under the 
control  of  a  signal  sequence  and  the  presence  of  glycosylation  (Kumar  et  al.,  2007). 
Multiple  forms  of  angiotensinogen  with  varying  degrees  of  glycosylation  have  been 
identified, suggesting complex intracellular distribution mechanisms (Kumar et al., 2007). 
AGT exists within the circulation as a reduced, unbridged form and an oxidised sulphydryl-
bridged form (40:60), which preferentially interacts with renin (Zhou et al., 2010), cleaving 
the leu-val peptide bond and creating the decapeptide (des-Asp) ang I. AGT appears to have 
no independent function, existing solely as a precursor to biologically active ang II.  
 
Ang II is formed by ACE-mediated removal of two C-terminal residues from ang I and its 
action via the AT1R stimulates smooth muscle Gq proteins, activating vascular cell smooth 
muscle contraction by an IP3-dependent mechanism. Whilst circulating ang II has a half-life 
of approximately 30 seconds, its intracellular half-life may be as long as 15–30 minutes. 
Ang  II  can  be  further  processed  to  fragments  of  its  original  size,  including  ang  III 
(angiotensin heptapeptide 2-8) and ang IV (angiotensin hexapeptide 3-8), both of which Hepatic Mitochondrial Renin-Angiotensin Systems 
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have  significantly  less  pressor  activity  than  ang  II,  although  ang  III  has  100  %  of  the 
aldosterone-producing activity. 
 
Ang III acts on the AT1R to produce similar effects to ang II, including vasoconstriction and 
aldosterone  release,  and  is  generated  from  ang  II  predominantly  by  the  action  of 
aminopeptidase  A;  however,  it  is  metabolically  cleared  five  times  faster  than  ang  II 
(Fyhrquist and Saijonmaa, 2008). 
 
Biologically active ang IV is generated from ang III by aminopeptidase M (predominantly), 
its  receptor  (AT4R)  being  an  insulin-regulated  amino  peptidase  receptor  (IRAP)  found 
within a broad range of tissues, with particularly high expression in the brain (Kumar et al., 
2007,  Zhuo  et  al.,  1998).  The  AT4  receptor  was  originally  described  as  a  high-affinity 
binding  site  for  ang  IV,  although  the  peptide  LVV-hemorphin  7  has  now  also  been 
demonstrated to be a biologically active AT4R ligand (Chai et al., 2004). Agonist action of 
ang IV at the AT4R causes improvements in memory and cognition, increased renal cortical 
blood  flow  and  decreased  Na
+  transport  in  renal  proximal  tubules,  and  may  counteract 
AT1R-mediated  cardiovascular  events  such  as  injury  in  response  to  ischaemia  and 
reperfusion, cardiac cell apoptosis and cardiomyocyte hypertrophy (Yang et al., Chai et al., 
2004, Kerins et al., 1995). 
 
Ang (1-7; angiotensin heptapeptide), the primary product of ACE2 action on ang II, acts 
through the Mas receptor (Santos et al., 2003) to produce antagonistic effects to ang II, and 
can also be generated by the action of other peptidases on ang II (Sampaio et al., 2007, 
Toblli et al., 2008, Almeida et al., 2000, Gironacci et al., 2004, Zhong et al., 2008, Grobe et 
al., 2007). 
 
 
I1. c. v. RAS Receptors 
AT1R, AT2R and the Mas Receptor are pharmacologically-distinct rhodopsin-like G-Protein 
Coupled  Receptors  (GPCR),  integral  membrane  proteins  with  an  extracellular  amino Hepatic Mitochondrial Renin-Angiotensin Systems 
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terminus,  seven  trans-membrane  alpha-helical  spanning  regions  with  alternating 
intracellular and extracellular loops, and a cytosolic Carboxyl terminus. They activate a 
single or multiple G-proteins, each of which has 3 subunits (alpha, beta and gamma), of 
which the alpha subunit dissociates upon activation, rendering it active to affect intracellular 
signalling peptides or target functional proteins directly. Upon binding to ang II, the AT1R 
translocates to the nucleus to affect transcription directly and resulting in reduced plasma 
membrane receptor density (Cook et al., 2006, Cook et al., 2004, Lee et al., 2004, Bkaily et 
al., 2003); however, significantly less is known of the function of the AT2R, although its 
levels appear to be significantly higher in the foetus than in the adult. 
 
Multiple  specific  antagonists  have  been  identified  for  most  RAS  receptors  including 
Losartan  and  PD123319,  which  are  specific,  competitive  antagonists  of  the  AT1R  and 
AT2R, respectively. 
 
 
 
I1. d. Specific Tissue RAS 
 
I1. d. i. Hepatic RAS 
All the components of the classical RAS (renin, angiotensinogen, ACE, ang II, AT1R and 
AT2R) have been identified in rat and human liver, where they have been implicated in the 
pathophysiology of various hepatic conditions, including chronic liver disease and fibrosis 
(Paizis et al., 2002, Paizis et al., 2005). Hepatic RAS activation and upregulation has been 
demonstrated following liver injury (from a number of various pathological insults), and 
RAS  components  have  been  shown  to  subsequently  localize  to  areas  of  active  fibrosis 
formation, where they can be identified in activated, but not quiescent, hepatic stellate cells 
(HSCs-  crucial  in  the  formation  of  liver  fibrosis)  (Bataller  et  al.,  2003b,  Bataller  and 
Brenner, 2005, Friedman, 2008). Within healthy liver, quiescent HSCs express very low 
levels of RAS components and are unable to secrete ang II (Bataller et al., 2003b); however, 
following injury to hepatic tissue, HSCs become activated, increasing their expression of 
RAS components and acquiring the ability to synthesise ang II, which further stimulates 
activation and proliferation of HSCs via the AT1R (Bataller et al., 2003b, Bataller et al., 
2000), possibly through an oxidative stress and ROS generation-related mechanism (via Hepatic Mitochondrial Renin-Angiotensin Systems 
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NADPH  Oxidase  and  a  JNK  (c-\Jun  N-terminal  kinase)/ERK  (extracellular-signal-
regulated-kinase)  transduction  pathway)  (Bataller  et  al.,  2003a);  and  may  also  promote 
activation and differentiation of HSCs into myofibroblasts (Bataller and Brenner, 2005). 
Addition of ang II to hepatic tissue increases collagen expression and HSC secretion of 
cytokines, such as transforming growth factor-β1 (TGF-β1), effects which are attenuated by 
NADPH  oxidase  inhibition  (Bataller  et  al.,  2003c);  whereas,  systemic  ang  II  infusion 
induces liver fibrosis and AT1R antagonism or gene deletion attenuates liver fibrosis in rat 
models of hepatic injury (Bataller et al., 2000, Hirose et al., 2007, Kim et al., 2008, Ibanez 
et al., 2007, Ueki et al., 2006, Yang et al., 2005, Tuncer et al., 2003, Bataller et al., 2005). In 
keeping with this, a number of prospective human studies have shown improvements in 
liver  fibrosis  (secondary  to  viral  hepatitis  or  NASH  (non-alcoholic  steato-hepatitis))  via 
treatment with competitive ACE inhibitors (e.g. Perindopril, Ramipril, Lisinopril) or AT1R 
blockers  (e.g.  Losartan),  further  suggesting  that  ang  II  significantly  contributes  to  the 
development of fibrosis (Colmenero et al., 2009, Debernardi-Venon et al., 2007, Sookoian 
et al., 2005, Terui et al., 2002, Yoshiji et al., 2005, Yoshiji et al., 2006, Yokohama et al., 
2006).  Further,  the  activation  of  HSCs  by  ang  II  promotes  contraction  of  the  hepatic 
sinusoidal vascular bed, contributing to the pathogenesis of portal hypertension in cirrhotic 
livers by increasing hepatic vascular resistance (Bataller et al., 2000, Rockey, 1997, Kaneda 
et al., 1998, Bhathal and Grossman, 1985). 
 
In keeping, ACE expression and activity is increased in cirrhotic livers, stimulating local 
synthesis of ang II, within a circulatory environment (in cirrhotic patients) that has been 
shown to already be more responsive to ang II (Herath et al., 2009, Paizis et al., 2002). 
Further RAS effects within hepatocytes can be seen upon mitotic and proliferation rates 
(Cook et al., 2001): in rat hepatoma cells transfected with mutated angiotensinogen cDNA 
(signal sequence-encoding region removed, to differentiate the relative effects of nuclear 
and  cell  surface  ang  II  receptors),  a  pro-mitotic/proliferation  effect  (caused  by 
autocrine/paracrine  stimulation  of  platelet-derived  growth  factor)  can  be  blocked  by 
Losartan (competitive AT1R antagonist). The same cells were also found to produce an 
alternative  renin  transcript,  renin  1A,  which  stayed  intracellularly  and  lacked  a  signal 
sequence. There is also evidence for a counter-balancing effect of the novel RAS pathway in 
the prevention of liver fibrosis and ang IV analogues have been shown to bind directly to 
hepatocyte  growth  factor  (HGF),  where  they  antagonize  its  ability  to  form  functional Hepatic Mitochondrial Renin-Angiotensin Systems 
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dimers, thus impairing HGF-dependent signaling, proliferation and scattering in multiple 
cell-types (Kawas et al., 2012). 
I1. d. ii. RAS in other tissues 
RAS expression has also been discovered in other tissues such as heart (Pieruzzi et al., 
1995), kidney (Pieruzzi et al., 1995, Neubauer et al., 2009), vasculature (Neubauer et al., 
2009), lung (Pieruzzi et al., 1995), brain (Lenkei et al., 1997), pancreas (Leung et al., 1997, 
Leung et al., 1999, Leung, 2007, Leung and Carlsson, 2001), small bowel and colon (Paul et 
al., 2006), and adrenal tissue (Nostramo et al., 2012). Thus, local tissue RAS are expressed 
in a variety of tissues and organ systems, where they play a role in multiple physiological 
and pathophysiological processes. The dual role of RAS, in that both its endocrine and 
paracrine systems act simultaneously, means that the system is extremely complex and its 
underlying mechanisms difficult to clearly elucidate. One of the major difficulties stems 
from the limitations of pharmacology in differentiating between RAS products synthesised 
locally and those generated systemically; however, it remains clear that tissue RAS play a 
crucial role in the functional regulation of the organ system in which they are produced. 
Thus,  drugs  including  ACE-inhibitors,  AT1  antagonists  and  renin  inhibitors  offer 
extraordinary therapeutic potential.   
 
I1.d. iii. Intracellular RAS expression 
Extracellular (endocrine and paracrine) RAS executes the classical functions of ang II via 
activation  of  cell  surface  G-protein  coupled  angiotensin  receptors,  AT1R  and  AT2R 
(Campbell, 1987, Carey and Siragy, 2003, de Gasparo et al., 2000, Mehta and Griendling, 
2007, Touyz and Schiffrin, 2000, Timmermans et al., 1993). However, such actions of ang 
II cannot explain the myriad roles of the RAS, or its antagonism, in both physiology and 
pathophysiology, leading various researchers to further investigate a putative intracellular 
RAS. In particular, ang II addition results in longer-term (hours, days, weeks) effects upon 
growth, mitogenesis and cellular proliferation, which are independent from the classical 
systemic effects (mediated via cell-surface receptors) occurring within seconds or minutes; 
and the lipophilicity of some RAS antagonists renders them less capable of crossing the cell 
membrane,  resulting  in  differential  effects  due  to  preferential  actions  at  extracellular  or 
intracellular RAS receptors. Some antagonists are therefore less effective at preventing the 
cardiac and renal complications for which they have been prescribed, suggesting that the 
pathogenesis of such disease derives from intracellular RAS, and further highlighting the Hepatic Mitochondrial Renin-Angiotensin Systems 
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necessity  of  intracrine  RAS  investigation.  For  such  investigation,  experimentation  has 
focused predominantly upon renal and adrenal tissue as these tissues not only contain all 
RAS components but their presence has been measured at high tissue concentrations (Ingert 
et al., 2002). 
 
The  classical  form  of  renin  is  a  339  to  343  secretory  amino  acid  peptide  formed  by 
proteolytic cleavage of the prorenin N-terminus. The kidney is the main site of secreted 
active renin and prorenin, although other tissues also secrete prorenin into the circulation 
(Sealey et al., 1986), where it acts as the circulatory precursor for active renin but can also 
be taken up into various tissues in its precursor form. Intracellularly, renin appears to be 
targeted to lysosomes, the regulated secretory pathway or alternate intracellular sites, with 
specific sorting being determined by the cell type and the precise expression and structure of 
the renin transcript in question. Within renal tissue, renin and prorenin are primarily located 
within  cells  of  the  juxtaglomerular  apparatus,  afferent  arterioles  of  smooth  muscle  and 
interlobular arterioles (Darby et al., 1985, Song et al., 1992, Taugner et al., 1981, Zhuo et 
al.,  1996),  where  renin  is  a  secretory  protein  that  increases  vascular  tone,  glomerular 
filtration pressure and sodium reabsorption via a negative feedback mechanism (Hackenthal 
et al., 1990). Here, renin is located in storage granules that demonstrate calcium-induced 
exocytosis, and are thought to be modified lysosomes as they contain lysosomal enzymes 
and phagocytic properties (Hackenthal et al., 1990, Mullins et al., 1982, Panthier et al., 
1982, Sharp et al., 1996, Clark et al., 1997, Mullins et al., 1990, Peters et al., 1993). A 
prorenin receptor (PRR; a 350 amino acid peptide with a single transmembrane domain) has 
also been discovered within glomerular mesangial cells, distal nephrons and collecting ducts 
(Advani et al., 2009, Nguyen et al., 1996, Sihn et al., 2010) (as well as being expressed in 
widely different tissues) to which both renin and prorenin are capable of binding. The PRR 
induces multiple physiological and pathophysiological effects such as activating ERK 1/2 
MAP  (extracellular  signal  regulated  kinase  1/2  mitogen-activated-protein)  kinase 
intracellular  signaling  pathways,  p38  MAP  kinase,  COX-2  (cyclooxygenase-2)  and 
fibronectin (Nguyen, 2010, Nguyen, 2011, Sihn et al., 2010, Nguyen and Contrepas, 2008). 
However, it remains unclear what the overall physiological role of the PRR is and whether it 
is preferentially physiologically activated by renin or prorenin (Nabi et al., 2006, Nguyen et 
al., 2002). There is some evidence that prorenin is taken up by various tissues where it may 
aid in generation of intracellular ang II either via an intracellular route (Nguyen et al., 1996, Hepatic Mitochondrial Renin-Angiotensin Systems 
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Prescott et al., 2002) or via prorenin activation at the cell surface, as well as potentially 
mediating intracellular actions of renin and prorenin (Danser, 2009, Sihn et al., Advani et 
al., 2009, Nguyen et al., 2002, Saris et al., 2006). 
 
However, within the adrenal gland, alternative renin transcripts have been identified which 
encode for a non-secretory form of renin and adrenocortical cells are capable of storing 
renin in its active form without requiring glycosylation prior to storage, as in renal tissue 
(Clausmeyer et al., 1999, Lee-Kirsch et al., 1999). Here, circulating ang II induces both 
adrenal aldosterone and local renin synthesis; thus, producing a positive feedback loop to 
further increase local ang II generation. Adrenal tissue is therefore not reliant upon the 
uptake of ang II from the circulation for the production of aldosterone and the non-desirable 
systemic results of increased ang II, such as the promotion of fibrosis, hypertrophy and 
proliferation are contained (Hollenberg et al., 1974, Williams and Hollenberg, 1991, Peters 
and Ganten, 1998). 
 
In the heart however, renin is not produced intracellularly under normal conditions (or is 
produced in extremely low amounts) and cardiomyocytes therefore predominantly rely upon 
mannose-6-phosphate receptor mediated endocytosis for uptake of renin from the circulation 
to lysosomal-like storage granules (reliant upon glycosylation, similar to renal tissue) (Ekker 
et  al.,  1989,  Danser  et  al.,  1994,  van  Kesteren  et  al.,  1997,  Saris  et  al.,  2001).  An 
independent pathway also internalises prorenin (following which it is subsequently cleaved 
to  active  renin),  with  unglycosylated  (but  not  glycosylated)  uptake  leading  to  increased 
intracellular ang II (presumably due to intracellular ang II generation) (Peters et al., 2002). 
Thus, rats expressing high circulating prorenin result in high intracellular ang II and cardiac 
damage, suggesting that prorenin uptake may be more important than active renin uptake in 
cardiac tissue (Peters et al., 2002). 
 
Most circulating angiotensinogen is synthesized and secreted by the liver but some is also 
generated  within  the  kidneys  (Kobori  et  al.,  2006,  Darby  and  Sernia,  1995). 
Angiotensinogen has also been located in perinuclear regions of glial cells (Sherrod et al., 
2005); although whether it is synthesized locally at extra-hepatic and extra-renal sites, or 
taken up from the circulation, remains unknown. Agt produced locally in proximal tubule Hepatic Mitochondrial Renin-Angiotensin Systems 
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cells is both secreted (into the tubular lumen) and contained intracellularly, where it leads to 
ang II formation (Lantelme et al., 2002, Navar et al., 2001, Rohrwasser et al., 1999). 
 
ACE  has  been  localized  within  multiple  tissues  including  kidney,  although  intracellular 
expression  levels  in  humans  appear  to  be  much  lower  than  that  of  many  experimental 
animals, including rats and dogs (Metzger et al., 1999). This may explain the significantly 
lower rates of ang I to ang II conversion in human renal tissue (approx. 10 % of arterially 
delivered ang I is converted to ang II) (Danser et al., 1998, Rosivall and Navar, 1983) and 
may imply that alternate (non-ACE) angiotensin processing enzymes are more important for 
the formation of intracellular ang II. In keeping, cathepsin D catalyzes the formation of 
AGT to ang I in rat vascular smooth muscle cells (Lavrentyev et al., 2007, Lavrentyev and 
Malik, 2009); and the content of intracellular ang II increases in diabetic rats with greater 
oxidative stress, via a non-ACE-dependent pathway (Singh et al., 2007, Singh et al., 2008). 
However,  ACE  activity  remains  important  in  renal  tissue,  where  it  is  crucial  in  the 
maintenance of steady state ang II levels (Modrall et al., Ingelfinger et al., 1999, Kobori et 
al., 2001a, Kobori et al., 2001b, Kobori et al., 2002). 
 
In proximal tubule cells, high-density, high-affinity AT1 receptors are localised on both 
basal and apical membranes, where binding of circulating and paracrine ang II leads to 
internalization of the ligand-receptor complex (Brown et al., 2009, Hunyady, 1999, Li and 
Zhuo, 2008a, Thekkumkara and Linas, 2002, Brown and Douglas, 1982, Douglas, 1987, 
Dulin et al., 1994, Cogan, 1990, Harris and Navar, 1985, Houillier et al., 1996, Von Thun et 
al., 1994, Wang and Chan, 1991, Zhuo et al., 1992, Imig et al., 1999, Shao et al., 2009, van 
Kats et al., 2001, Zhuo et al., 2002, Zhuo and Li, 2007, Zou et al., 1998). It has been 
postulated that this internalization process helped to desensitise the cell to ongoing ang II 
stimulation by removing an activated receptor from the cell surface and translocating it to 
the cell interior where it is subsequently recycled, whilst ang II is delivered either to the 
endosomal or lysosomal pathway (Ferguson, 2001, Gonzalez-Gaitan, 2003, Hunyady et al., 
2000,  Zhang  et  al.,  1997,  Hein  et  al.,  1997).  In  keeping,  AT1R  blockade  or  deletion 
significantly reduces intra-renal ang II content, which is restored by ang II administration, 
suggesting that, in renal tissue at least, ang II is taken up from outside the cell or leads to 
stimulation of intracellular generation, and internalisation of the receptor-ligand complex Hepatic Mitochondrial Renin-Angiotensin Systems 
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may aid in the regulation of this pathway (Campbell, 1996, Cervenka et al., 2008, Li et al., 
2007, Li and Zhuo, 2007, Sadjadi et al., 2005). Once within the cell, it is not clear how ang 
II escapes the lysosomal or endosomal pathway to bind intracellular receptors; although 
endosomal sorting may provide a delayed intracellular release mechanism to protect from 
immediate  ang  II  metabolism  (Imig  et  al.,  1999)  or  a  pathway  to  aid  in  regulation  of 
continuous ang II signaling (Murphy et al., 2009).  
 
The  precise  mechanisms  underlying  ang  II-receptor  complex  endocytosis  have  not  been 
clearly  elucidated  and  in  non-renal  cell  types,  such  as  vascular  smooth  muscle  cells,  a 
clathrin-coated pit-dependent pathway would appear to be the crucial mechanism for ang II-
receptor uptake (Anborgh et al., 2000, Ferguson, 2001, Rajagopal et al., 2006, Thomas et 
al., 1996) and in other cell types non-canonical, alternate pathways may also be important 
(Hunyady et al., 2000, Rajagopal et al., 2006, Li et al., 2006, Zhuo and Li, 2007, Zhuo et al., 
2006a,  Li  et  al.,  2009).  Following  internalization,  ang  II  pathways  and  trafficking 
mechanisms remain largely unknown. Internalised ang II could have a number of functions, 
including recycling and secretion for extracellular action, migrating to the nucleus to exert 
transcriptional effects or undergoing processing to enable it to act intracellularly, potentially 
via stimulation of the inositol 1,4,5 triphosphate pathway (Chen et al., 2000). A nuclear 
targeting and activation sequence was recently discovered in the AT1R (Morinelli et al., 
2007) and AT1 receptors have been discovered in peri-nuclear and nuclear regions of HEK 
293 (human embryonic kidney) cells, cardiomyocytes, vascular smooth muscle cells and 
hepatocytes; although, whether these represent typical or internalized cell-surface receptors 
remains unknown (Chen et al., 2000, 2007, Licea et al., 2002, Cook et al., 2006, Cook et al., 
2007). Ang II action, via nuclear AT1 receptors, results in increased transcription of TGF-1 
(tumour  growth  factor-1)  and  MCP-1  (monocyte  chemoattractant  protein-1),  as  well  as 
increased  nitric  oxide  and  superoxide  production,  in  isolated  rat  renal  cortical  cells 
(Gwathmey et al., 2009, Gwathmey et al., Li and Zhuo, 2008b); whereas, micro-injection of 
ang II (one method of directly investigating intracellular effects) leads to intracellular and 
nuclear calcium increases in a variety of cell-types including proximal tubule and vascular 
smooth muscle cells (Haller et al., 1996, Haller et al., 1999, De Mello, 1998, De Mello, 
2006,  Zhuo,  200).  In  keeping,  micro-injection  of  Losartan  prevents  calcium  responses 
secondary  to  micro-injected  ang  II,  but  not  those  secondary  to  extracellular  ang  II, 
suggesting that direct intracellular effects are occurring (Zhuo et al., 2006b).  Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      27	 ﾠ
I2. A Metabolic Role for RAS 
 
I2. a. RAS and Performance 
The powerful benefits of ACE inhibition (ACE-I) in the treatment of heart failure have yet 
to be fully explained. Similarly, the mechanisms by which ACE inhibition reduces long-
term  cardiovascular  risk  are  incompletely  understood.  In  both  cases,  a  role  for  altered 
cellular metabolism has been postulated. Renin-angiotensin system activity is associated 
with variations in human physical performance: the presence (Insertion, I allele) rather than 
the absence (Deletion, D allele) of a 287 base pair fragment in the ACE gene is associated 
with lower circulating (Rigat et al., 1990) and tissue (Danser et al., 1995, Costerousse et al., 
1993) ACE activity, which in turn is associated with fatigue resistance (Montgomery et al., 
1998) and endurance performance (Myerson et al., 1999, Tsianos et al., 2005). Amongst 
British Olympic-standard runners, I allele frequency increases with distance run (I allele 
proportion 0.35, 0.53 and 0.62 amongst those running ≤ 200 m, 400-3000 m and ≥ 5000 m 
respectively  (p  =  0.009))  (Myerson  et  al.,  1999).  Amongst  young  male  army  recruits 
undergoing 12 weeks of military physical training, duration of standardised repetitive loaded 
(15 kg) elbow flexion improved by 79.4 (+25.2), 24.7 (+8.8), and 7.1 (+14.9) seconds for 
those of II, ID and DD genotype respectively (p<0.001 for II vs. DD) (Montgomery et al., 
1998).  Such  improvements  in  endurance  performance/fatigue-resistance  are  thought  to 
represent improved muscle metabolic efficiency, suggesting that low ACE activity (marked 
by the I allele) is associated with enhanced muscle metabolic efficiency.  
 
Such associations may in part be mediated through altered cellular metabolism: low ACE 
genotypes  are  associated  with  a  relative  conservation  of  fat  stores  during  high-intensity 
exercise  training  (Montgomery  et  al.,  1998),  greater  training-related  gains  in  ‘delta 
efficiency’ (the ratio of the change in muscle work performed/min to the change in energy 
expended/min (measured in a regression equation via assessment of rate of oxygen uptake 
and respiratory exchange ratio, while performing on a cycle ergometer) (Williams et al., 
2004))  and  reductions  in  oxygen  consumption  per  unit  of  external  work  (Woods  et  al., 
2002), and especially with successful performance in hypoxic environments (Montgomery 
et al., 1998, Tsianos et al., 2005). The I allele has been associated with increased maximum Hepatic Mitochondrial Renin-Angiotensin Systems 
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altitude achieved (a form of extreme hypoxic endurance exercise) during ascent among elite 
high altitude mountaineers (8559 +/- 565 m for IIs, 8107 +/- 653 m for IDs and 8079 +/- 947 
m  for  DDs  (p  =  0.007))  (Thompson  et  al.,  2007);  and  similarly  amongst  ascent  to  the 
summit  of  Mont  Blanc  (100%  of  II,  94.9%  of  ID,  87.7%  of  DD  individuals;  P=0.048) 
(Tsianos et al., 2005), effects which may in part depend upon regulation of BK2 receptor 
activity (Williams et al., 2004). The I-allele has similarly been associated with successful 
performance in ascents to 4800 m and beyond 8000 m (Thompson et al., 2007, Tsianos et 
al., 2006, Tsianos et al., 2005).  
 
In keeping, pharmacological ACE inhibition protects the heart from subsequent ischaemic 
injury  (Marktanner  et  al.,  2006),  whilst  genetic  elevation  of  ACE  activity  negates  such 
preconditioning  effects  (Messadi  et  al.,  2010).  Combined  ACE  inhibition  and  AT1R 
antagonism  reduce  renal  oxygen  consumption  related  to  sodium  transport  (Deng  et  al., 
2009). Meanwhile, ang II infusion increases oxygen consumption in the isolated perfused 
hindlimb (Colquhoun et al., 1988) and in liver (Matsumura et al., 1992), effects which may 
contribute  (Cassis  et  al.,  2002)  to  the  (pressor-independent)  muscle  wasting  seen  with 
systemic ang II infusion (Brink et al., 2001).  
 
These data support a role for lower ACE activity interacting with physical training in the 
regulation of metabolic efficiency. They suggest increased RAS activity to be associated 
with reduced metabolic efficiency. Conversely, the benefits of ACE inhibition in patients 
with  CHF  (congestive  heart  failure)  seem  mediated  though  peripheral  (skeletal  muscle) 
metabolic  effects  rather  than  through  central  (cardio-respiratory)  effects  (Jondeau  et  al., 
1997). Forearm blood flow (measured via plethysmograph) is lower in CHF than control 
subjects (whilst performing the same load during dynamic handgrip exercise), both during 
rest and exercise, and is compensated for by increased oxygen extraction (thus maintaining 
forearm oxygen consumption); however, captopril (ACE-I) use increased forearm oxygen 
extraction and blood flow, thus increasing efficiency of oxygen utilization (Imaizumi et al., 
1990). In rats with CHF, muscle ATP and creatine phosphate levels decline more quickly 
with exercise than in controls, and lactate levels rise faster. Six weeks of ACE inhibition 
reverses these effects, suggesting that ACE inhibition may restore skeletal muscle metabolic 
efficiency (Yamaguchi et al., 1999); similarly, 10 weeks of ACE inhibition in rats leads to Hepatic Mitochondrial Renin-Angiotensin Systems 
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an increase in functional response to endurance training (Habouzit et al., 2009). Such effects 
on metabolic efficiency may account for the dramatic beneficial effects of treatment with 
ACE inhibitors in patients with CHF (Jondeau et al., 1997). 
 
I2. b. RAS and Cachexia 
The mechanisms underlying the development of cachexia remain unclear, although ang II 
levels appear to be associated in a causal fashion, acting via anorexigenic and catabolic 
effects (Brink et al., 2001). While ang II infusions in rats led to transient initial decreases in 
oxygen  consumption;  significant  reductions  in  weight  and  food  intake  at  28  days  were 
associated  with  a  rebound  increase  in  oxygen  consumption,  potentially  contributing  to 
sustained reductions in body weight (Cassis et al., 2002). Ang II addition has been shown to 
result in decreased protein synthesis and increased protein degradation via stimulation of the 
ubiquitin-proteosome  pathway  (a  pathway  of  cytosolic  protein  degradation  involving 
ubiquitin,  a  7.5kDa,  76-amino  acid  ATP-dependent  protease  that  is  found  ubiquitously 
throughout  the  cell  and  proteosomes,  specific  protein-degrading  organelles)  and  ang  II-
mediated activation of protein kinase C (Sanders et al., 2005). Further, gastrointestinal and 
lung cancer patients with an ACE D allele exhibit lower total fat mass, percent body fat and 
lean body mass when compared to an II genotype patient group (Vigano et al., 2009).  
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I3. RAS & Mitochondria 
 
I3. a. Mitochondrial Structure & Function 
Mitochondria are membrane-enclosed organelles found within the cells of most eukaryotes, 
and which are responsible for the production of adenosine triphosphate (ATP), the high-
energy molecule utilized as energy in most cellular processes. Mitochondria range in size 
from 0.5-10 µm in diameter and the number of mitochondria in a cell varies widely by 
organism and tissue type: many cells have only a single mitochondrion, whereas others can 
contain several thousand. Hepatocytes, in particular, contain 1000-2000 mitochondria per 
cell,  comprising  up  to  20  %  of  cell  volume.  Mitochondria  are  usually  located  between 
myofibrils,  often  forming  a  branched  network  with  the  cytoskeleton,  which  aids  in 
maintenance of mitochondrial shape and can affect mitochondrial function.  
 
I3. a. i. Outer Mitochondrial Membrane 
The outer membrane encloses the entire organelle, which is separated by an intermembrane 
space from an inner mitochondrial membrane, which, in turn, bounds the mitochondrial 
matrix.  Both  outer  and  inner  membranes  are  composed  of  phospholipid  bilayers  and 
proteins,  although  the  outer  membrane  has  a  protein-to-phospholipid  ratio  similar  to 
eukaryotic plasma membrane (approximately 1 : 1 by weight). The outer membrane also 
contains  large  numbers  of  integral  proteins  (porins)  forming  channels  that  allow  small 
molecules to freely diffuse across the membrane. Larger proteins can only actively enter the 
mitochondrion via the binding of an N-terminus signalling sequence to a translocase within 
the outer membrane.
 The outer membrane is also capable of associating with the membrane 
of the endoplasmic reticulum, forming a structure called MAM (mitochondria-associated-
membranes)  that  is  crucial  in  ER-mitochondria  calcium  signalling.  Outer  membrane 
disruption  allows  proteins  within  the  intermembrane  space  to  leak  into  the  cytosol, 
subsequently resulting in cell death.  
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I3. a. ii. Inner Mitochondrial Membrane 
The inner membrane contains over 100 different polypeptides and has a high protein-to-
phospholipid ratio (over 3:1 by weight), and therefore contains approximately 20% of all 
mitochondrial protein. Despite this, it contains no porins and is rich in cardiolipin, rendering 
it  highly  impermeable.  Thus,  almost  all  ions  and  molecules  require  specific  membrane 
transporters  to  enter  or  exit  the  matrix.  The  inner  mitochondrial  membrane  contains 
numerous  invaginations,  called  cristae,  which  expand  the  surface  area  of  the  inner 
mitochondrial membrane to up to five times greater than that of the outer membrane in 
hepatic cells and even more in skeletal muscle cells, thus enhancing its ability to produce 
ATP.  The  inner  membrane  contains  the  four  complexes  of  the  electron  transport  chain 
(ETC;  complex  I-IV)  and  the  cristae  are  studded  with  oxysomes  (F1  or  elementary 
particles), which contain ATP synthase for ATP production. The inner membrane also has 
an electrochemical gradient across it formed by the action of the ETC enzymes. 
 
I3. a. iii. Intermembrane Space 
The  intermembrane  space  is  bound  by  the  outer  and  inner  membranes  and  has  similar 
concentrations of small molecules to cytoplasm (due to the free permeability of the outer 
membrane), although concentrations of large molecules remain different (due to the fact that 
specific membrane transporter proteins are required for larger molecules to cross the outer 
membrane).  Cytochrome  c,  a  small  haem  protein  crucial  to  mitochondrial  function,  is 
specifically located to the intermembrane space, via its anchoring with cardiolipin, where it 
carries electrons from complex III to IV, as well as playing a role in initiation of apoptosis. 
 
I3. a. iv. Mitochondrial Matrix 
The matrix contains a highly concentrated mixture of enzymes responsible for oxidation of 
pyruvate and fatty acids, and the Krebs cycle (Citric Acid/ Tricarboxylic Acid), and contains 
approximately two thirds of mitochondrial protein, as well as ribosomes, RNA, and several 
copies of the mitochondrial genome. 
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I3. a. v. Mitochondrial Genome & Proteome 
Mitochondria have an independent genome, although the precise nature of mitochondrial 
proteins varies depending upon the tissue and species that the mitochondrion is derived 
from. In humans, the mitochondrial genome is a circular DNA molecule of approximately 
16 kilobases, encoding 615 distinct protein types, derived from 37 total genes (13 peptide 
genes). Thirteen genes encode for the subunits of respiratory complexes I, III, IV and V, 22 
for mitochondrial transfer RNA (tRNA) and 2 for ribosomal RNA. The genes are highly 
conserved but may vary in location and each mitochondrion can contain up to ten copies of 
its DNA, which has a high proportion of coding DNA and an absence of introns and repeats. 
Mitochondrial  genes  are  transcribed  as  multigenic  transcripts,  which  are  cleaved  and 
polyadenylated to yield mature mRNAs. 
 
Proteins not encoded by the mitochondrial genome must therefore enter from the cytoplasm, 
with small molecules entering by diffusion via porins, whilst others are actively transported. 
Human mitochondria are also capable of importing both messenger RNA (mRNA) (Ahmed 
and Fisher, 2009) and tRNA (Rubio et al., 2008).  Diverse proteins (beyond those needed 
for the metabolic pathways described above) are also imported after binding to translocase 
of  the  outer  mitochondrial  membrane,  and  thence  to  distinct  translocases  of  the  inner 
mitochondrial membrane (Rehling et al., 2001). A few proteins are synthesized on matrix 
ribosomes  and  exported  into  the  inner  membrane  by  the  oxidase  assembly  (OXA) 
machinery (Schmidt et al., 2010). As a result, whilst the mitochondrial genome encodes 
only  13  proteins,  upwards  of  1450  are  identified  in  the  human  mitochondrial  proteome 
(Human mitochondrial protein database, 2010), whose folding and assembly are maintained 
by a complex machinery which includes dedicated proteases and chaperones (Haynes and 
Ron, 2010). 
 
I3. a. vi. Mitochondrial Function 
Mitochondria are responsible for energy production via respiration (see Figure I4). Through 
glycolysis within the cytosol, glucose is converted to two pyruvate molecules, which are 
transported across the inner mitochondrial membrane and are subsequently oxidized and 
combined with coenzyme A to form carbon dioxide, acetyl-CoA and NADH by the pyruvate Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      33	 ﾠ
dehydrogenase  complex  within  the  mitochondrial  matrix.  Acetyl-CoA  is  the  primary 
substrate of the Krebs cycle, which acts largely within the mitochondrial matrix (apart from 
succinate dehydrogenase, which is bound to the inner mitochondrial membrane as part of 
complex II), each cycle yielding three reduced nicotinamide adenine dinucleotide molecules 
(NADH) and one reduced flavin adenine dinucleotide molecule (FADH2), which act as a 
source of electrons for the electron transport chain (ETC), thus driving ATP synthesis via 
oxidative phosphorylation.  
 
The ETC comprises four separate protein complexes within the inner membrane, complex I 
(NADH  reductase),  II  (succinate  dehydrogenase),  III  (cytochrome  c  reductase)  and  IV 
(cytochrome a). Redox energy from NADH and FADH2 is transferred to oxygen via the 
passage of electrons down the chain from one complex to the next, each of which has a 
greater reduction potential than the last. At each step, the incremental release of energy is 
utilized  to  pump  hydrogen  ions  across  the  inner  mitochondrial  membrane  into  the 
intermembrane space, creating a strong, electrical, chemi-osmotic gradient across the inner 
membrane  as  the  proton  concentration  in  the  intermembrane  space  increases.  The 
subsequent return of these hydrogen ions across the membrane and into the matrix drives the 
synthesis  of  ATP,  by  ATP  synthase,  from  ADP  and  inorganic  phosphate  (oxidative 
phosphorylation), with hydrogen ions, electrons and oxygen yielding water. Similar reduced 
molecules can be imported from the cytosol via the malate-aspartate system or feed into the 
ETC  via  glycerol  phosphate  shuttles.  When  oxygen  is  limited,  glycolytic  products  are 
metabolized by anaerobic respiration, a process that is independent of the mitochondria. 
However, the production of ATP from glucose has an approximately 13-fold higher yield 
during aerobic respiration, as compared to anaerobic respiration.  
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Figure I4. The mitochondrial electron transport chain (UCP- Uncoupling protein; GLUT- Glucose 
transporter; ATP- Adenosine triphosphate; ADP- Adenosine diphosphate; ANT- ADP/ATP translocator; FAD- 
Flavin adenine dinucleotide; NAD- Nicotinamide adenine dinucleotide). 
 
 
The process of respiration is highly efficient; however, under certain conditions, a proton 
leak uncoupled from ATP synthesis (uncoupling) may reduce the generation of reactive 
oxygen species (ROS), such as superoxide. Such ROS are natural by-products of cellular 
metabolism, occurring in up to 2% of electrons passing through the ETC and have important 
roles in redox signaling (Lee and Griendling, 2008). However, when ROS levels are left 
unchecked, they can result in severe impairment of cellular function and ultimately lead to 
cell death. Uncoupling proteins (UCPs) are mitochondrial anion carriers found in the inner 
mitochondrial  membrane  and  are  one  of  the  cellular  mechanisms  responsible  for  the 
regulation of cellular ROS levels (Rousset et al., 2004, Mailloux and Harper, 2011). UCPs 
are capable of uncoupling generation of ATP from the action of the ETC, by altering the 
potential difference across the mitochondrial membrane, resulting in the production of heat 
only  from  the  consumption  of  oxygen.  The  mechanism  of  mitochondrial  membrane 
potential alteration has been demonstrated to vary, but can occur via proton translocation or 
via cycling of protonated fatty acids across the mitochondrial membrane (Garlid et al., 1998, 
Jaburek et al., 1999). UCP 2 is a ubiquitous molecule, whereas UCP 3 is mainly expressed 
in skeletal muscle; however, both are activated by the presence of ROS, which modulate the 
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UCP molecule via covalent modification by glutathione, to provide a negative feedback 
loop for mitochondrial ROS production (Mailloux and Harper, 2011, Rousset et al., 2004, 
Negre-Salvayre et al., 1997). 
 
Further mitochondrial functions include crucial roles in the reception and transmission of 
cellular signals; the regulation of membrane potential, cell differentiation, cycling, growth 
and apoptosis; haem and steroid synthesis, and ammonia detoxification within hepatic cells; 
and  the  regulation  of  reactive  oxygen  species’  synthesis  and  tissue  oxygen  gradients. 
Mitochondria are also important regulators of local intracellular calcium ([Ca
2+]i) and there 
is significant calcium interchange between mitochondria and ER (Szabadkai and Rizzuto, 
2004), and the ability of mitochondria to rapidly accumulate and release [Ca
2+]i makes them 
effective calcium buffers for various cellular microdomains. Calcium is transported into the 
mitochondrial matrix by a calcium uniporter on the inner mitochondrial membrane (which is 
driven by the electrochemical gradient of the mitochondrial membrane potential), where it 
causes a transient depolarization in the mitochondrial membrane potential and directly or 
indirectly regulates both mitochondrial and cytoplasmic metabolic processes (Miller, 1998).  
Within  the  mitochondrion,  calcium  is  crucial  for  the  functioning  of  citric  acid  cycle 
dehydrogenase enzymes and has a role in mitochondrial respiration, dynamics and levels of 
oxidative  stress  (Saotome  et  al.,  2008,  Pandya  et  al.,  2013).  Calcium  release  from  the 
mitochondria is triggered via the action of a sodium-calcium exchanger and a calcium-
induced-calcium-release  mechanism  and  subsequent  alterations  in  intracellular  calcium 
levels remain necessary for effecting various second messenger systems (Hajnoczky et al., 
2002). Larger [Ca
2+]i surges, however, can result in significant alterations in mitochondrial 
membrane  potential,  potentially  triggering  apoptotic  mechanisms,  via  collapse  of  the 
mitochondrial membrane potential, when a certain calcium threshold is surpassed (Rizzuto 
et  al.,  2009).  Thus,  fine  regulation  of  calcium  signaling  is  required  and  dysregulated 
mitochondrial calcium regulation has been implicated in multiple disease states (Decuypere 
et al., 2011). 
 
I3. b. RAS Components Within Mitochondria 
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technique which has been shown to completely eliminate circulating renin, whilst increasing 
renin and aldosterone synthesis (Doi et al., 1984), although the rise in aldosterone can be 
inhibited by administration of Losartan (Doi et al., 1984, Peters et al., 1999). The authors 
performed subcellular fractionation and percoll density gradient separation of the adrenal 
glands  in  combination  with  radioimmunoassay  for  protein  and  enzyme  content. 
Immunohistochemical  analysis  revealed  the  presence  of  dense  granules  within  zona 
glomerulosa cells, which increased in number following bilateral nephrectomy, and which 
stained  for  the  presence  of  renin  (see  Figure  I5).  Similarly,  following  percoll  density 
gradient  centrifugation  of  adrenal  capsules  and  immunogold  staining,  renin  was  found 
mainly in dense granules of mitochondrial fractions, where radioimmunoassay for renin 
activity was 15 times greater in nephrectomised rats than intact rats. The authors argued that 
these results provide evidence that cells of the adrenal gland synthesize renin and store it 
within specific secretory granules that can be located within mitochondria. However, their 
study methodology excluded organelles of high density (5600 g), which may have contained 
mitochondria and dense bodies; and no direct immunocytochemistry was performed. 
 
Figure I5. Electron micrographs of sections from Percoll density gradient fractions. (A) 
Electron-dense granules and a condensed mitochondrion (*) from high density fraction of 
nephrectomized rat adrenal fixed in glutaraldehyde osmium (x 72,000 magnification). (B) 
Mitochondria from low density fraction stained with anti-renin demonstrated no specific 
localization (x 49,000 magnification). (C) Granules in high density fraction stained with 
anti-renin demonstrate numerous particles overlying the granules (x 135,000 magnification) 
(Mizuno et al., 1988).  
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Figure 3. Electron micrographs of sections from Percoll density gra-
client fractions. (A) Electron-dense granules and a condensed mito-
chondrion (*) from high density fraction of nephrectomized rat adre-
nal fixed in glutaraldehyde-osmium. X< 72,000. (B) Mfitochondria in
orthodox conformation from low density fraction reacted with a
1:1I00 dilution of rabbit anti-renin and goat anti-rabbit IgG-colloidal
gold. A scattering of gold particles is seen over the section, but there
is no specific localization. X 49,000. (C) Granules in high density
fraction reacted as in B. Numerous gold particles overlie the gran-
ules. X 135,000. The diameter of the granules was between 0.2 and
0.7 um, which is somewhat smaller than that ofthe renin secretory
granules of rat kidney cortex (28).
1012 K Mizuno, L. H. Hoffman, J. C. McKenzie, and T. Inagami
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Peters  et  al  (Peters  et  al.,  1996)  attempted  to  circumvent  these  drawbacks  during  their 
investigation of Sprague-Dawley rats undergoing bilateral nephrectomy and haemodialysis, 
with subsequent surgical excision and chemical post-fixing of adrenal glands. They exposed 
ultra-thin sections to antibodies against renin (recognising renin and prorenin), ACE and 
angiotensinogen, as well as performing differential centrifugation and separation of cellular 
organelles  and  determining  prorenin,  renin  and  angiotensinogen  concentrations  by 
radioimmunoassay. Following bilateral nephrectomy, plasma renin concentration decreased 
rapidly within ten hours, followed by a further decrease to undetectable levels within the 
next 20 hours. In contrast, plasma active renin in haemodialysed control rats increased. The 
levels of plasma prorenin increased in both control and nephrectomized rats; however, the 
addition of a specific rat renin inhibitor (CH-732) inhibited ang I generation in plasma of 
dialyzed control rats only (by 65%) and not in nephrectomized rats; the authors concluding 
that true active renin and prorenin were eliminated from the circulation and that any renin 
detectable in adrenal glands can therefore be attributed to local synthesis only as the animals 
were without circulating renin for at least 20 hours. Plasma angiotensinogen was strongly 
elevated by nephrectomy and remained elevated for the duration of the study period. 
 
Utilising  anti-renin  antibodies  (anti-mouse  &  anti-rat)  and  immuno-gold  labeling,  renin 
immunoreactivity was found over membrane-bound structures of moderate electron density 
within  zona  glomerulosa  cells,  the  authors  concluding  that  these  most  likely  resembled 
immature renin vesicles of juxtaglomerular cells within the kidney and were therefore likely 
to represent storage or transport; and within mitochondria where gold staining was restricted 
to high density, rounded inclusion bodies (see Figure I6). These structures were further 
characterised  and  imaged  by  epon-embedding  to  improve  morphology  preservation  (see 
Figure I7). In control rats, ACE was located within mitochondria particularly concentrated 
over  intramitochondrial  dense  bodes;  whereas  angiotensinogen  and  cathepsin  D  (as  a 
lysosomal marker) were only found within cytoplasmic vesicles. Bilateral nephrectomy led 
to  an  increase  in  renin  particles  within  cytoplasmic  vesicles  and  mitochondria,  and  the 
immunogold  staining  technique  was  believed  to  be  specific  as  signals  within  both 
mitochondria and cytoplasmic vesicles were absent following preadsorption of anti-renin 
antiserum with purified renin. 
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Intracellular organelles of zona glomerulosa of both control and nephrectomised rats were 
separated  by  differential  centrifugation,  and  their  renin  content  was  determined.  Peak 
mitochondrial  fractions  were  at  400-1000  g  (as  indicated  by  malate  dehydrogenase 
concentration); whereas, peak lysosomal fractions were 3,000-15,000 g (as indicated by acid 
phosphatase concentration). The intracellular concentration of active renin was increased 10 
x in anephric rats and two peaks of active renin were observed, one overlapping with the 
lysosomal  fraction  (the  authors  concluding  that  this  probably  represented  cytoplasmic 
vesicles) and the other with a 600 g mitochondrial fraction (see Figure I8). Similar results 
were  observed  in  control  rats  although  renin  concentrations  were  much  lower  and  the 
mitochondrial peak, in particular, was barely detectable. Aliquots of the subcellular fractions 
were subsequently utilized for immunocytochemistry and renin immunoreactivity was again 
confirmed within mitochondrial fractions. Further investigation demonstrated ACE within 
mitochondria  and  mitochondrial  dense  bodies  and  angiotensinogen  within  cytoplasmatic 
vesicles of rat adrenal cortex of untreated Sprague-Dawley rats demonstrate. The authors 
thus concluded that the study provides evidence for the existence of an intracellular RAS in 
the adrenal cortex and further, that mitochondria here may be independently capable of 
synthesising RAS components, specifically renin (Peters et al., 1996). Although the study 
did not pursue the investigation of other RAS components, elimination of renin from the rat 
circulation prior to adrenal gland analysis provides good support for intra-mitochondrial 
RAS synthesis in adrenal cortex. 
   Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      39	 ﾠ
 
Figure  I6.  Electron  microscopy  and  immunocytochemical  localization  within  rat 
adrenal  zona  glomerulosa  of  Sprague-Dawley  rats  demonstrate  cytoplasmic  vesicles 
with  immunogold  signals  (a;  white  arrow;  magnification  x  23,000);  mitochondrial 
dense bodies containing renin (b; arrows; magnification x 23,000); intramitochondrial 
dense bodies (c; arrowheads; magnification x 4700); cathepsin D within cytoplasmic 
vesicles (d; arrowhead; magnification x 23,000) (Peters et al., 1996).  
 
Figure  I7.  Electron  microscopy  and  immunocytochemical  localization  within  rat 
adrenal  cortex  of  Sprague-Dawley  rats  demonstrate  ACE  within  mitochondria  and Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      40	 ﾠ
mitochondrial dense bodies (e; arrowhead; magnification x 23,000); angiotensinogen 
within  cytoplasmatic  vesicles  (f;  arrows;  magnification  x  23,000);  Epon-embedded 
adrenal  section  demonstrating  dense  body  within  mitochondria  (g;  arrowhead; 
magnification x  30,000); Tannin-prestained Epon-embedded adrenal section showing 
two  dense  bodies  within  the  same  mitochondrion  (h;  arrowheads;  magnification  x 
23,000) (Peters et al., 1996). 
 
 
Figure I8. Immunocytochemistry of zona glomerulosa subcellular fractions (Peters et al., 
1996). 
a) Absence of vesicles and extramitochondrial dense bodies in 600 g mitochondrial fraction, 
thus demonstrating no contamination of the fraction. Multiple mitochondria are present, one 
containing  an  intramitochondrial  dense  body  (Arrowhead;  magnification  x  10,  000).  b) 
Immunocytochemistry  of  660  g  mitochondrial  fraction  demonstrating  renin 
immunoreactivity (arrow; magnification x 23, 000). c) 9000 g fraction containing vesicles, 
one of which has renin immunoreactivity (magnification not supplied).  
 
E448  RENIN  WITHIN  ADRENOCORTICAL  MITOCHONDRIA 
Fig.  5.  Immunocytochemistry  of  the  same  subcellular  fractions  as 
analyzed  in  Fig.  4.  a:  absence  of  vesicles  and  extramitochondrial 
dense  bodies  in  “600-g”  fraction.  Many  mitochondria  are  seen;  one  of 
them  contains  an  intramitochondrial  dense  body  (arrowhead);  magni- 
fication:  X  10,000.  b:  intramitochondrial  dense  bodies  of  600-g  frac- 
tion  with  renin  IR  (arrow);  anti-renin  (MSR),  l:l,OOO;  magnification: 
~23,000.  c:  “9,000-g”  fraction  contains  vesicles,  one  of  which  has 
renin-specific  signals. 
to  be  of  interest  according  to  our  data,  were  excluded 
from  analysis.  Thus  our  study  is  not  in  contradiction 
but  complementary  and  additive  to previous  work. 
As shown  in  Fig.  2, mitochondria  of the  zona  glomeru- 
losa  cell  contain  ACE  IR.  These  immunocytologic  data, 
as  well  as  those  for  angiotensinogen,  still  need  to  be 
confirmed  by  biochemical  methods.  Previous  reports  on 
the  presence  of ACE  in  the  adrenal  gland  are  inconsis- 
tent.  Strittmatter  et  al.  (301,  observed  13Hlcaptopril 
binding  to  bovine  but  not  to  rat  glomerulosa  cells  by 
autoradiography  on tissue  slices.  Oda  et  al.  (241, on  the 
other  hand,  have  provided  indirect  evidence  for  the 
presence  ofACE  in  rat  glomerulosa  cells by  demonstrat- 
ing  that  zona  glomerulosa  cells  in  serum-free  primary 
culture  can  convert  ANG  I  to  ANG  II  and  that  this 
conversion  is inhibited  by  a converting-enzyme  inhibi- 
tor.  Furthermore,  Oda  et  al.  (24)  and  Yamaguchi  et  al. 
(36)  demonstrated,  in  isolated  glomerulosa  cell  cul- 
tures,  that  aldosterone  synthesis  is dependent  on  local 
ACE  activity. 
The  presence  of  components  of  the  RAS  within 
mitochondria  was  a  surprising  finding.  The  intramito- 
chondrial  dense  bodies  have  previously  been  investi- 
gated  by  Kai  et  al.  (14)  and  Hatano  et  al.  (13)  in  bovine 
adrenocortical  cells.  These  inclusion  bodies  were  shown 
to  be  rich  in  protein  (14).  Furthermore,  they  have  been 
shown  to  contain  adrenodoxin  IR  (131,  an  essential 
redox  component  for  the  transfer  of  electrons  to  cyto- 
chrome  P-450  enzymes.  The  authors  have  speculated 
that  this  particular  topography  may  be relevant  for  the 
synthesis  of  aldosterone.  It  is  almost  certain  that  the 
dense  bodies  observed  in  bovine  adrenocortical  cells 
correspond  to  the  renin-containing  intramitochondrial 
dense  bodies  of  the  rat  described  here.  Intramitochon- 
drial  deposits  of  high  electron  density  have  also  been 
described  by  Giacomelli  et  al.  (9).  These  deposits  are 
upregulated  by  a  low-sodium  diet,  a  condition  that 
stimulates  both  aldosterone  synthesis  and  intra- 
adrenal  renin  expression  (6).  The  authors  suggested 
that  the  deposits  may  contain  aldosterone.  Although 
steroids,  according  to the  general  opinion,  diffuse  freely, 
Laird  et  al.  (17)  have  shown  that,  in  the  rat  zona 
glomerulosa,  a  considerable  portion  of  M-hydroxyster- 
oids  is sequestered  intracellularly,  even  against  a large 
concentration  gradient.  This  pool  of  stored  steroids  can 
be  released  by  trypsin  digestion,  indicating  the  pres- 
ence  of  tight  intracellular  steroid-protein  complexes. 
Coincidentally,  trypsin  digestion  has  been  shown  to 
decrease  the  density  of  intramitochondrial  bodies  sig- 
nificantly  (14).  It  is therefore  tempting  to  propose  that 
the  intramitochondrial  dense  bodies  represent  such  a 
steroid-retaining  pool  and  that  the  intracellular  adre- 
nal  RAS  is involved  in  generation,  storage,  or  secretion 
of this  material. 
Although  our  data  suggest  that  an  intracellular  RAS 
exists  in  rat  glomerulosa  cells,  they  do  not  complete  a 
picture  of  how  this  system  operates.  One  of  the  major 
unanswered  questions  is  how  the  components  of  the 
RAS  enter  mitochondria  and  are  sequestered  into 
electron-dense  bodies.  Because  the  mitochondrial  ge- 
nome  does not  include  the  genes  for  renin,  angiotensino- 
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The rat cerebellum contains all components of the renin-angiotensin system (Lippoldt et al., 
1994) and ang II has been shown to act as both a neurotransmitter and neurohormone (Fuxe 
et al., 1976, Lind et al., 1985). Further, titrated ang II, when administered to rodents, traffics 
to AT1Rs on the outer mitochondrial membrane of the rat sensory vagal complex (Robertson 
and  Khairallah,  1971b,  Re,  2003,  Huang  et  al.,  2003).  Erdmann  et  al  (1996)  therefore 
extended  these  previous  findings  to  investigate  the  presence  of  RAS  components  in  rat 
cerebellar neurons. The authors excised and fixed the brains of 15 male Sprague-Dawley 
rats followed by processing for conventional cryostat or cryoultramicrotomy and staining 
for  ang  II  (monoclonal  and  polyclonal  antibodies).  Different  fixatives  led  to  different 
appearances  of  ang  II:  formaldehyde  and  picric  acid  led  to  a  patchy  yellow-brownish 
staining in different layers of the cerebellar cortex, especially the granular layer; whereas, 
the addition of glutaraldehyde to the fixative revealed a nuclear localization of ang II mainly 
in Purkinje cells (see Figure I9). However, when semi-thin cryosections were utilized rather 
than  conventional  cryostat  techniques,  improved  structural  preservation  allowed  clear 
identification of ang II immunoreactivity in the nuclei of Purkinje, granule, basket, and 
stellate cells. Ang II immunoreactivity was also sporadically identified in the cytoplasm of 
different  cell  types,  in  vesicle-like  structures  of  the  cytoplasm  and  in  mitochondria. 
Preadsorption of the primary antibody abolished the ang II immunolabeling in nuclei and 
cytoplasm of all cell types but within mitochondria approximately one third of the labeling 
remained unchanged even after preadsorption.  The authors concluded that when taken in 
the context of previous studies that have demonstrated other RAS components, such as renin 
and ACE (Fuxe et al., 1980, Chai et al., 1987), the findings provide good evidence for the 
presence of intraneuronal generation and processing of ang II, particularly in Purkinje cells. 
However,  immunohistochemical  identification  of  small  molecular  weight  antigens  relies 
upon  the  fixative  inducing  a  coupling  reaction  with  tissue  proteins,  leading  to 
immobilization  of  the  substance  studied  (Soinila  et  al.,  1992);  but  within  the  brain,  the 
presence of the blood-brain barrier means that all areas are not directly accessible to the 
bloodstream and that fixation may therefore be incomplete. Significant redistribution of the 
antigen under investigation may therefore occur during fixation and subsequent processing, 
meaning that results are not necessarily representative of true locations (Slot et al., 1989). 
Further, previous studies also demonstrate that angiotensinogen immunoreactivity within the 
rat brain is highly dependent upon the tissue treatment and sectioning techniques employed 
and the methods employed within the study may have therefore similarly affected study Hepatic Mitochondrial Renin-Angiotensin Systems 
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results (Campbell et al., 1991). In keeping with this is the fact that mitochondrial labeling in 
this  study  could  not  be  abolished  after  preadsorption  of  the  primary  antibody  with  the 
peptide and therefore may contain a significant amount of nonspecific binding. 
 
 
Figure I9.  Electron Microscopy and immunocytochemical localization  (monoclonal 
antibody)  of  ang  II  in:  nucleus  of  purkinje  cell  and  vesicle-like  structures  within 
cytoplasm (A); control image with no staining (B); ang II labelling of endothelial cell 
nucleus,  preferentially  of  euchromatin,  and  in  mitochondria  abutting  neuropil  (C) 
(magnification x 70,000; N-nuclei; c- Cytoplasm; m- Mitochondria; ec- Euchromatin) 
(Erdmann et al., 1996). 
 
The mitochondrial genome contains no genes for RAS components and the discovery of 
renin and other RAS components within mitochondria therefore raised the question of 
how  the  proteins  enter  the  mitochondria.  Clausmeyer  et  al  (1999  and  2000) 
hypothesized that mitochondrial forms of RAS components must be derived from the 
nuclear  genome,  synthesized  within  the  cytosol  and  imported  following  post-Hepatic Mitochondrial Renin-Angiotensin Systems 
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translational modifications. The authors further suggested that the differential targeting 
of  renin  to  mitochondria,  rather  than  to  a  secretory  pathway,  might  occur  via  an 
additional downstream initiation of translation, resulting in the lack of an ER signal 
sequence and escape from the secretory pathway. They therefore constructed amino-
terminal deletion mutants of prorenin, active renin and several intermediate forms, by 
PCR, and analysed them in conjunction with isolated mitochondria of the rat adrenal 
gland, as well as characterizing several transcripts of the renin gene. Of the six renin 
variants,  only  two  were  transported  with  considerable  efficiency  into  mitochondria 
(D26  and  D36),  both  of  which  lacked  the  complete  ER-targeting  sequence  of 
preprorenin and they concluded that a form of renin lacking 36 amino acids, namely the 
complete  ER  signal  sequence,  and  10  amino  acids  of  the  profragment,  meets  the 
requirements  for  mitochondrial  import.  There  was  no  observed  processing  of  the 
imported renin variants, indicating that the common proteolytic cleavage of an amino-
terminal targeting sequence upon import into the mitochondrial matrix, did not occur 
and that these proteins may have contained an internal targeting signal instead, which 
may  lie  between  amino  acids  36  and  50;  although  this  region  differed  from 
mitochondrial targeting sequences in that it contained some negatively charged amino 
acids, alongside three arginine residues. However, a number of mitochondrial proteins 
contain an internal targeting sequence that is not cleaved (e.g. cytochrome c (Folsch et 
al., 1996, Nicholson et al., 1988, Lill et al., 1992)) and are usually located within the 
inner  membrane  or  inter-membrane  space.  However,  renin  has  been  located  within 
dense  bodies,  which  are  most  likely  to  be  located  within  the  mitochondrial  matrix, 
requiring transport across the inner membrane and further investigations are required to 
demonstrate  activity  of  such  renin  proteins  in  vivo.    Analysis  of  renin  mRNA  also 
identified two transcripts with different 5’- regions: besides the full-length transcript, 
an additional mRNA lacking exon 1, but containing an 80-nucleotide region having its 
origin  in  intron  1,  was  discovered.  The  authors  concluded  that  this  represented  an 
alternative  spliced  transcript,  in  which  exon  1  appears  to  be  replaced  by  another, 
previously  undescribed  exon  (exon  1A).  However,  besides  a  possible  role  in  the 
regulation of mitochondrial aldosterone production, further functions of this novel renin 
remain unknown. 
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The same group went on to extend their observations of this novel non-secretory, cytosolic 
renin  transcript  (exon(1A-9)  renin),  which  is  translated  into  a  truncated  prorenin 
commencing at the first-in-frame ATG (translation start site) in exon 2, resulting in a protein 
that lacks the prefragment of secretory renin as well as the first 10 amino acids of the 
conventional protein. In the rat most tissues have been found to express both transcripts, the 
kidney exon(1-9) only and the heart expresses the exon(1A-9) transcript exclusively, where 
its levels increase after myocardial infarction (Clausmeyer et al., 2000; Wanka et al., 2009). 
The authors therefore over-expressed both conventional ‘secretory’ renin (exon(1-9) renin) 
and novel ‘cytosolic’ renin (exon(2-9) renin) in H9c2 cells (a rat embryonal cardiac muscle-
derived cell line) and subsequently performed confocal microscopy after double-staining for 
renin  and  mitochondrial  markers,  as  well  as  performing  subcellular  fractionation  and 
assessing  ang  I  concentration  by  radioimmunoassay  as  a  measure  of  renin’s  ability  to 
generate ang I. In H9c2 cells expressing exon(1A-9) renin, renin immunoreactivity was 
found exclusively within mitochondria (see Figure I10). Following subcellular fractionation, 
inactive renin was enriched in a 200 g mitochondrial fraction (as confirmed by the presence 
of the mitochondrial marker malate dehydrogenase) in non-transfected H9c2 cells. Over-
expression  of  exon(2-9)  renin  protein  led  to  increased  inactive  and  active  renin 
concentrations in the 200 g mitochondrial fraction; whereas, in a second light mitochondrial 
fraction  (3000  g),  inactive,  but  not  active,  renin  was  also  increased.  Following  over-
expression of exon(1-9) renin, inactive renin was enriched in a 15,000 g light vesicular 
fraction only. Inactive and active renin concentrations were also increased in the medium of 
exon(1-9) cells, but not in exon(2-9) transfected cells supporting the hypothesis that exon(1-
9) renin is secretory, but exon(2-9) is cytosolic. Cellular proliferation rate was reduced by 
secretory and cytosolic renin, necrosis was increased by secretory renin but decreased by 
cytosolic renin, and mitochondrial apoptosis, as indicated by phosphatidylserin translocation 
to the outer membrane, was unaffected by secretory renin but increased by cytosolic renin.  
 
The authors concluded that renin is sorted to different intracellular compartments within 
H9c2 cells dependent upon the presence of exon 1 or 1A and the truncated exon(2-9) renin 
protein  encoded  by  the  exon(1A-9)  transcript  lacks  10  out  of  43  amino  acids  of  the 
profragment of secretory prorenin. Further, the authors report that, since cytosolic renin is 
up-regulated following myocardial infarction, it may play a protective role in ischemia-
related  processes  by  reducing  the  rate  of  necrosis  and  increasing  apoptosis,  thereby Hepatic Mitochondrial Renin-Angiotensin Systems 
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preventing unfavourable fibrosis and cardiac remodeling. 
 
 
 
Figure I10. Immunohistochemical localization of renin in H9c2 cells. Anti-renin antibody 
(upper left panel, green); Mitotracker Red for mitochondrial staining (upper right panel, 
red). Merged confocal images demonstrated that renin co-localizes to mitochondria (lower 
left panel; colocalization: yellow). Merged confocal image of non-specific rabbit antiserum 
and Mitotracker Red as negative control (lower right panel) (Wanka et al., 2009). 
 
 
Abadir et al (2011) investigated the role of the RAS in intra-mitochondrial nitric oxide (NO) 
production  by  performing  immunoelectron  microscopy  for  various  RAS  components  in 
sections from human skeletal muscle, cardiac myocytes, renal tubular cells, neuronal cells, 
vascular endothelial cells and hepatocytes, as well as transfecting human fibroblasts with an 
AT2R  construct,  performing  subcellular  fractionation,  and  measuring  mitochondrial  NO 
production and respiration. Electron microscopy demonstrated that AT1R immunoreactivity 
was present on monocyte cell membranes, but was not regularly present in mitochondria 
from young monocytes or tubular renal cells; whereas AT2R immunoreactivity was present 
in human monocyte cell membranes and mouse tissues (see Figures I11-14). Mouse heart 
2930 © 2008 The Authors
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concentrations  were  increased  only  in  the  medium of
exon(1–9)renin cells, when compared with control cells, but
not in exon(2–9)renin-transfected cells (inactive renin: H9c2-
pIRES: 1.0   0.8 ng AngI/hr/10
6 cells; H9c2-exon(1–9)renin:
5981.2   931.7 ng AngI/hr/10
6 cells; H9c2-exon(2–9)renin:
1.0   0.5 ng AngI/hr/10
6 cells; active renin: H9c2-pIRES: 1.1
  0.5 ng AngI/hr/10
6 cells; H9c2-exon(1–9)renin: 32.6   5.4
ng  AngI/hr/10
6 cells;  H9c2-exon(2–9)renin:  1.6    0.9  ng
AngI/hr/10
6 cells; Fig. 4).
Functional differences between cytosolic
renin and prorenin
After having established that cytosolic and secretory prorenin are
differently sorted intracellularly, we next examined the effects of
the different transcripts on cell functions.
Protein content, growth rate and proliferation
First, exon(1–9)renin and exon(2–9)renin-transfected cells exhibited
marked  differences  in  cell  growth.  The  transfection  with
exon(1–9)renin but not with exon(2–9)renin induced cellular hyper-
trophy.  Cellular  protein  content  was  also  increased  exclusively  in
exon(1–9)renin transfected cells (H9c2 cells: 2.16   0.26 mg/10
6
cells,  H9c2-pIRES  cells:  2.21    0.18  mg/10
6 cells;  H9c2-
exon(1–9)renin:  3.71    0.54  mg/10
6 cells;  P   0.01;  H9c2-
exon(2–9)renin cells:  2.81    0.40  mg/10
6 cells;  n.s.;  Fig.  5A).
Furthermore,  exon(1–9)renin-transfected  cells  were  considerably
larger than control-transfected or exon(2–9)renin-transfected cells, as
visualized by using the fluorescent dyes acridine orange and ethidium
bromide  (5  B-E).  Additionally,  an  increased  number  of  apparently
dead cells was found in both exon(1–9)- and exon(2–9)renin-trans-
fected cells, as indicated by ethidium bromide staining.
Second, growth rates were reduced in both renin transfected cell
lines (H9c2: 7.1   0.6; H9c2-pIRES cells: 5.7   0.5; n.s.; H9c2-
exon(1–9)renin cells: 2.9   0.3; P   0.05; H9c2-exon(2–9)renin:
4.0   0.3 mg/10
6 cells; P   0.05; Fig. 5F). Also, proliferation rate
was significantly decreased in the renin-transfected cell lines, when
compared with pIRES-transfected control cells (H9c2-pIRES: 0.33
  0.06;  H9c2-exon(1–9)renin:  0.12    0.02;  P   0.05;  H9c2-
exon(2–9)renin: 0.15   0.03; P   0.05) (Fig. 5G).
Exon(1–9)renin increases the rate of
necrosis in H9c2 cells
A  major  difference  with  functional  consequences  between
exon(1–9)renin- and exon(2–9)renin-transfected cells was the
Fig.  2 Immunhistochemical  localization  of
renin in H9c2 cells. Renin was detected with
anti-renin  antibody  (upper  left  panel,  green)
and  mitochondria  were  stained  with
Mitotracker Red CMXRos (upper right panel,
red).  Merged  confocal  image  demonstrates
that renin localizes to the mitochondria (lower-
left  panel,  colocalization:  yellow).  Negative
control:  Merged  confocal  image  of  non-spe-
cific  rabbit  antiserum  and  Mitotracker  Red
CMXRos (lower-right panel). Bar   15  m.Hepatic Mitochondrial Renin-Angiotensin Systems 
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homogenates  were  subsequently  fractionated  by  differential  centrifugation  and  density 
gradient separation to demonstrate that AT2R immunoreactivity increased with progressive 
mitochondrial purification as indicated by cytochrome c oxidase activity. Double-labeling 
also  demonstrated  co-localisation  of  AT2R  and  Ang  within  mouse  hepatocytes,  kidney 
tubular cells, brain neurons, and heart myocytes. The authors report that further inspection 
of the immunoelectron images suggested that mitochondrial AT2R is present on the inner 
mitochondrial  membrane  so  proceeded  with  isolating  inner  mitochondrial  membrane-
enriched preparations from mouse liver to demonstrate that AT2R immunoreactivity co-
purified  with  ATP  synthase,  a  marker  of  the  inner  mitochondrial  membrane.  Further, 
following transfection of human fibroblasts with a GFP-AT2R construct and subsequent 
counterstaining  with  Mitotracker  Red  to  indicate  mitochondria,  significant  overlap  was 
found with a high spatial correlation (R
2=0.72). NO production was also dose-dependently 
activated by the AT2R agonist CGP421140 in isolated mitochondria, and this effect was 
prevented  by  AT2R  blocker  PD-123319  and  the  fact  that  mitochondrial  respiration  and 
membrane  potential  were  unaffected  means  that  observed  effects  were  unlikely  to  be 
attributable to non-specific toxic effects of any of the added substrates upon mitochondrial 
energetics. However, the use of a single antibody for the assessment of AT2R renders the 
study potentially open to methodological limitations and the mitochondrial immunogold and 
immunofluorescence  labeling  results  reported  by  Abadir  et  al  (2011)  should  thus  be 
interpreted with significant caution. Moreover, the study applied only CGP 42112, an AT2R 
agonist, which has been reported to antagonise the AT1R as well (Brechler et al., 1993), and 
functional impacts of natural AT receptor ligands were not demonstrated. Further, different 
experiments were performed in different cell types and tissues and therefore the consistency 
of such results in one cell type cannot be proven. 
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Figure  I11.  Immunoelectron  microscopic  localization  of  AT1Rs  in  sections  of  human 
monocyte (A and B) and mouse kidney tubular cells (C and D) using gold bead labeling 
(arrows). (A) AT1Rs are present on human monocyte cell membrane; (B) AT1Rs are present 
in the cytoplasm; (C) AT1R labeling is present in close proximity to mitochondria; (D) 
AT1Rs are rarely present within mitochondria (Abadir et al., 2011). 
 
 
Figure  I12.  Immunoelectron  microscopic  localization  of  AT2Rs  in  sections  of  human 
monocyte (A and B) and mouse renal tubular cells (C and D) using gold bead labeling 
(arrows).  
(A) demonstrates AT2Rs on human monocyte cell membrane; (B–D) demonstrate heavy 
AT2R staining within mitochondria (Abadir et al., 2011). 
sequently by density gradient centrifugation. The density-puri ed
mitochondria were probed with speci c antibodies. AT2R im-
munoreactivity increased with progressive puri cation of mito-
chondria, for which cytochrome c oxidase (CoxIV) was used as a
marker. Importantly, the immunoreactivity of Na
+/K
+ ATPase,
a plasma membrane marker, declined with progressive enrich-
ment of mitochondria. This is consistent with mitochondrial
enrichment of AT2Rs (Fig. S1 A and B). In contrast, AT1Rs did
not enrich with mitochondrial fractions.
We quanti ed through EM the relative expression of AT2Rs
per mitochondria in cells obtained from different human and
mouse tissues (Fig. S1C).
Colocalization of Ang and AT2Rs. Given that a functional MAS
would require the presence of local Ang to activate the receptor,
we next sought evidence for mitochondrial Ang by immunoe-
lectron microscopy. Using a gold-conjugated secondary antibody
to anti-Ang antibody (6 nm gold), we demonstrated the presence
of mitochondrial Ang in mouse hepatocytes (Fig. 3A), kidney
tubular cells (Fig. 3B), brain neurons (Fig. 3C), and heart myo-
cytes (Fig. 3D). Moreover, Ang was not randomly distributed
within mitochondria; rather, it colocalized with mtAT2R, detec-
ted with a gold-conjugated secondary antibody to anti-AT2R
antibody (12 nm gold). The abundant distribution of mtAT2R in
the young animals, observed in electron microscope images, was
correlated with a scarcity of mtAT1R. Despite the observation
of many Ang immunolabeled particles in electron microscope
images, Ang was not detected in Western blots of isolated, density-
puri ed mitochondria, indicating that Ang is loosely bound and is
lost upon washing the isolated mitochondria.
AT2R Transfection of Fibroblast Cells. To ensure that the results
described above were not attributable to nonspeci c or off-target
binding of antibody to mitochondrial targets, we con rmed mi-
tochondrial localization of AT2Rs by using a GFP-AT2R fusion
construct. Brie y, human  broblasts were transfected with
pcDNA-Cycle 3 GFP-AT2R or positive control using pcDNA-
EGFP-C1 before counterstaining with the mitochondrial  uo-
rescence marker MitoTracker Red. GFP-AT2R  uorescence was
con ned to discrete intracellular puncta (Fig. 4B), mirroring the
distribution of MitoTracker Red (Fig. 4A). Spatial overlap of the
two signals, denoting subcellular colocalization, is shown in Fig.
4C. The extent of colocalization was assessed quantitatively over
a series of confocal Z sections (0.37  m); spatial signal correla-
tion between the two  uorophores was high (R
2 = 0.72). Thus,
the high density of AT2Rs observed in the mitochondria in
electron microscope images was corroborated by tracking the
Cycle 3 GFP-AT2R fusion protein in live human  broblasts,
where it was predominantly colocalized with the mitochondrial
marker MitoTracker Red.
AT2R Localization Within Mitochondria. Having con rmed the
presence of mtAT2Rs by two independent methods, we sought to
determine the precise location of these receptors within the mi-
tochondria. Further inspection of the immunoelectron micro-
graphs in Figs. 2 and 3 suggested that the mtAT2R is resident in
the inner, rather than the outer, mitochondrial membranes. To
con rm this observation by a different method, we isolated
innermitochondrialmembrane-enrichedmembranesfrommouse
liver according to previously published methods (19). We de-
termined the speci c immunoreactivity of AT2R in the inner
mitochondrial membrane as described in the previous section.
AT2R immunoreactivity copuri ed with that of ATP synthase  ,
an inner mitochondrial membrane marker. In contrast, markers
of the plasma membrane (Na
+/K
+ ATPase) and the outer mito-
chondrial membrane [voltage-dependent anion channel (VDAC)]
were progressively removed by inner mitochondrial membrane
puri cation (Fig. 5A). These results buttress the results of the
immunoelectron microscopy studies and are consistent with lo-
calization of AT2R in the inner mitochondrial membrane.
AT2Rs Modulate Mitochondrial NO Production. To determine
whether mtAT2R activation might modulate mitochondrial NO
production in a manner analogous to the actions of non-mtAT2Rs
on other NO isoforms, we examined the direct effects of AT2R
agonists and antagonists on isolated kidney mitochondria. Trans-
Fig. 1. Immuno-electron microscopic localization of AT1Rs in sections of
human monocyte (A and B)a n dm o u s ek i d n e yt u b u l a rc e l l s( C and D) using
gold bead labeling (arrows) for AT1Rs. A shows AT1Rs on human monocyte
cell membrane and in the cytoplasm (B). C shows labeling in close proximity
to mitochondria and rarely in the mitochondria (D).
Fig. 2. Immuno-electron microscopic localization of AT2Rs in sections of hu-
man monocyte (A and B) and mouse renal tubular cells (C and D) using gold
beads labeling (arrows) for AT2Rs. A shows AT2Rs on human monocyte cell
membrane, and B–D reveal heavy labeling for AT2Rs within mitochondria.
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sequently by density gradient centrifugation. The density-puri ed
mitochondria were probed with speci c antibodies. AT2R im-
munoreactivity increased with progressive puri cation of mito-
chondria, for which cytochrome c oxidase (CoxIV) was used as a
marker. Importantly, the immunoreactivity of Na
+/K
+ ATPase,
a plasma membrane marker, declined with progressive enrich-
ment of mitochondria. This is consistent with mitochondrial
enrichment of AT2Rs (Fig. S1 A and B). In contrast, AT1Rs did
not enrich with mitochondrial fractions.
We quanti ed through EM the relative expression of AT2Rs
per mitochondria in cells obtained from different human and
mouse tissues (Fig. S1C).
Colocalization of Ang and AT2Rs. Given that a functional MAS
would require the presence of local Ang to activate the receptor,
we next sought evidence for mitochondrial Ang by immunoe-
lectron microscopy. Using a gold-conjugated secondary antibody
to anti-Ang antibody (6 nm gold), we demonstrated the presence
of mitochondrial Ang in mouse hepatocytes (Fig. 3A), kidney
tubular cells (Fig. 3B), brain neurons (Fig. 3C), and heart myo-
cytes (Fig. 3D). Moreover, Ang was not randomly distributed
within mitochondria; rather, it colocalized with mtAT2R, detec-
ted with a gold-conjugated secondary antibody to anti-AT2R
antibody (12 nm gold). The abundant distribution of mtAT2R in
the young animals, observed in electron microscope images, was
correlated with a scarcity of mtAT1R. Despite the observation
of many Ang immunolabeled particles in electron microscope
images, Ang was not detected in Western blots of isolated, density-
puri ed mitochondria, indicating that Ang is loosely bound and is
lost upon washing the isolated mitochondria.
AT2R Transfection of Fibroblast Cells. To ensure that the results
described above were not attributable to nonspeci c or off-target
binding of antibody to mitochondrial targets, we con rmed mi-
tochondrial localization of AT2Rs by using a GFP-AT2R fusion
construct. Brie y, human  broblasts were transfected with
pcDNA-Cycle 3 GFP-AT2R or positive control using pcDNA-
EGFP-C1 before counterstaining with the mitochondrial  uo-
rescence marker MitoTracker Red. GFP-AT2R  uorescence was
con ned to discrete intracellular puncta (Fig. 4B), mirroring the
distribution of MitoTracker Red (Fig. 4A). Spatial overlap of the
two signals, denoting subcellular colocalization, is shown in Fig.
4C. The extent of colocalization was assessed quantitatively over
a series of confocal Z sections (0.37  m); spatial signal correla-
tion between the two  uorophores was high (R
2 = 0.72). Thus,
the high density of AT2Rs observed in the mitochondria in
electron microscope images was corroborated by tracking the
Cycle 3 GFP-AT2R fusion protein in live human  broblasts,
where it was predominantly colocalized with the mitochondrial
marker MitoTracker Red.
AT2R Localization Within Mitochondria. Having con rmed the
presence of mtAT2Rs by two independent methods, we sought to
determine the precise location of these receptors within the mi-
tochondria. Further inspection of the immunoelectron micro-
graphs in Figs. 2 and 3 suggested that the mtAT2R is resident in
the inner, rather than the outer, mitochondrial membranes. To
con rm this observation by a different method, we isolated
innermitochondrialmembrane-enrichedmembranesfrommouse
liver according to previously published methods (19). We de-
termined the speci c immunoreactivity of AT2R in the inner
mitochondrial membrane as described in the previous section.
AT2R immunoreactivity copuri ed with that of ATP synthase  ,
an inner mitochondrial membrane marker. In contrast, markers
of the plasma membrane (Na
+/K
+ ATPase) and the outer mito-
chondrial membrane [voltage-dependent anion channel (VDAC)]
were progressively removed by inner mitochondrial membrane
puri cation (Fig. 5A). These results buttress the results of the
immunoelectron microscopy studies and are consistent with lo-
calization of AT2R in the inner mitochondrial membrane.
AT2Rs Modulate Mitochondrial NO Production. To determine
whether mtAT2R activation might modulate mitochondrial NO
production in a manner analogous to the actions of non-mtAT2Rs
on other NO isoforms, we examined the direct effects of AT2R
agonists and antagonists on isolated kidney mitochondria. Trans-
Fig. 1. Immuno-electron microscopic localization of AT1Rs in sections of
human monocyte (A and B)a n dm o u s ek i d n e yt u b u l a rc e l l s( C and D) using
gold bead labeling (arrows) for AT1Rs. A shows AT1Rs on human monocyte
cell membrane and in the cytoplasm (B). C shows labeling in close proximity
to mitochondria and rarely in the mitochondria (D).
Fig. 2. Immuno-electron microscopic localization of AT2Rs in sections of hu-
man monocyte (A and B) and mouse renal tubular cells (C and D) using gold
beads labeling (arrows) for AT2Rs. A shows AT2Rs on human monocyte cell
membrane, and B–D reveal heavy labeling for AT2Rs within mitochondria.
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Figure  I13.  Immunoelectron  microscopic  localization  of  AT2R  binding  to  Angiotensin 
within mitochondria utilising a gold-labeled anti-AT2R antibody (12 nm gold) and a gold-
labeled anti-Ang antibody (6 nm gold). Shown is colocalization of AT2Rs with Ang in 
sections  of  (A)  mouse  hepatocytes;  (B)  kidney  tubular  cells;  (C)  neurons;  (D)  cardiac 
myocytes (Abadir et al., 2011). 
 
 
 
Figure I14. Transfected AT2Rs colocalize with mitochondria in human fibroblasts.  
(B) Human fibroblast cells were transfected with GFP-AT2R construct or positive control 
(F) and counterstained with MitoTracker Red (A & E). The merged images show yellow 
fluorescence  (C  &  G).  Fluoro-graphic  analysis  (D  &  H)  reveals  a  high  correlation 
coefficient (R
2 = 0.72) (Abadir et al., 2011). 
mission electron microscopy and Western blot analyses were used
to con rm minimal contamination of the isolated mitochondria
withothercellfractionsandatypicalmorphologyofmitochondria.
The NO  uorescent molecular detection probe kit (Enzo Life
Sciences) was used according to the manufacturer’s instructions
(20). Isolated mitochondria were treated for 30 min with the NO
scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-
oxyl-3-oxide (c-PTIO) followed by a 15-min incubation with the
AT2R agonist CGP421140 and/or the antagonist PD-123319.
Positive control samples were treated with the NOS substrate L-
arginine,andnegativecontrolsamplesweregeneratedbytreatment
with NO scavenger (c-PTIO). Isolated mitochondria were treated
and then incubated with a speci c  uorescent probe for real-time
measurement of NO. Fluorescence signal was measured by using
a multimode microplate reader equipped with Cyanine 5 (650/670
nm). Treatment of mitochondria with CGP421140 caused a con-
centration-dependent increase in mitochondrial NO production
(Fig. 6A); speci cally, 10 nM was suf cient to stimulate NO pro-
duction [from 0.52 ± 0.0009  uorescence arbitrary units (AU) at
baseline control to 0.6 + 0.01 AU, P < 0.001]. Moreover,
CGP421140-stimulated NO production was mitigated by pre-
treatment with PD-123319 (1   ; 0.55 ± 0.006 AU, P < 0.01;
Fig. 6A).
AT2Rs Modulate Mitochondrial Respiration. To determine how
mtAT2R stimulation might in uence global mitochondrial func-
tion, we examined effects on respiration in rat heart mitochon-
dria. Glutamate/malate-supported respiration (state 2) (21) was
initially 17.8 ± 1.06 pmol/min per  g, Addition of ADP increased
respiration (state 3) to 84.12 ± 1.24 pmol/min per  g( P <
0.0005). We subsequently found that the addition of 100 nM
CGP421140 caused a signi cant decrease in state 3 respiration
(Fig. 6C; 39.47 ± 4.37 pmol/min per  g, P < 0.005). The dose of
100 nM CGP421140 was selected based on a series of experi-
ments used to determine the dose of CGP421140 needed to in-
 uence mitochondrial respiration (Fig. 6B). The effects of
CGP421140werenotlikelyattributabletononspeci cuncoupling
because control experiments showed that 100 nM CGP421140
had little effect on mitochondrial membrane potential (  m) or
NADH level (Fig. 6D). Importantly, CGP421140-mediated in-
hibition of respiration was prevented by blocking the AT2R;
PD-123319 (1  M) restored CGP421140-inhibited state 3 respi-
ration (Fig. 6C; 66.83 ± 2.1 pmol/min per  g, P < 0.01). The ad-
dition of L-N
G-nitroarginine methyl ester (L-NAME; 1  M),
an arginine analog that inhibits NO production, reversed the
CGP421140 effect on mitochondrial respiration (Fig. 6C; 67.4 ±
4.3 pmol/min per  g, P < 0.05), indicating that the functional
effects of mtAT2R activation on mitochondrial respiration are via
an NO-dependent mechanism.
To further validate this effect of MAS on mitochondrial respi-
ration, we studied liver mitochondria with different mitochondrial
substrates. Liver mitochondria respiring with glutamate/malate
as the substrate gave results similar to those obtained in isolated
cardiac mitochondria. The AT2R agonist inhibited state 3 respi-
rations in the nanomolar range for both glutamate/malate- and
succinate-supported respiration. In succinate-supported respira-
tion, the inhibitory response was slightly more pronounced at 1 nM
than for glutamate/malate-supported respiration (Fig. S2).
Age-Related Changes in the MAS. Although still controversial,
substantial evidence documents a decline in the canonical Ang
system with age (22–24), and mtNOS activity is reportedly re-
duced with aging (18). We examined the effect of aging on the
MAS. Kidney tubular cell sections from 20- or 70-wk-old C57BL/
6 mice and aged (70-wk-old) mice treated with losartan at a dose
of 40–60 mg/kg per day for 20 wk were labeled with antibodies
and visualized with immunoelectron microscopy. Representative
mitochondria, labeled for AT1R (Fig. 7 A–C) and AT2R (Fig. 7
D–F) are shown. Younger mice (Fig. 7 A and D) and older mice
treated with losartan (Fig. 7 C and F) had similar densities of
labeled AT2R, whereas older untreated mice (Fig. 7 B and E)
had a lower AT2R density. Our results demonstrate a signi cant
decrease in the expression of mtAT2R with aging (from 25.5 +
Fig. 4. Transfected AT2Rs colocalize
with mitochondria in human  broblasts.
Human  broblast cells were transfected
with pcDNA-Cycle 3 GFP-AT2R construct
(B)o rp o s i t i v ec o n t r o lu s i n gp c D N A -
EGFP-C1 (F) and counterstained with
MitoTracker Red (A and E) (100  oil
immersion). The merged images show
yellow  uorescence (C and G). Fluoro-
graphic analysis (D and H) reveals a high
correlation coef cient (R
2 = 0.72), sug-
gesting a strong colocalization between
AT2Rs and MitoTracker within the mi-
tochondria.
Fig. 3. Immunoelectron microscopic localization of AT2Rb i n d i n gt oA n gi n
the mitochondria by using a gold-labeled anti-AT2R antibody (12 nm gold)
and a gold-labeled anti-Ang antibody (6 nm gold). Shown is colocalization of
AT2Rs with Ang in sections of mouse hepatocytes (A), kidney tubular cells (B),
neurons (C), and cardiac myocytes (D).
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(20). Isolated mitochondria were treated for 30 min with the NO
scavenger 2-(4-carboxyphenyl)-4,4,5,5-tetramethylimidazoline-1-
oxyl-3-oxide (c-PTIO) followed by a 15-min incubation with the
AT2R agonist CGP421140 and/or the antagonist PD-123319.
Positive control samples were treated with the NOS substrate L-
arginine,andnegativecontrolsamplesweregeneratedbytreatment
with NO scavenger (c-PTIO). Isolated mitochondria were treated
and then incubated with a speci c  uorescent probe for real-time
measurement of NO. Fluorescence signal was measured by using
a multimode microplate reader equipped with Cyanine 5 (650/670
nm). Treatment of mitochondria with CGP421140 caused a con-
centration-dependent increase in mitochondrial NO production
(Fig. 6A); speci cally, 10 nM was suf cient to stimulate NO pro-
duction [from 0.52 ± 0.0009  uorescence arbitrary units (AU) at
baseline control to 0.6 + 0.01 AU, P < 0.001]. Moreover,
CGP421140-stimulated NO production was mitigated by pre-
treatment with PD-123319 (1   ; 0.55 ± 0.006 AU, P < 0.01;
Fig. 6A).
AT2Rs Modulate Mitochondrial Respiration. To determine how
mtAT2R stimulation might in uence global mitochondrial func-
tion, we examined effects on respiration in rat heart mitochon-
dria. Glutamate/malate-supported respiration (state 2) (21) was
initially 17.8 ± 1.06 pmol/min per  g, Addition of ADP increased
respiration (state 3) to 84.12 ± 1.24 pmol/min per  g( P <
0.0005). We subsequently found that the addition of 100 nM
CGP421140 caused a signi cant decrease in state 3 respiration
(Fig. 6C; 39.47 ± 4.37 pmol/min per  g, P < 0.005). The dose of
100 nM CGP421140 was selected based on a series of experi-
ments used to determine the dose of CGP421140 needed to in-
 uence mitochondrial respiration (Fig. 6B). The effects of
CGP421140werenotlikelyattributabletononspeci cuncoupling
because control experiments showed that 100 nM CGP421140
had little effect on mitochondrial membrane potential (  m) or
NADH level (Fig. 6D). Importantly, CGP421140-mediated in-
hibition of respiration was prevented by blocking the AT2R;
PD-123319 (1  M) restored CGP421140-inhibited state 3 respi-
ration (Fig. 6C; 66.83 ± 2.1 pmol/min per  g, P < 0.01). The ad-
dition of L-N
G-nitroarginine methyl ester (L-NAME; 1  M),
an arginine analog that inhibits NO production, reversed the
CGP421140 effect on mitochondrial respiration (Fig. 6C; 67.4 ±
4.3 pmol/min per  g, P < 0.05), indicating that the functional
effects of mtAT2R activation on mitochondrial respiration are via
an NO-dependent mechanism.
To further validate this effect of MAS on mitochondrial respi-
ration, we studied liver mitochondria with different mitochondrial
substrates. Liver mitochondria respiring with glutamate/malate
as the substrate gave results similar to those obtained in isolated
cardiac mitochondria. The AT2R agonist inhibited state 3 respi-
rations in the nanomolar range for both glutamate/malate- and
succinate-supported respiration. In succinate-supported respira-
tion, the inhibitory response was slightly more pronounced at 1 nM
than for glutamate/malate-supported respiration (Fig. S2).
Age-Related Changes in the MAS. Although still controversial,
substantial evidence documents a decline in the canonical Ang
system with age (22–24), and mtNOS activity is reportedly re-
duced with aging (18). We examined the effect of aging on the
MAS. Kidney tubular cell sections from 20- or 70-wk-old C57BL/
6 mice and aged (70-wk-old) mice treated with losartan at a dose
of 40–60 mg/kg per day for 20 wk were labeled with antibodies
and visualized with immunoelectron microscopy. Representative
mitochondria, labeled for AT1R (Fig. 7 A–C) and AT2R (Fig. 7
D–F) are shown. Younger mice (Fig. 7 A and D) and older mice
treated with losartan (Fig. 7 C and F) had similar densities of
labeled AT2R, whereas older untreated mice (Fig. 7 B and E)
had a lower AT2R density. Our results demonstrate a signi cant
decrease in the expression of mtAT2R with aging (from 25.5 +
Fig. 4. Transfected AT2Rs colocalize
with mitochondria in human  broblasts.
Human  broblast cells were transfected
with pcDNA-Cycle 3 GFP-AT2R construct
(B)o rp o s i t i v ec o n t r o lu s i n gp c D N A -
EGFP-C1 (F) and counterstained with
MitoTracker Red (A and E) (100  oil
immersion). The merged images show
yellow  uorescence (C and G). Fluoro-
graphic analysis (D and H) reveals a high
correlation coef cient (R
2 = 0.72), sug-
gesting a strong colocalization between
AT2Rs and MitoTracker within the mi-
tochondria.
Fig. 3. Immunoelectron microscopic localization of AT2Rb i n d i n gt oA n gi n
the mitochondria by using a gold-labeled anti-AT2R antibody (12 nm gold)
and a gold-labeled anti-Ang antibody (6 nm gold). Shown is colocalization of
AT2Rs with Ang in sections of mouse hepatocytes (A), kidney tubular cells (B),
neurons (C), and cardiac myocytes (D).
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I3. c. RAS Effects Upon Mitochondria 
 
I3. c. i. Mitochondrial Morphology & Number 
Long-term  administration  of  ang  II  to  rats  leads  to  significant  decreases  in 
mitochondrial  number  (de  Cavanagh  et  al.,  2007,  Basso  et  al.,  2007)  and  reduced 
expression  of  mitochondrial  metabolism  genes  such  as  those  involved  in  the  Krebs 
cycle (Larkin et al., 2004). It also mediates age-related structural changes (e.g. loss of 
cristae, mitochondrial swelling and decreased overall number of mitochondria) within 
mitochondria (de Cavanagh et al., 2007, Basso et al., 2007). RAS-inhibition (via AT1R 
blockers or ACE-I), however, is capable of reversing these effects (Chen et al., 2004, de 
Cavanagh  et  al.,  2003,  De  Cavanagh  et  al.,  2005,  de  Cavanagh  et  al.,  2006,  de 
Cavanagh  et  al.,  2008a),  preserving  mitochondrial  number  and  morphology,  and 
reversing  age-related  structural  changes  (Basso  et  al.,  2007).  This  also  upregulates 
expression of energy production genes (mitochondrial ETC and krebs cycle genes) in 
diabetic mice (Chen et al., 2004). Further genes downregulated by ang II action at the 
AT2R  include  those  involved  in  mitochondrial  biogenesis,  leading  to  reduced 
mitochondrial  content  and  mitochondrial  membrane  potential  in  C2C12  (mouse 
myoblast cell-line) cells and reduced mitochondrial content in mouse skeletal muscle 
(Mitsuishi et al., 2009). 
 
Ang  II  may  also  induce  integrin  signaling,  resulting  in  the  release  of  transforming 
growth factor-1 (TGF-1), modification of extracellular matrix (ECM) composition and 
structure, and cytoskeleton reorganisation (de Cavanagh et al., 2009). Mitochondria rely 
upon cytoskeletal dynamics for physiological motility, morphology and localization, 
and  may  therefore  have  secondary  effects  upon  mitochondrial  function,  potentially 
contributing to pathological conditions, such as cardiovascular and renal fibrosis (de 
Cavanagh et al., 2009). 
 
 
I3. c. ii. Age-Related Changes & Life-Span 
Ang II may act as a mediator of the aging process by augmenting mitochondrial oxidant 
damage. The administration of AT1R blockers or of ACE-I reduces oxidant production, Hepatic Mitochondrial Renin-Angiotensin Systems 
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preserves  mitochondrial  number  and  morphology,  and  prevents  the  reduction  in 
mitochondrial DNA content associated with aging. AT1R deficient mice demonstrate a 
25%  longer  life-span  than  mice  with  AT1  receptors  (mean  life  span  31.20±2.31  vs. 
24.81±3.10 months) (Cassis et al., 2010). The aging process is frequently associated 
with a reduction in mitochondrial number and changes in mitochondrial structure, such 
as swelling, shortening of the cristae, and matrix vacuolization, and therefore lowering 
RAS levels may prolong life by preventing such changes. Such AT1R knockout mice 
also have increased numbers of mitochondria; upregulation of pro-survival genes sirtuin 
3 (NAD-dependant deacetylase important in ageing, stress resistance and regulation of 
metabolism) and Nampt (nicotinamide phosphoribosyltransferase, a glycosyltransferase 
involved  in  nicotinamide  metabolism);  decreased  end-organ  damage,  cardiovascular 
injury and atherosclerosis; and decreased ROS and peroxynitrite despite normal body-
weight, physical activity and food intake (Benigni et al., 2009, Cassis et al., 2010). 
 
 
I3. c. iii. RAS and Reactive Oxygen Species 
Ang  II  increases  mitochondrial  ROS  production  and  may  contribute  to  oxidative  stress 
damage by uncoupling endothelial nitric oxide synthase, switching generation of nitric oxide 
(NO) to superoxide production (via NF-kappaβ) (Dikalova et al., Kimura et al., 2005). Ang 
II also binds to the AT1R, leading to generation of ROS within the cytosol, through PKC-
dependent (protein kinase c) activation of NAD(P)H Oxidase (Doughan and Dikalov, 2005). 
Subsequent  interaction  between  NO  and  superoxide  generates  peroxynitrite,  a  cytotoxic 
anion that inhibits mitochondrial electron transport, as well as destroying DNA and cellular 
proteins. Such highly reactive oxygen species can create a positive feedback loop by further 
activation  of  cellular  NADPH  oxidase  (see  Figure  I15)  and  can  also  directly  inactivate 
mitochondrial  complexes,  possibly  via  tyrosine  nitration,  and  result  in  uncoupling  of 
oxidative phosphorylation (Vatassery et al., 2004). Ang II similarly increases mitochondrial 
ROS and superoxide production in neurons, which mediates ang II-induced activation of 
calmodulin kinase II and inhibition of neuronal potassium current (Yin et al., 2010). 
 
Thus, ang II stimulates both cytosolic and mitochondrial reactive oxygen species (ROS) 
generation, as well as altering O2 consumption and contributing to cachexia (Brink et al., Hepatic Mitochondrial Renin-Angiotensin Systems 
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1996, Cassis et al., 2002). Selective blockade of NADPH oxidase (by apocynin) or PKC (by 
chelerythrine) dramatically attenuates mitochondrial ROS generation in response to ang II 
within isolated mitochondria or intact bovine aortic endothelial cells (Doughan et al., 2008). 
Meanwhile, SiRNA (small interfering RNA) depletion of p22phox, an essential component 
of NADPH Oxidase, leads to further significant decreases in mitochondrial ROS production 
in  mitochondria  isolated  from  ang  II-treated  cells  (Doughan  et  al.,  2008).  Ang  II 
administration also results in reductions in mitochondrial glutathione, the major endogenous 
antioxidant  (which  can  be  prevented  with  RAS  antagonists)  (Vatassery  et  al.,  2004, 
Pompella et al., 2003, Doughan et al., 2008), potentially sensitizing mitochondria to further 
ROS damage, as well as diminishing mitochondrial respiratory control ratio (Doughan et al., 
2008). 
 
Thus, under normal physiological conditions, the capacity of ang II to promote oxidative 
stress is tightly regulated. By contrast, in conditions associated with RAS overactivation, 
such  as  hypertension,  diabetes  and  ageing,  dysregulation  of  ang  II-dependent  ROS 
generation may become a significant contributor to cell oxidation and tissue damage, as well 
as  reduction  of  bioenergetic  synthesis  and  derangement  of  mitochondrial  ROS-mediated 
signals.  In keeping with this, ang II administration to Ren2 rats (which over-express renin, 
and  exhibit  elevated  endogenous  ang  II  levels)  causes  ultrastructural  abnormalities, 
decreased  mitochondrial  content,  decreased  palmitate  oxidation,  decreased  enzymatic 
activity  and  decreased  levels  of  cytochrome  c,  cytochrome  c  oxidase  subunit  I,  and 
mitochondrial transcription factor A (Wei et al., 2009). These effects are ameliorated by 
ARB administration, substantially attenuating mitochondrial lipid peroxidation in hepatic 
tissue and preventing hepatic steatosis (Wei et al., 2009).  
 
 
I3. c. iv. RAS and Mitochondrial Function (see Figure I15) 
Isolated mitochondria from rats treated with the ACE inhibitor enalapril exhibit significantly 
lower  energy  transfer  through  complexes  I  to  III  (measured  as  the  ratio  of 
NADH/cytochrome c oxidoreductase activity), as well as lower cytochrome oxidase activity 
and higher UCP-2 content (Piotrkowski et al., 2007), with the authors suggesting that these Hepatic Mitochondrial Renin-Angiotensin Systems 
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data  demonstrate  a  direct  effect  of  ACE  inhibition  upon  mitochondria;  however,  no 
mechanism for such action, and no further discussion of why a reduction in energy transfer 
at the ETC would be beneficial, was postulated.  
 
In treated heart failure patients, cardiac oxidative capacity was found to be 25 % lower than 
in patients without heart failure; however, ACE-I was capable of partially protecting cardiac 
mitochondrial function (oxygen consumption measured in fresh saponin-skinned fibers from 
rat  left  ventricle)  and  transcription  cascade  (downregulation  of  expression  of  multiple 
mitochondrial  genes  encoded  by  both  nuclear  and  mitochondrial  genomes,  including 
mitochondrial  transcription  factor  A  and  COX)  in  a  rat  model  of  myocardial  infarction 
(Garnier et al., 2009). Rats treated with a low (no effects upon blood pressure) dose of 
enalapril  demonstrated  lower  MMP-2  (Matrix  Metalloproteinase  2)  activity,  but  higher 
levels  of  cytochrome  c  oxidoreductase  activity,  eNOS  protein  and  activity  and  mtNOS 
activity (Piotrkowski et al., 2009). 
 
Ang  II  also  depolarises  mitochondrial  membrane  potential  in  islated  mitochondria  from 
bovine aortic endothelial cells (Dikalova et al., 2010); whereas, Losartan treatment results in 
an increased rate of ATP production and in elevated concentrations of coenzyme Q9 and 
Q10 (Sumbalova et al., 2010). Recent novel findings also suggest that ang II stimulates 
opening of mitochondrial K
+ATP channels, depolarizes mitochondrial membrane potential 
and  increases  mitochondrial  ROS  production,  resulting  in  activation  of  redox-sensitive 
MAPK (mitogen-activated protein kinase) (Zhang et al., 2007). Hepatic Mitochondrial Renin-Angiotensin Systems 
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Figure I15. Ang II induces endothelial Nitric Oxide Synthase uncoupling, switching from 
Nitric Oxide to Superoxide production, as well as potentially having direct action upon 
mitochondrial reactive oxygen species production; a pathway that occurs even under normal 
physiological conditions (pathway in black), but when the RAS pathway is increasingly 
activated to above physiological levels (pathway in red), it may lead to various pathological 
states. 
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I4. Summary & Rationale 
 
I4a. Summary of Published Literature  
Ang II has been detected in rat heart, brain and smooth muscle cell mitochondria, utilising 
125-I  labeled  ang  II  (Robertson  and  Khairallah,  1971a,  Sirett  et  al.,  1977),  and  ang  II 
immunoreactivity  has  also  been  observed  in  rat  cerebellar  cortex  mitochondria  via 
immunogold  staining  techniques  (Erdmann  et  al.,  1996).  Further,  in  rat  adrenal  zona 
glomerulosa, renin, angiotensinogen and ACE have been detected within intramitochondrial 
dense bodies (Peters et al., 1996). Such data suggest the intramitochondrial generation of 
ang II, which might have direct effects on mitochondrial function. In support, ang II can 
stimulate production of mitochondrial reactive oxygen species in vascular smooth muscle 
cells  and  in  rat  aorta  in  vivo  (Kimura  et  al.,  2005),  via  NAD(P)H  oxidase  activation 
(Doughan and Dikalov, 2005). Recent observations also reveal that ang II administration 
leads  to  a  decrease  in  mitochondrial  membrane  potential,  possibly  as  a  result  of  ROS 
generation (Kimura et al., 2005). RAS antagonists are capable of preventing or reversing 
many of these effects: ACE-inhibitors prevent age-related changes in mitochondrial number 
and form in murine renal cells, myocardiocytes and hepatocytes (Ferder et al., 1993, de 
Cavanagh et al., 2007, de Cavanagh et al., 2003). Furthermore, the expression of genes 
related to mitochondrial energy production is up-regulated in captopril-treated diabetic rats 
(Chen et al., 2004). 
 
Therefore, studies to date appear to indirectly suggest that a mitochondrial RAS exists, and 
that  it  may  contribute  to  physiological  mitochondrial  function  and  pathophysiological 
mitochondrial dysfunction. Ang II antagonism, meanwhile, is not only capable of preventing 
these effects, but also improves mitochondrial function. However, the precise mechanisms 
underlying such mitochondrial effects require further elucidation and might be mediated 
through  diverse  cellular  signaling  pathways,  or  alternatively  via  direct  effects  upon 
mitochondria, as suggested by the presence of RAS components in/on mitochondria. 
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I4b. A Mitochondrial RAS: Unanswered Questions 
The mitochondrial genome does not contain DNA for any RAS components and therefore it 
must  be  inferred  that  RAS  components  located  within  mitochondria  have  been  nuclear-
encoded and imported from the cytoplasm (Neupert, 1997). Indeed, many mitochondrial 
proteins  are  nuclear-generated,  containing  an  amino-terminal  mitochondrial  localization 
sequence  that  allows  mitochondrial  delivery  via  cytosolic  chaperones,  where  receptor-
mediated  ATP-dependent  uptake  occurs  (Roise  and  Schatz,  1988).  However,  no  RAS 
components have been shown to be synthesized with such a targeting sequence, although the 
identification  of  a  number  of  nuclear-encoded  mitochondrial  transmembrane  proteins 
without such a targeting sequence (such as adenine nucleotide translocase) and some that 
contain an altered targeting sequence (e.g. CYP11B1 and P450SCC) does not completely 
exclude the mitochondrial import of RAS components (Pfanner et al., 1987, von Heijne et 
al., 1989).  
 
Renin  is  the  most  investigated  putative  mitochondrial  RAS  component  to  date  and 
traditionally was considered to be a secretory protein targeted to the secretory pathway via 
the  ER  and  golgi  apparatus,  a  pathway  that  does  not  allow  segregation  of  renin  or  its 
precursors to the mitochondria. However, multiple renin transcripts are now known to exist, 
one of which has been shown to contain an amphiphilic structure that may be capable of 
acting  as  a  mitochondrial  import  sequence  for  receptor-mediated  mitochondrial  uptake. 
Further, some renin transcripts are now known to contain alternative start sites that may 
contain  an  extended  amino-terminal  with  high  hydrophobicity  that  could  be  used  for 
mitochondrial import (Dzau et al., 1988). Another possibility is the existence of an internal 
targeting signal, such as that found in cytochrome c, which is not cleaved (Folsch et al., 
1996,  Nicholson  et  al.,  1988,  Lill  et  al.,  1992).  However,  renin  has  been  identified  in 
mitochondrial dense bodies (Peters et al., 1996), which are likely to be located within the 
mitochondrial  matrix,  requiring  transport  across  both  the  mitochondrial  inner  and  outer 
membrane; whereas, proteins with an internal targeting sequence are usually located on the 
inner membrane or in the inter-membrane space (Clausmeyer et al., 1999). 
 
Similarly, Abadir et al (2011) reported the presence of the AT2R on mitochondrial inner 
membranes; however, the mechanism required for the transport of a seven transmembrane 
domain G-coupled receptor across the outer mitochondrial membrane remains unknown. Hepatic Mitochondrial Renin-Angiotensin Systems 
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A1. Aims 
The identification of a functioning mitochondrial RAS (mRAS) may aid in understanding 
the mechanism of interaction between mitochondria and various disease states, and existing 
data suggest the association of individual RAS components with mitochondria, where they 
may influence mitochondrial function. However, such studies are few and contain inherent 
and multiple limitations at a basic level: they address a limited range of cells only, have 
often relied upon immunocytochemistry/immunohistochemistry alone to demonstrate RAS 
components, have rarely sought to identify the co-existence of multiple RAS components, 
and have failed to seek the presence of some entirely. Thus, the existence of a putative 
mitochondrial RAS remains in doubt and further exploration, utilizing alternate techniques, 
is required. 
 
These issues were addressed by determining the presence of all major RAS components in 
the mitochondria of liver cells (from rat liver tissue and liver cell-line, rather than just cell-
line alone; contain high density of mitochondria) utilizing a number of antibodies (rather 
than  relying  on  a  single  antibody)  and  techniques  (rather  than  immunocytochemistry/ 
immunohistochemistry alone). 
 
 
A2. Hypotheses 
The hypotheses tested were: 
1.  RAS components can be found within mitochondria derived from rat liver tissue and 
a  liver  cell-line,  utilizing  Western  blotting,  confocal  microscopy  and  electron 
microscopy techniques. 
2.  Addition of RAS components to liver cells adversely affects a variety of hepatic 
mitochondrial  functions  (as  assessed  via  measurement  of  oxygen  consumption, 
mitochondrial  membrane  potential,  NADH  concentration  and  calcium 
concentration);  whereas,  RAS  antagonism  leads  to  improvements  in  hepatic 
mitochondrial function. Hepatic Mitochondrial Renin-Angiotensin Systems 
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A3. Experimental Plan 
 
A3.i.  Investigation  of  the  Presence  of  RAS  Components  within  Hepatic 
Mitochondria 
Initially, a plan was devised to investigate the presence of RAS components within rat liver 
tissue and a liver cell-line utilizing the following techniques and chronology. 
 
A3.i.  a.  Western  Blotting:  Western  blotting  was  performed  upon  subcellular  fractions 
(produced via differential centrifugation), including mitochondrial fractions, isolated from 
both rat liver tissue and a liver cell-line. The purity of each subcellular fraction was assessed 
by staining for proteins known to be located within each specific sub-fraction. The presence 
of all RAS components was subsequently assessed in each sub-cellular fraction. Multiple 
antibodies (from multiple manufacturers) to each RAS component were sourced and utilized 
to  assess  the  specificity  and  sensitivity  of  such  antibodies  and  to  avoid  the  problems 
associated  with  the  use  of  single  antibodies.  The  optimal  antibodies  for  each  RAS 
component were subsequently utilized for confocal and electron microscopy.  
 
A3.i.  b. Immunofluorescence & Confocal Microcopy: Immunofluorescence and confocal 
microscopy was performed upon whole cells from a liver cell-line and the presence of all 
RAS components was assessed. The intra-cellular and intra-mitochondrial location of RAS 
components was subsequently investigated and co-staining for known nuclear (DNA) and 
mitochondrial  (ATP  Synthase)  constituents  was  performed  to  act  as  positive  controls. 
Further  negative  control  images  were  taken  by  performing  staining  with  primary  and 
secondary antibody alone.   
 
A3.i.  c.  Immunogold  Staining  and  Electron  Microscopy:  Immunogold  staining  and 
electron  microscopy  was  performed  upon  rat  liver  tissue  and  a  liver  cell-line  and  the 
presence of all RAS components were assessed. Negative control images were taken by 
performing staining with primary and secondary antibody alone.   
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A3.ii.  Investigation  of  the  Effects  of  RAS  Agonism/Antagonism  upon 
Mitochondrial Function 
Subsequently, I planned to investigate the result of adding RAS agonists and antagonists to 
live cells from a liver cell-line, utilizing the following techniques and chronology. 
 
A3.ii.  a.  Functional  Fluorescence  Microscopy:  The  effect  of  adding  angiotensin  II, 
losartan and PD123319 upon cellular NADH and calcium concentration, and mitochondrial 
membrane potential, was assessed. 
 
A3.ii.  b.  Oxygen  Consumption:  The  effect  of  adding  angiotensin  II,  losartan  and 
PD123319 upon oxygen consumption was assessed. 
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METHODS 
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M1: Materials 
 
M1. a. Dyes & Probes 
 
M1. a. i. Tetramethylrhodamine, methyl ester (TMRM) (Invitrogen Molecular Probes, 
Carlsbad, CA, USA) 
TMRM  is  a  cationic,  mitochondrial-selective  probe  that  is  utilised  for  labeling  and 
measuring  mitochondrial  membrane  potential  within  intact,  living  cells  via  confocal 
microscopy, flow cytometry or fluorometric measurements (Floryk and Houstek, 1999) . 
Due to its optical and chemical properties, alterations in mitochondrial membrane potential 
are observed as variations in fluorescence intensity but not in emission spectra (Loew et al., 
1993), thus distinguishing between signals from probe located within mitochondria, and 
signals  from  probe  situated  within  other  cellular  compartments.  Such  changes  in 
fluorescence intensity are usually expressed relative to control measurements rather than as 
exact  values,  which  can  be  difficult  to  accurately  determine.  It  is  added  in  low 
concentrations  (see  discussion  of  specific  experiments  for  exact  concentrations  used)  to 
avoid aggregation and fluorescence quenching and is subsequently excited at 500 nm. This 
approach allows sensitive measurements of changes in mitochondrial membrane potential 
and TMRM can be utilised in conjunction with confocal microscopy to perform analyses 
over time, or to assess the effects of adding or inhibiting certain molecules.  
 
M1. a. ii. Acetoxymethyl ester Fluo-4 AM  (Invitrogen Molecular Probes, Carlsbad, 
CA, USA) 
Fluo-4 is a green-fluorescent probe that binds to calcium and is utilised for measurement of 
calcium  concentration  within  living  cells.  It  is  commonly  administered  as  the  non-
fluorescent  Fluo-4  AM,  which  is  subsequently  cleaved  within  the  cell  to  produce  free, 
fluorescent  Fluo-4,  which  has  high  cell  permeability,  undergoes  40-100  x  increase  in 
fluorescence intensity upon calcium binding and is excited at wavelengths of 488 nm (Gee 
et al., 2000). It can similarly be observed with confocal microscopy in analyses of calcium 
concentration alterations over time. Hepatic Mitochondrial Renin-Angiotensin Systems 
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M1. a. iii. Hoescht 33258  (Sigma-Aldrich, St. Louis, MO, USA) 
Hoescht 33258 is a water-soluble, cell-permeable, Bis-benzimide dye, which binds to the 
minor  groove  of  double-stranded  deoxyribonucleic  acid  (DNA),  particularly  those 
sequences rich in adenine and thymine (Portugal and Waring, 1988). It can be utilised to 
stain DNA in live or fixed cells (Latt et al., 1975, Latt and Stetten, 1976) and is excited by 
ultraviolet light at 350 nm, emitting a blue fluorescent light at an emission maximum of 461 
nm. 
 
 
	 ﾠ
M1. b. Reagents 
 
M1. b. i. Rotenone  (Sigma-Aldrich, St. Louis, MO, USA) 
Rotenone  is  a  water-insoluble,  respiratory  chain  inhibitor  that  blocks  respiration  in  the 
presence  of  ADP  by  inhibiting  the  transfer  of  electrons  from  iron-sulphur  centres  in 
complexes  I  and  II  of  the  electron  transport  chain  to  Coenzyme  Q10  (ubiquinone) 
(Kuznetsov et al., 2008). Coenzyme Q10 is fat-soluble and acts as a mobile electron carrier 
in the mitochondrial membrane, delivering electrons to complex III and acting as a crucial 
cog in the electron transport chain machinery. 
 
Coenzyme Q10 and the electron transport chain are ubiquitous within eukaryotic cells and 
rotenone is therefore a potent poison, being historically used as an insecticide, pesticide and 
piscicide. 
 
M1. b. ii. Oligomycin (Sigma-Aldrich, St. Louis, MO, USA) 
Oligomycin is a macrolide isolated from Streptomyces diastatochromogenes that acts as an 
electron  transport  chain  inhibitor  by  inhibiting  phosphorylation  and  abolishing  ADP-
stimulated respiration in intact mitochondria. Oligomycin binds to oligomycin sensitivity 
conferring protein in the F0 polypeptide (subunits 6 and 9) of ATP synthase, a proton pore 
located  within  the  mitochondrial  membrane;  thereby  blocking  proton  conductance  and 
synthesis of mitochondrial ATP (Hundal et al., 1984).  
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M1.  b.  iii.  Carbonilcyanide  p-triflouromethoxyphenylhydrazone  (FCCP)  (Sigma-
Aldrich, St. Louis, MO, USA) 
FCCP is a small, amphipathic molecule that acts as a proton ionophore, forming a shield 
around  transported  protons  and  allowing  the  formation  of  a  polar  environment  for  the 
contained ion with a hydrophobic outer surface; and it is therefore capable of depolarizing 
both plasma membranes and mitochondrial membranes (To et al., 2010). Such activity is 
capable  of  resulting  in  uncoupling  the  link  between  the  respiratory  chain  and 
phosphorylation systems within intact mitochondria, dissipating the proton gradient before it 
can be used for oxidative phosphorylation. 
 
M1. b. iv. Angiotensin II (Alexis Biochemicals (Enzo Life Sciences), Exeter, UK; Cat. No. 
ALX-151-039-M005) 
The biological characteristics of Angiotensin II are described earlier (see Introduction page 
18 for more information). 
 
 
M1. b. v. Losartan Potassium (Tocris Bioscience, Bristol, UK; Cat. No. 3798) 
Losartan is a selective, competitive antagonist of the AT1R. Systemically it antagonises 
vasoconstriction and release of aldosterone, thereby resulting in reduction in blood pressure 
through  decreases  in  both  total  peripheral  resistance  and  venous  return.  It  has  similar 
antagonistic  effects  at  a  paracrine  and  autocrine  level.  It  is  well  absorbed  orally  and 
therefore  commonly  utilised  for  the  treatment  of  hypertension  (as  with  other  RAS 
antagonists e.g. ACE-inhibitors) and renal disease secondary to diabetes and hypertension. 
 
 
M1. b. vi. PD123319 ditrifluoroacetate ((6S)-1-[[4-(dimethylamino)-3- 
methylphenyl]methyl]-5-(2,2-diphenylacetyl)-6,7-dihydro-4H-imidazo[4,5-c]pyridine-
6-carboxylic acid (Tocris Bioscience, Bristol, UK; Cat. No. 1361) 
PD123319  is  a  potent,  selective,  non-peptide  AT2R  antagonist.  It  may  also  have  some 
antagonistic effects upon the action of Ang 1-7 (Walters et al., 2005, Bosnyak et al., 2011). Hepatic Mitochondrial Renin-Angiotensin Systems 
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M1. b. vii. Histamine (Sigma-Aldrich, St. Louis, MO, USA) 
Histamine  is  an  organic,  nitrogen-based  compound  with  multiple  functions,  including  a 
crucial role in immune responses. Its actions occur via binding with one of four histamine 
receptors (H1-4), all of which are G-protein coupled receptors, leading to an increase in 
intracellular calcium. 
 
 
 
M1. b. viii. Antibodies 
Primary  and  secondary  antibodies  to  both  RAS  components  and  standard  cellular 
components were sourced from a variety of manufacturers and utilized at manufacturers 
recommended concentrations (see Appendix Tables App2. a. and App2. b., pages 216-220 
for further details). 
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M2. Cell-lines & Tissues 
 
M2. a. HeLa Cells 
A cell-line derived from cervical cancer cells, which contain a chromosome number of 82, 
with four copies of chromosome 12 and three copies of chromosomes 6, 8, and 17. The cells 
proliferate  rapidly  and  contain  a  version  of  telomerase,  which  prevents  the  incremental 
shortening  of  telomeres  during  cell  division,  allowing  them  to  circumvent  the  Hayflick 
Limit and achieve immortality (Ivankovic et al., 2007). HeLa cells contain no functioning 
angiotensin receptors [personal communication: Peter Varnai (Semmelweis Medical School, 
Budapest, Hungary)]. HeLa cells were kept in an incubator at 38 °C inside a 75 cm
2 flask 
containing Dulbecco’s modified eagle’s medium (DMEM (Cat. No.41966052); Invitrogen, 
Carlsbad, CA, USA), foetal bovine serum (FBS) and streptomycin. 
 
 
M2. b. HepG2 Cells 
An  immortal  cell-line  derived  from  well-differentiated  hepatocellular  carcinoma  cells, 
which contain 55 chromosomes. HepG2 cells display robust morphological and functional 
differentiation, rendering them a good model for the in vitro study of human hepatocytes. 
 
HepG2 cells were kept in an incubator at 38 °C inside a 75 cm
2 flask containing Dulbecco’s 
modified eagle’s medium (DMEM (Cat. No.41966052); Invitrogen, Carlsbad, CA, USA), 
FBS and streptomycin. 
 
 
M2. c. Rat Liver Tissue 
Rat livers were surgically removed from Sprague-Dawley rats held at University College 
London (London, UK), where all Home Office regulations and codes regarding the housing 
and maintenance of the animals are strictly adhered to. Rats were humanely euthanised by 
placing them in a chamber within which the concentration of CO2 was gradually increased. Hepatic Mitochondrial Renin-Angiotensin Systems 
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The  rats  were  subsequently  dissected  and  the  liver  removed  by  surgical  division  of  its 
anatomical attachments.  
 
 
M2. d. Cell Culture 
M2. d. i. Cell Passage 
Cells were viewed under a light microscope to ensure 90–100 % cellular confluence within 
a flask. Spent medium was subsequently removed from the flask and the cells washed with 
phosphate buffered saline (PBS) and 1 ml of dilute trypsin (serine protease) solution added 
to the flask to hydrolyse and break attachments between the cells and the flask. The flask 
was then incubated at 38 °C for 3-5 minutes and the flask imaged again to ensure the cells 
have separated from the flask and are now suspended in solution. DMEM (6ml containing 
FBS and streptomycin) was added to the flask and rinsed over the separated cells. The 
subsequent mixture of DMEM containing cells in solution was collected by pipette and a 
third (2.3 ml of total 7 ml) of the solution added to three new 75cm
2 flasks, which were 
supplemented with a further 12 ml of medium before being labeled and placed back in an 
incubator at 38 °C.  
 
M2. d. ii. Freezing Cells 
A 2.3 ml solution of cells/medium was centrifuged at 250 g for four minutes at 4 °C and 
spent medium separated from the cellular pellet. The pellet was then resuspended in 500 µl 
of FBS:Dimethyl Sulfoxide (DMSO) (90 % : 10 %) solution in a cryotube wrapped in 
paraffin-coated film. The cryotube was labeled, placed in ice for half an hour and then 
transferred to a freezer at -20 °C. 
 
M2. d. iii. Coverslips 
Cell/medium solution (7 ml) from cell passage was further diluted with 5 ml of DMEM. The 
subsequent 12 ml of solution was gently agitated and 2 ml of solution added to each well of 
a 6-well plate, within which a 22 mm cover-slip had already been placed. The 6-well plate Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      67	 ﾠ
was labeled and returned to an incubator at 38 °C to allow the cells to grow on the coverslip. 
Cover-slips  were  subsequently  removed  following  adequate  growth  by  removing  spent 
medium with a pipette and extracting the cover-slip from the well utilising forceps. 
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M3. Cellular Sub-Fractionation & Mitochondrial  
Isolation 
 
M3. a. Principle 
Differential centrifugation and percoll density gradient separation is a method of separating 
cellular  compartments  (cellular  sub-fractionation)  based  upon  their  density  (low  density 
components being cell membrane, mitochondrial associated membranes and endoplasmic 
reticulum; high density being mitochondria and nucleus), and was performed based upon 
standard methodologies (Sims and Anderson, 2008). Typically, sub-cellular fractionation 
performed on cells grown in flasks will yield smaller fractions than large pieces of tissues, 
rendering some of the sub-fractions isolated unsuitable for further experimentation because 
of the low protein concentration and volume. 
 
M3. b. Sample Homogenisation 
Freshly  harvested  livers  from  Sprague-Dawley  rats  or  cells  gathered  from  flasks 
immediately following trypsin isolation were stored in cold PBS, on ice, and kept on ice 
throughout the mitochondrial isolation process (minimum 4° C). Rat liver samples were 
initially homogenized by cutting into small pieces/mincing with scissors, while repeatedly 
washing  with  PBS  until  the  supernatant  was  clear  and  blood-free  (to  prevent  sample 
contamination by blood cells). The cell or tissue samples were mixed with Solution A (1 ml 
per  gram  of  tissue)  and  Protease  Inhibitor  (Protease  Inhibitor  cocktail  P8340;  Sigma-
Aldrich,  St.  Louis,  MI,  USA)  added  (1  µl  per  gram  of  tissue).  Samples  were  further 
homogenised utilising a Dounse homogeniser (at least 40 runs total: 20 runs with loose-
fitting Teflon pestle and 20 runs with tight-fitting Teflon pestle) and a drill-powered Potter-
Elvehjem homogeniser (at least ten runs).  The resultant homogenate (H) was aliquoted into 
2  ml  samples  and  was  either  stored  at  -20 
oC  in  cryotubes  or  immediately  underwent 
differential centrifugation. 
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M3. c. Differential Centrifugation (See Figure M1) 
The homogenate (H) was centrifuged at 800 times gravity (g) at 4 °C for ten minutes in a 
Beckman  J2-MC  centrifuge  (with  JA-20  rotor)  to  yield  a  nuclear  pellet  (N)  and  a 
postnuclear supernatant (PNS). N was subsequently resuspended in solution A.  
 
PNS was spun at 10,300 g for ten minutes at 4 °C in a Beckman J2-MC centrifuge (with a 
JA-20 rotor) to yield a crude mitochondrial pellet (CM) and a postmitochondrial supernatant 
(PMS).  
 
PMS was centrifuged at 25,000 g for 30 minutes at 4 °C in a Beckman J2-MC centrifuge 
(with  a  JA20  rotor)  to  yield  an  enriched  lysosomal  pellet  (L)  and  a  postlysosomal 
supernatant (PLS). 
 
PLS was centrifuged at 100,000 g for one hour at 4 °C in a Beckman 70 Ti rotor centrifuge 
to yield a microsomal pellet (MS) and a supernatant enriched with cytosolic proteins (C). 
MS was resuspended in Solution A. All samples under investigation (H, C, N, L, MS, CM, 
PM, MAM) were subsequently aliquoted and stored at -20 C. 
 
 
M3. d. Percoll Density Gradient Separation 
CM was gently layered on top of Solution B and 30 % Percoll (by volume) in a 10 ml 
polycarbonate ultracentrifuge tube and centrifuged at 95,000 g for 30 minutes at 4 °C in a 
Beckman  L-70  Ultra-Centrifuge  (with  SW41  T  rotor)  to  yield  two  fractions:  an  upper 
diffuse white band (mitochondria associated membranes; MAM) and a lower, denser band 
containing purified mitochondria (PM) (see Figure M2). 
 
PM was removed carefully, diluted with Solution A and washed twice by centrifuging at 
6300 g for ten minutes to remove the Percoll, and then resuspended in Solution A and stored 
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The MAM fraction was carefully removed and washed by centrifuging in Solution A at 
6300 g for ten minutes at 4 °C. The supernatant was further centrifuged at 100,000 g for one 
hour at 4 °C in a Beckman 70 Ti rotor and the pellet resuspended in Solution A. 
 
The various pellets subsequently underwent protein quantification. 
Figure M1. Summary of mitochondrial isolation by differential centrifugation and percoll 
density gradient separation. 
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Figure M2. Schematic diagram of mitochondria-associated membranes (MAM) and pure 
mitochondria  (PM)  layers  isolated  following  cellular  sub-fractionation  by  differential 
centrifugation and percoll density gradient separation. 
 
 
M3. e. Protein Quantification 
The  following  process,  utilizing  a  BCA  (Bicinchoninic  acid)  protein  assay  kit,  allowed 
colourimetric detection and quantification of total protein concentrations by relying on the 
chelation of copper with peptides/proteins containing three or more amino acid residues, 
within an alkaline environment (containing sodium potassium tartrate), to form a light blue 
complex  through  the  production  of  reduced  Cu
1+  from  Cu
2+  (Biuret  reaction).  Cu
1+  is 
subsequently detected by chelation of two BCA molecules with one Cu
1+ ion, in a highly 
sensitive and selective fashion, producing a water-soluble, purple solution, which exhibited 
a strong linear absorbance at 562 nm with increasing protein concentrations. The absorbance 
was then compared to samples containing standard concentrations of common proteins, such 
as  BSA,  which  have  been  prepared  alongside  the  sample  under  analysis.  Protein 
quantification was performed utilising a BCA protein assay kit (Thermo Scientific (Cat. No. 
#23225);  Waltham,  MA,  USA)  and  standard  methodology  (for  full  protocol  see 
http://www.piercenet.com/instructions/2161296.pdf).   
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A set of protein solutions containing set concentrations were created, utilising the BSA 
ampoules  contained  within  the  protein  assay  kit,  to  produce  a  range  of  diluted  protein 
standards within a working range of 20-2000 µg/ml protein concentration. The working 
reagent containing Cu
2+ ions and an alkaline environment was also made up in preparation 
for the reaction. The samples under investigation were also pipetted into 25 µl aliquots, 
ready for analysis. Each standard or sample (25 ul) was subsequently placed into a well in a 
32-well  microplate.  Working  reagent  (200  ul)  was  added  to  each  well  and  the  solution 
placed on a shaker for 30 seconds, before incubation at 37 °C for 30 minutes. Absorbance 
was subsequently measured at 562 nm on a plate reader. The average 562 nm absorbance of 
the blank standards prepared (containing no protein) was subtracted from all other standards 
and  samples.  A  standard  curve  was  subsequently  plotted  of  the  corrected  562  nm 
measurement of each BSA standard (y axis) against its concentration in µg/ml (x axis). This 
standardised curve was subsequently utilised to determine the protein concentrations of all 
unknown samples. 
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M4. Western Blotting 
 
M4. a. Principle 
Western  blotting  is  a  process  by  which  proteins  are  separated  by  polyacrylamide  gel 
electrophoresis,  before  being  transferred  to  a  nitrocellulose  or  polyvinylidene  difluoride 
(PVDF)  membrane.  The  membrane  is  subsequently  imaged  by  applying  a  secondary 
antibody  linked  to  a  reporter  enzyme,  usually  horseradish  peroxidase,  which 
chemiluminesces  when  exposed  to  light  revealing  protein  ‘bands’  on  the  surface  of  the 
membrane. Optical density analysis is subsequently utilised to determine the relative amount 
of protein present in each band and band size approximations are made by comparing the 
stained bands to the marker loaded at the time of electrophoresis.   
 
 
M4. b. Polyacrylamide Gel Electrophoresis 
Samples  derived  from  cellular  sub-fractionation  were  separated  by  polyacrylamide  gel 
electrophoresis  utilising  standard  techniques,  following  protein  quantification  (See 
http://tools.invitrogen.com/content/sfs/manuals/blotmod_pro.pdf and 
 http://tools.invitrogen.com/content/sfs/manuals/surelock_man.pdf  for  full  protocol). 
Samples  were  initially  diluted  into  30  µl  aliquots  containing  30  µg  of  protein  under 
investigation per sample (as per protein quantification results). The separate sample aliquots 
were subsequently pipetted into wells in a Bis-Tris gel (NuPAGE® Novex 4-12% Bis-Tris 
gel (1.5 mm, 10 well) (Invitrogen (Cat. No. NP0335BOX); Carlsbad, CA, USA)), with 6-8 
µl of protein size standards (Precision Plus protein standards (Bio Rad Laboratories (Cat. 
No. 161-0374); Hercules, CA, USA)) pipetted into the final 10th well. The gel was placed 
into an XCell II™ SureLock Mini Cell apparatus (Invitrogen (Cat. No. E19051); Carlsbad, 
CA, USA) containing running buffer (MOPS SDS running buffer (20x) (Invitrogen (Cat. 
No. NP0001); Carlsbad, CA, USA)) diluted with distilled water and 200 V applied for 45-60 
minutes (see Figure M3). Hepatic Mitochondrial Renin-Angiotensin Systems 
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Figure M3. Image of polyacrylamide gel electrophoresis utilising protein samples in a 4-12 
% Bis-Tris gel. Blue wells contain 30 µl of solution containing 30 µg of protein sample; 
whereas, purple wells contain 6-8 µl of protein size standards. 
 
M4. c. Transfer to PVDF Membrane 
Once electrophoresis was complete, the gel was removed from its cassette utilising a palette 
knife and placed in a sandwich setup within an electro-transfer apparatus (XCell II™ Blot 
Module apparatus, Invitrogen (Cat. No. E19051); Carlsbad, CA, USA) for transfer to a 
PVDF  membrane  (Immobilon-P  transfer  membrane,  Millipore  (Cat.  No.  IPVH00010); 
Billerica, MA, USA). The chamber was filled with transfer buffer (50 ml of NuPage transfer 
buffer (Invitrogen (Cat. No. SKU#NP0006)), methanol (100 ml) and distilled water (850 
ml) and 10 V applied continuously overnight at 4 °C. 
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M4. d. PVDF Membrane Antibody Staining 
The PVDF membrane was removed from the sandwich setup and placed in a glass jar. Non-
specific membrane-binding was prevented (‘blocking’) by soaking the membrane in PBS 
containing 5 % bovine serum albumin (BSA; Albumin from bovine serum (pH 5.4), Sigma-
Aldrich (Cat. No. A8022); St. Louis, MI, USA) solution containing a low percentage of 
Tween20 detergent for two hours at room temperature, while gently agitating on a rocker. 
Following blocking, a dilute PBS solution of primary antibody, BSA (2.5 %) and Tween20 
(0.1 %) was incubated with the membrane under gentle agitation for one hour at room 
temperature (specific antibody concentrations varied depending upon antibody utilised- see 
Appendix  Table  APP2.  a.  and  APP2.  b.).  Unbound  primary  antibody  was  removed  by 
subsequently  rinsing  the  membrane  in  a  low  concentration  of  PBS/Tween20  (0.1  %) 
solution twice for 30 minutes each, and the membrane then exposed to a a dilute PBS 
solution containing secondary antibody and BSA (2.5 %)/Tween20 (0.1 %) solution linked 
to a reporter enzyme (usually horseradish peroxidase) for one hour at room temperature, 
while  gently  agitating.  The  membrane  was  again  rinsed  in  low  concentration  Tween20 
solution twice for 30 minutes at room temperature to remove all excess antibody. 
 
 
M4. e. Membrane Imaging 
Immunoreactive bands were detected by placing the membrane on an acetate sheet and 
chemiluminescent detection reagents added (ECL Plus Western Blotting Detection Reagents 
(Cat. No. RPN2132), GE Healthcare/Amersham, Little Chalfont, UK). Excess solution was 
removed utilising absorbent filter paper and the membrane placed in a chamber (Chemidoc 
MP system, BioRad, Hercules, CA, USA) for antibody detection by chemiluminescence.  
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M5. Immunofluorescence 
 
M5. a. Principle 
The basic principle of immunofluorescence depends upon selectively exciting fluorescent 
molecules applied to cells or tissue sections, in such a way that each fluorescent molecule 
exists as a separate light source. When a molecule of fluorescent dye absorbs a quantum of 
light of sufficient energy, an electron is elevated to a higher energy level thus forming an 
excited state.  This electron will eventually return to its previous ‘ground’ state, and when it 
does it may emit a quantum of light.  In general less energy is emitted than was adsorbed 
and therefore the wavelength of fluorescent light emitted is no longer the same as that of the 
initial  light  adsorbed.    Thus  fluorescence  microscopy  is  useful  in  that  not  only  is  it 
extremely sensitive, but it is also highly specific. Fluorescence microscopy can also allow 
the analysis of the molecular properties and environment of the fluorescent molecules.  
 
Confocal microscopy is a technique that allows the analysis of light focused at an extremely 
narrow  band  within  a  specimen.    Thus  it  allows  the  user  to  gather  depth-selective 
information on the three-dimensional structure of a microscopic object, without mechanical 
sectioning and without confusion that can be caused by images derived from the areas above 
and below the section. The confocal microscope employs an illuminating laser light system 
that is very strongly convergent, producing a very shallow scanning spot in the object plane.  
The  light  or  fluorescence  reflected  back  from  this  spot  is  in  turn  directed  to  a 
photomultiplier through a detector pinhole.  The light is analysed here and displayed by a 
computer as a pixel on a screen.  In order to gain a complete image of the object, a system 
of mirrors is used to move the light point over the specimen, illuminating a single spot at a 
time.  The information from each individual spot is recorded and stored in the computer, and 
the image is simultaneously displayed on a high-resolution video monitor to create a visual 
image. The conjugation of the detector pinhole to the illumination pinhole ensures that it is 
only  information  from  the  focal  plane  that  reaches  the  detector.    This  accounts  for  the 
confocal microscope’s unique ability to create images of sections through a sample, and the 
user can literally dissect layer by layer through the entire thickness of the specimen. The 
out-of-focus regions are also subtracted from the image by the computer programme, thus 
enhancing its sharpness. Hepatic Mitochondrial Renin-Angiotensin Systems 
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M5. b. Cell Fixation & Permeabilisation 
Cells were grown on cover-slips, within a 6-well plate, in an incubator at 38 °C. When 
cover-slips were approximately two-thirds covered in confluent cells, spent medium was 
removed and the cover-slips were twice washed briefly with PBS (2 ml per well) at room 
temperature.  The  cells  were  subsequently  fixed  by  incubating  the  cover-slips  with  4  % 
paraformaldehyde for five minutes at room temperature (1 ml per well), and then twice 
washed at room temperature in PBS (2 ml per well), while gently agitating on a rocker. For 
further fixation, pre-cooled acetone (-20 °C; 1 ml per well) was added to the cover slips, 
which were left for ten minutes at -20 °C and then twice washed at room temperature in 
PBS  (2  ml  per  well),  while  gently  agitating  on  a  rocker.  The  cells  were  subsequently 
permeabilised by incubating cover-slips twice with 0.025 % Triton X-100 for five minutes 
at room temperature (1 ml per well), before washing twice with PBS (2 ml per well). To 
prevent non-specific antibody binding, the cover-slips were rested in blocking solution (10 
% donkey serum in PBS; Donkey Serum, Sigma-Aldrich (Cat. No. D9663); St Louis MI, 
USA) for 30 minutes at 4 °C, and then washed in 1 % donkey serum in PBS for five 
minutes. 
 
M5. c. Antibody Staining 
Following fixation and permeabilisation, the cover-slips were incubated for 18 hours (or 
overnight) at 4 °C with the primary antibody solution (primary antibody in 1 % donkey 
serum/PBS solution) in a sandwich setup (see Figure M4). The concentration of primary 
antibody  varied  according  to  the  specific  antibody  utilised  (for  further  information  see 
Appendix Tables App2. a. and APP2. b., pages 216-220).  Hepatic Mitochondrial Renin-Angiotensin Systems 
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Figure  M4.  Schematic  diagram  of  sandwich  setup  for  antibody  staining  and 
immunofluorescence. 
 
 
The cells were subsequently washed in PBS and 0.025 % Triton X-100 three times for five 
minutes  each,  while  gently  agitating  on  a  rocker  at  room  temperature.  They  were  then 
incubated  with  the  secondary  antibody  solution  (secondary  antibody  in  1  %  donkey 
serum/PBS solution) in a sandwich setup (see Figure M4) for one hour at room temperature 
in the absence of light. The concentration of secondary antibody applied varied according to 
the specific antibody utilised (see Appendix Tables App2. a. and APP2. b., pages 216-220 
for further information). The cells were washed again (PBS; two times for ten minutes, 
while  agitating,  in  the  absence  of  light)  and  then  incubated  with  Hoescht  33258  (1 
(Antibody) : 1000 (PBS); vol : vol) for one minute in a 6-well plate (1 ml per well), in the 
absence of light. The cells were washed again in PBS for ten minutes in the absence of light, 
the slides dabbed dry with filter paper and placed cell-side down onto a glass slide. The 
edges were sealed with nail varnish, protected from light by wrapping in foil and imaged. 
 
 
M5. d. Confocal Microscopy of Stained Cells 
Immunofluorescence was performed on a Zeiss LSM 510 META confocal microscope (Carl 
Zeiss; Oberkochen, Germany). 
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M6. Functional Fluorescence Microscopy 
 
M6. a. Principle 
Functional fluorescence microscopy refers to the process of imaging live cells on a confocal 
microscope to assess how the addition of certain substrates alters cellular processes in real-
time. It relies upon the initial addition of various fluorescent molecules to the live cell, 
which are detected at specific wavelengths, the intensity of which alter as the metabolic 
process  under  examination  changes;  thus  allowing  quantitative  study  of  molecular 
interactions within live cells (for further information see ‘M1. Materials’; page 61). Utilising 
this technique it is possible to measure real-time changes in cellular calcium and NADH 
concentration,  and  mitochondrial  membrane  potential,  as  well  as  various  other  cellular 
processes. 
 
M6. b. Preparation of Cover-Slips 
Live cells (HeLa or HepG2) were grown on 22 mm cover-slips in an incubator at 38 °C (for 
further  information  see  ‘M2.  Cell  Culture’;  page  66).  When  the  cells  reached  50-60  % 
confluent growth on the cover-slip, 25 µl TMRM and 1 µl Fluo-4 were added to the medium 
solution and the cover-slips again left at 38 °C in an incubator for 30 minutes. Finally, the 
cover-slips were washed with PBS three times to remove all excess dye. 
 
M6. c. Functional Microscopy 
The cover-slips were placed on a heated stage at 38 °C in a confocal microscope with UV 
laser capabilities (Zeiss LSM 510 META confocal microscope (Carl Zeiss; Oberkochen, 
Germany)) and left to equilibrate for 10 minutes prior to further assessment. A UV laser at 
543  nm  was  applied  to  the  live  cells  to  measure  mitochondrial  membrane  potential,  as 
extrapolated from TMRM fluorescence; cytosolic calcium was measured via excitation of 
Fluo-4 at 488 nm; and NADH concentration detected via autofluorescence at 364 nm. 
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A baseline measurement was taken for five minutes and various solutions added to the 
cover-slip with a pipette, to assess effects upon excitation at the various wavelengths under 
investigation. Solutions were added at 1 µM concentration and included angiotensin II, 
histamine, FCCP and rotenone (for further information see ‘M1. Materials’; page 61). 
 
M6. d. Results Analysis 
Intensity  of  fluorescence  at  the  various  wavelengths  was  assessed  utilising  pre-installed 
optical  density  software.  Alterations  in  fluorescence  between  baseline  and  post-reagent 
addition,  within  a  whole  field  under  investigation,  were  subsequently  quantified  and 
calculated. 
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M7. Immunogold Labeling & Electron Microscopy 
 
M7. a. Principle 
Transmission electron microscopes (EM) employ an electron beam emitted from an electron 
source, usually a tungsten filament cathode, which is controlled and focused by electrostatic 
and  electromagnetic  lenses,  to  illuminate  a  specimen  and  produce  a  magnified  image; 
whereas, scanning EM produces images by scanning over a sample with a high energy 
focused  beam  of  electrons,  which  interact  with  electrons  within  the  sample,  producing 
secondary electrons, transmitted electrons and back-scattered electrons, as well as X-rays, 
light and current. Electrons have wavelengths 100,000 x shorter than visible light (photons) 
and  electron  microscopes  therefore  achieve  much  greater  resolution  than  light-powered 
optical microscopes, potentially achieving magnifications of up to 10,000,000 x. Biological 
specimens for EM analysis are fixed, dehydrated and embedded within polymer resin, to 
allow thin sections to be prepared for analysis.  
 
M7. b. LR White processing 
Rat liver samples were dissected into small pieces with scissors/scalpel and fixed for 8-12 
hours (or overnight) in 4 % paraformaldehyde / 0.5 % glutaraldehyde (in 0.1 M cocadylate 
buffer at pH 7.4). Samples were subsequently washed in 4 % sucrose (in 0.1 M cocadylate 
(pH 7.4)) three times and stored at 4 ºC before being dehydrated in graded concentrations of 
ethanol (50 %; 70 %; 80 %; 85 %; and 95 %) for 60 minutes each, followed by three 
separate 30 minute exposures to 100 % ethanol.   
 
Samples were then infiltrated at room temperature with LR White low viscosity acrylic 
embedding medium (a polyhydroxy-aromatic, hydrophilic acrylic resin with low toxicity, 
ultra-low viscosity and low miscibility with water and gently shaken on a rotor for three 
separate four hour periods in graded solutions of LR White : 100 % ethanol solution (ratios 
of 1 : 1, 2 : 1 and 3 : 1) before being left in pure LR White for two 12-hour periods. Samples 
were then embedded and polymerized at 60 ºC for 20-24 hours. 
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M7. c. Immunogold Labeling 
Embedded tissue was subsequently cut into ultra-thin sections and mounted on formvar-
coated grids and allowed to dry. Once dried, the grids were washed with 0.05 M Tris-
buffered saline (TBS) containing 1 % bovine serum albumin (BSA; Albumin from bovine 
serum (pH 5.4; Sigma-Aldrich, St Louis, MI, USA)) for 10 minutes at room temperature and 
sections were then incubated overnight with the primary antibody of choice (in 0.05 M TBS 
with 1 % BSA at 4º C).  
 
The  grids  were  then  washed  in  0.05  M  TBS  with  0.05  %  Tween-20  three  times  and 
incubated for 1 hour at room temperature with the secondary antibody of choice (in 0.05 M 
TBS with 1 % BSA at 4 ºC). 
 
Finally, the grids were washed in 0.05 M TBS with 0.05 % Tween-20 three times (each 5 
min length), and again in double-distilled water, before being allowed to dry. Sections were 
then  counterstained  with  4  %  uranyl  acetate  for  20  min,  followed  by  lead  citrate  for  5 
minutes, both at room temperature. 
 
M7. d. Electron Microscopy 
Fresh rat liver samples were delivered on ice to the electron microscopy unit at the Royal 
Free  Hospital  (Electron  Microscopy  Unit,  UCL  Medical  School,  Royal  Free  Campus, 
Rowland  Hill  Street,  Hampstead,  London  NW3  2PF),  where  sample  preparation  by 
dehydration, fixation and embedding, as well as all electron microscopy, was performed by 
experienced EM operators.  
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M8. Immunoprecipitation 
 
M8. a. Principle 
Crosslink  immunoprecipitation  refers  to  the  process  of  antigen  purification  utilising  a 
specific  antibody.  The  principle  involves  crosslinking  to  covalently  attach  a  specific 
antibody to a protein A/G agarose resin (recombinant protein combining antibody-binding 
domains from protein A and G), which is then incubated with a protein mixture containing 
the antigen, allowing the antibody : antigen complex to form. After washing to remove 
unbound, undesired sample components, the antibody : antigen complex, immobilised by 
crosslinking  with  disuccinmidyl  suberate  (DSS)  on  beaded  agarose  resin,  is  eluted  and 
separated by centrifugation (see Figure M5). 
Samples under investigation were immunoprecipitated utilising a Pierce Crosslink IP kit 
(Thermo Scientific (Cat. No.#26147); Waltham, MA, USA), with all steps carried out at 4 
°C (unless otherwise stated) and all centrifugations at low speed (1000-3000 g) for 30-60 
seconds (see http://www.piercenet.com/instructions/2162134.pdf for full protocol). 
 
 
Figure  M5.  A  schematic  diagram  demonstrating  crosslink  immunoprecipitation.  Figure 
taken from Piercenet (see http://www.piercenet.com/browse.cfm?fldID=FE0FBC6F-61BB-
41DF-AD2E-008247C95177). 
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M8. b. Binding of antibody with Protein A/G Agarose Resin 
A solution containing 10 µg of antibody was prepared through dilution of the antibody with 
coupling buffer and ultrapure water and then added to 20 µl of Pierce Protein A/G Plus 
Agarose  resin  and  mixed  on  a  rotor  for  30-60  minutes;  followed  by  washing  via 
centrifugation with coupling buffer. 
 
M8. c. Crosslinking of bound antibody 
The  prepared  antibody  :  resin  complex  was  incubated  with  DSS,  ultrapure  water  and 
coupling buffer and placed on a mixer for 30-60 minutes at room temperature. The solution 
was  washed  in  Elution  buffer  and  IP  /  Lysis  Wash  buffer  via  centrifugation,  prior  to 
proceeding to immunoprecipitation. 
 
M8. d. Immunoprecipitation 
The sample under investigation was diluted with IP / Lysis Wash buffer to create a volume 
of 300-600 µl containing 500-1000 µg of total protein. This was added to the prepared 
antibody : resin complex and incubated overnight on a rotor at 4 °C. 
 
M8. e. Antigen Elution 
The mixture was washed via centrifugation with IP / Lysis Wash buffer and Conditioning 
buffer and 5 ul of 1 M Tris (pH 9.5) added to neutralise the low pH and allow functional 
assays.  The  sample  was  incubated  and  centrifuged  with  elution  buffer  and  the  eluate 
collected for further analysis or stored at -20 °C. 
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M9. Mass Spectrometry 
 
M9. a. Principle 
Mass spectrometers are analytical tools that measure the molecular mass of samples applied 
to  them  with  an  exceedingly  high  degree  of  accuracy  that  allows  both  quantitative  and 
qualitative uses. Mass spectrometry can be used to quantify the amount of a compound or 
molecule in a sample, detect even minor changes in mass (such as the alteration of one 
amino  acid),  the  molecular  formula  of  organic  compounds,  or  a  compound’s  structural 
information, by observing its fragmentation.  
 
Mass spectrometers contain three fundamental parts: an ion source, which can convert gas 
phase  sample  molecules  into  ions  or  move  ions  in  solution  into  the  gas  phase;  a  mass 
analyser,  which  is  capable  of  sorting  ions  by  their  mass  via  the  application  of 
electromagnetic fields; and a detector, which assesses the abundance of each ion present. All 
three parts are maintained within a vacuum to allow the ionised molecules to travel from 
one end of the machinery to the other without the hindrance of air molecules and the whole 
system  is  controlled  by  computer  software.  Heavier  ions  travel  more  slowly  across  the 
machinery  and  the  subsequent  mass  :  charge  ratio  (m  /  z  spectrum)  is  compared  to  a 
database. Often a sequence tag of only 4-5 amino acids can be utilised to identify a protein 
or peptide from a database. 
 
The sample under investigation is introduced into the ionisation source, where its molecules 
become ionised. The ions are subsequently separated by the analyser according to their mass 
to charge ratio and the separated ions are subsequently detected in the detector and their 
frequency also assessed for subsequent presentation in the form of an m/z spectrum. 
MALDI–TOF (Matrix-Assisted Laser Desorption Ionisation–Time Of Flight) (Hillenkamp 
et al., 1991) is a type of mass spectrometer that is particularly useful in the assessment of 
thermolabile,  non-volatile  organic  compounds  of  high  molecular  mass  such  as  proteins, 
peptides  and  glycoproteins.  MALDI  involves  pre-mixing  the  sample  with  a  highly-
absorbent matrix compound in a volatile solvent, which is capable of converting laser light 
into excitation energy, with subsequent sample bombardment by laser light (usually pulsed Hepatic Mitochondrial Renin-Angiotensin Systems 
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nitrogen  laser  of  337  nm  wavelength)  to  produce  ionisation.  Proteomic  analysis  can  be 
performed utilising this technique by excising bands or spots from a gel, enzymatically 
digesting the peptides or proteins within each band or spot and then analysing the resultant 
mixture  via  MALDI-TOF.  The  result  can  be  compared  to  a  database  of  known 
peptides/proteins, where it is either identified as a known protein, or not identified because it 
is  previously  uncharacterised,  or  the  result  does  not  provide  enough  information  to 
distinguish it between a few potential results and further information is required, either 
through increasing the concentration of the molecule or cleaning of the sample. 
 
 
M9. b. Sample Preparation for Mass Spectrometry 
Samples under investigation underwent gel electrophoresis on a 4-12 % Bis-Tris gel, prior 
to  silver  staining  and  subsequent  excision  of  protein  bands  of  interest.  The  bands 
subsequently  underwent  reduction  and  alkylation,  prior  to  deglycosylation  and  trypsin 
digestion prior to proteomic analysis via mass spectrometry. 
  
M9. b. i. Silver Staining  
(see http://tools.invitrogen.com/content/sfs/manuals/silverquest_man.pdf for full protocol)  
Silver  staining  was  performed  utilising  the  SilverQuest
TM  Silver  Staining  Kit  For  Mass 
Spectrometry (Compatible Silver Staining of Proteins in Polyacrylamide Gels by Invitrogen, 
Carlsbad,  CA,  USA;  Catalogue  Number  LC6070).  Silver  staining  is  based  upon  the 
chemical reduction of silver ions to metallic silver on a protein band and is a sensitive 
method of detecting most proteins, capable of picking up protein concentrations at sub-
nanogram levels and is 30-fold more sensitive than coomassie staining (Rabilloud et al., 
1994). Ultrapure water was used throughout and all incubations were performed on a rotary 
shaker at a speed of 1 revolution/second at room temperature. 
 
After gel electrophoresis, the gel was removed from the cassette and placed in a glass jar, 
where it was rinsed with ultrapure water. The gel was subsequently fixed in 100 ml of 
fixative for 20 minutes. The fixative was subsequently removed and the gel washed in 30 % 
ethanol  before  that  was  also  removed  and  100  ml  of  sensitizing  solution  added  for  10 Hepatic Mitochondrial Renin-Angiotensin Systems 
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minutes. The sensitizing solution was removed and the gel washed again in 30 % ethanol for 
10 minutes and then in 100 ml of ultrapure water for 10 minutes before being incubated in 
100 ml of staining solution for 15 minutes. The staining solution was subsequently removed 
and the gel washed with ultrapure water for one minute before being incubated in 100 ml of 
developing solution for 4-8 minutes until the desired band intensity was achieved, at which 
point 10 ml of stopper was added to the gel still immersed in developing solution and the 
reaction  incubated  for  10  minutes.  When  the  solution  colour  changed  from  pink  to 
colourless (indicating that the development reaction has ceased) all solution was removed 
from the container and the gel washed in ultrapure water for 10 minutes. 
 
M9. b. ii. Deglycosylation (For full protocol see:  
http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Bulletin/pp0201bul.Par.0001.File.tm
p/pp0201bul.pdf) 
Deglycosylation  was  performed  using  the  Glycoprofile  II  Enzymatic  In-Solution  N-
Deglycosylation Kit (Sigma Aldrich, St. Louis, MI, USA; Cat No. PPO201). Glycosylation 
is  a  common  post-translational  modification  of  proteins  in  eukaryotic  cells,  where  such 
glycoproteins are crucial for a number of biological functions. Human glycoproteins contain 
one  of  three  major  types  of  oligosaccharide  or  glycan:  N-linked,  O-linked  or 
glycosylphosphatidylinositol  lipid  anchors,  although  variations  in  glycan  structure  and 
degree  of  saturation  of  available  glycosylation  sites  often  results  in  considerable 
heterogeneity in the mass and charge of glycoproteins. Removing a class of glycan aids in 
the  study  of  glycoproteins  and  removal  of  N-linked  glycans  in  particular  reduces  the 
heterogeneity of both mass and charge to assist in analysis by mass spectrometry. N-linked 
glycans link to the protein backbone via amide bonds to asparagine residues (whereas, O-
linked  attach  to  the  hydroxyl  group  of  serine  or  threonine),  which  can  be  broken  by 
enzymatic degradation utilizing peptide N-glycosidase F (PNGase F). The ensuing peptide 
is left intact apart from the deamination of asparagine to aspartic acid at the site of the 
attachment. 
 
The RNase B Standard (90 µl of 1.1 mg / ml) was added to a siliconised Eppendorf tube and 
5  µl  of  the  denaturant  Solution  (2  %  octyl  β-D-glucopyranoside  with  100  mM  2-Hepatic Mitochondrial Renin-Angiotensin Systems 
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mercaptoethanol) added and mixed briefly before incubation at 100 °C for 10 minutes. The 
solution was allowed to cool to room temperature and gently spun briefly before 5 µl of (1 
X)  Reaction  Buffer  was  added  and  the  solution  was  mixed  and  spun  again  briefly 
(glycoprotein concentration now 1 mg / ml). The solution was separated into two 50 µl 
aliquots, one to act as a control and the other as the working mixture. Then 5 µl of PNGase 
F Enzyme Solution (500 units / ml; 2.5 units of enzyme) was added to the working solution 
and 5 µl of ultrapure water to the control sample, and the solutions spun briefly before 
incubating at 37 °C overnight with 1000 µg of protein sample. The reaction was stopped by 
heating the solution at 100 °C for 10 minutes, before the solution was allowed to cool to 
room temperature and spun briefly in preparation for analysis. 
 
 
 
M9. b. iii. Trypsin Digestion  
(for full protocol see 
http://www.sigmaaldrich.com/etc/medialib/docs/Sigma/Bulletin/pp0100bul.Par.0001.File.tm
p/pp0100bul.pdf) 
Protein bands of interest were digested by the serine protease, trypsin, which hydrolyses 
peptide bonds at the carboxyl side of arginine and lysine residues, resulting in a solution 
containing  highly  specific  cleavage  sites  and  peptide  fragments.  Trypsin  digestion  was 
performed using the Trypsin Profile IGD Kit (Sigma Aldrich, St. Louis, MI, USA; Cat No. 
PPO100) and standard methodologies (Speicher et al., 2000, Sechi and Chait, 1998). 
The band of interest was excised from a gel, using a razor blade, and placed in a siliconised 
eppendorf tube using tweezers. The gel piece underwent destaining through twice adding 
200  µl  of  Destaining  Solution  and  incubating  at  37  °C  for  30  minutes.  Each  time,  the 
resulting solution was removed and discarded. The gel piece was subsequently dried in a 
centrifugal evaporator (Savant Speed Vac; Thermoscientific, Waltham, MA, USA) for 30 
minutes. 20 µl of trypsin solution (containing 0.4 ug of trypsin) and 50 µl of the Trypsin 
Reaction  Buffer  was  subsequently  added  to  the  gel  piece  and  the  solution  incubated 
overnight at 37 °C. The resultant solution, containing the extracted peptides was removed 
from the eppendorf tube and transferred to a new siliconised eppendorf tube and delivered 
for mass spectrometry as soon as possible. Hepatic Mitochondrial Renin-Angiotensin Systems 
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M9. c. Mass Spectrometry 
Mass  spectrometry  was  performed  on  a  dual-source  (MALDI  and  ESI  (Electrospray 
Ionisation)) time-of-flight mass spectrometer, by experienced technical staff, at one of two 
centres: Institute of Child Health, University College London, London, UK or Taplin Mass 
Spectrometry Facility, Harvard Medical School, Boston, USA. 
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M10. Oxygen Consumption 
 
M10. a. Principle 
Clark electrodes measure oxygen on a catalytic platinum surface. The electrode is isolated 
from the reaction chamber (containing cells or isolated mitochondria) by a thin membrane 
permeable  to  molecular  oxygen  and  allows  oxygen  to  reach  the  cathode,  where  it  is 
electrolytically  reduced.  This  electrolytic  reduction  allows  a  current  to  flow,  which  is 
proportional to the O2 in the solution, provided that the solution is constantly stirred/mixed. 
 
M10. b. Sample Preparation 
Live cells (HeLa or HepG2) were grown in culture flasks in medium at 38 °C. A dilute 
trypsin  solution  was  added  to  the  cells  in  the  flask  to  separate  them  and  the  cells  in 
suspension  placed  in  a  plastic  culture  tube  in  ice.  Cells  in  50  µl  of  the  solution  were 
subsequently manually counted under a light microscope to provide a representative number 
for the whole solution and, following appropriate calculation, 2 million cells were added to 
200 µl KRB and the solution gently mixed to provide an even suspension.  
 
 
M10. c. Measurement of Mitochondrial Oxygen Consumption 
The solution containing KRB and 2 million cells was placed within the chamber with a 
magnetic stirrer and allowed to equilibrate at 38 °C for five minutes. The rate of oxygen 
consumption was then set to 100 %, representing the baseline rate of oxygen consumption 
utilizing endogenous substrates and ADP. The baseline rate was subsequently measured for 
two  minutes.  Various  reagent  solutions  (1  µM  solutions)  were  subsequently  added  by 
pipette, via a hole in the chamber lid, including angiotensin II, histamine, oligomycin and 
FCCP, and the rate of oxygen consumption again measured for two minutes after addition of 
each reagent. The average rate of oxygen consumption was subsequently calculated by pre-
installed computer software (LabChart 7 Reader; Dunedin, New Zealand) and expressed as 
a change in oxygen consumption per minute, compared to a basal level of 100 % (therefore 
0.02 equals decrease in oxygen consumption of 2 % per minute from basal rate).   Hepatic Mitochondrial Renin-Angiotensin Systems 
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Abstract 
 
Introduction: Individual RAS components have previously been shown to be associated 
with mitochondria. However, such studies are few, address a limited range of cells, have 
often  relied  upon  immunohistochemistry  alone  to  demonstrate  RAS  components,  have 
rarely sought to identify the co-existence of multiple RAS components, and have failed to 
seek the presence of some entirely. Therefore, which RAS components are found within 
mitochondria and their precise intra-mitochondrial location remains unclear. 
Methods: RAS components in the mitochondria of rat liver cells and HepG2 cells were 
investigated via immunogold labeling and electron microscopy, immunofluorescence and 
confocal microscopy, and Western blotting. 
Results: Western blotting demonstrated renin, AT1R, AT2R and angiotensin within sub-
fractionated  mitochondrial  compartments  in  both  rat  liver  tissue  and  HepG2  cells; 
immunofluorescence and confocal microscopy of HepG2 cells demonstrated the presence of 
all classical RAS components within HepG2 cells, with renin, ang and ACE co-localising 
with mitochondria; and immunogold labelling and electron microscopy demonstrated ACE, 
ang, AT1R and AT2R in association with rat liver mitochondria and mitochondria of the 
HepG2 cell line. ACE, at its usual size of 170-180 kDa was absent from all mitochondrial 
sub-fractions in both rat liver tissue and HepG2 cells; however, there was enrichment of a 
55 kDa molecule, when stained with ACE C-terminal antibodies. 
Discussion: Taken together, the data presented in this chapter suggest the possibility of 
certain  RAS  components  being  present  within  mitochondria;  however,  the  results  are 
inconsistent between techniques and therefore cannot provide unequivocal evidence for the 
presence of a mitochondrial RAS. The unexpected finding of a 55 kDa molecule stained 
with ACE (C-terminal) antibody may potentially represent a novel, truncated form of ACE. 
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R1.1 Introduction 
Individual RAS components have been shown to be associated with mitochondria (for full 
discussion see ‘I3: RAS & Mitochondria’; page 30). However, such studies are few, address 
a limited range of cells, have often relied upon immunohistochemistry alone to demonstrate 
RAS  components,  have  rarely  sought  to  identify  the  co-existence  of  multiple  RAS 
components, and have failed to seek the presence of some entirely. Indeed, the reliance on 
one  antibody  in  each  of  the  above  studies  renders  the  authors  interpretations  open  to 
significant  criticism.  Further,  results  may  be  explained  by  non-specific  binding  (e.g. 
Erdmann et al., 1996) and criticised for the lack of consistency in the authors’ choice of 
cells and tissues (e.g. Abadir et al., 2011). Therefore, which RAS components are found 
within  mitochondria  and  their  precise  intra-mitochondrial  location  requires  further 
elucidation. 
 
In an attempt to circumvent the above issues, the presence of all major RAS components 
were  sought  in  the  mitochondria  of  rat  liver  cells  and  HepG2  cells  using  immunogold 
labeling  and  electron  microscopy,  immunofluorescence  and  confocal  microscopy,  and 
Western  blotting.  Thus,  a  variety  of  techniques,  as  well  as  tissues  and  cell-lines,  were 
utilised to provide an overall, robust assessment of whether RAS components were actually 
present within hepatic mitochondria. Both tissues and cell-lines were utilised to overcome 
the drawbacks of using one or other alone. Liver cell lines and tissue were utilised (as 
opposed to tissue or cell-lines derived from other body areas) due to the high density of 
mitochondria within hepatocytes and the subsequent high mitochondrial yield on subcellular 
fractionation. 
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R1.2 Methods 
  
R1.2.a. Western Blotting 
Western  blotting  was  performed  following  subcellular  fractionation  and  percoll  density 
gradient  separation  of  subcellular  components  (including  ‘pure’  mitochondria)  of  whole 
tissues (rat liver) and cell cultures (HepG2 cells). Lower volumes and protein concentrations 
were generally achieved following fractionation of cell-lines (as opposed to tissue), typically 
yielding poorer quality results. The purity of each subcellular compartment was confirmed 
following  subcellular  fractionation  and  percoll  density  gradient  separation  utilising 
antibodies  to  various  known  cellular  components.  Antibodies  from  various  well-known 
manufacturers were utilised to allow comparison of staining accuracy during assessment of 
RAS components (for further information see Appendix Tables APP2. a. and APP2. b., 
pages 216-220). Each experiment was performed at least three times to ensure consistency 
of results. 
 
R1.2.b. Imunofluorescence & Confocal Microscopy 
HepG2  cells  underwent  processing  and  fixation,  prior  to  antibody  staining  for 
immunofluorescence,  utilising  techniques  already  described  (for  further  information  see 
‘M5. Immunofluorescence’; page 76). Whole cells were incubated with primary antibodies 
to RAS components and known mitochondrial proteins, prior to incubating with fluorescent 
secondary antibodies and imaging on a confocal microscope.   
 
Mitochondria were labelled using primary antibodies to ATP5b (the beta subunit of the F1 
catalytic core located within the mitochondrial matrix), and Alexa Fluor (fluorescent green) 
secondary  antibodies.  Nuclei  were  labelled  with  Hoechst  33258,  which  emits  a  blue 
fluorescent light once excited by ultraviolet light. RAS components were similarly stained 
with secondary antibodies labelled with Alexa Fluor (for further information see Appendix 
Tables APP2. a. and APP2. b., pages 216-220). 
 Hepatic Mitochondrial Renin-Angiotensin Systems 
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R1.2.c. Immunogold Labelling & Electron Microscopy 
Rat liver samples were processed utilising the LR white protocol and immunogold labelled 
by incubation with primary antibodies to RAS components and their requisite secondary 
antibodies (for further information see Appendix Tables APP2. a. and APP2. b., pages 216-
220)  before  imaging  via  electron  microscopy.  High-quality  electron  microscopy  was 
performed  at  the  Electron  Microscopy  unit  of  the  Royal  Free  Hospital  (UCL  Medical 
School, London), utilising freshly dissected rat liver tissue or trypsinised HepG2 cells.  
 
Santa Cruz Biotechnology (Dallas, Texas, USA) primary antibodies were again utilised for 
ease of comparison with other experimental techniques and were used at manufacturer’s 
recommended concentrations (see Appendix Tables APP2. a. and APP2. b., pages 216-220). 
Each experiment was performed at least three times to ensure consistency of results. 
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R1.3 Results 
 
R1.3. a. Western Blotting 
R1.3. a.i. Controls: Confirmation of purity of sub-cellular isolates 
Mitochondrial isolation was performed utilising standardised and recognised techniques (for 
further information see ‘M3. Cellular Sub-Fractionation & Mitochondrial Isolation’; page 
68).  Following  each  individual  sub-fractionation,  success  of  the  process  was  confirmed 
using Western blotting and clear demonstration of well-established mitochondrial markers 
such as VDAC (voltage-dependent anion channel), a 280 amino acid porin ion channel 
located  on  the  outer  mitochondrial  membrane  (Shoshan-Barmatz  et  al.,  2010);  grp75 
(glucose-regulated protein 75; mortalin), a member of the hsp70 family of chaperone/stress 
proteins located within the mitochondrial matrix (Lindquist, 1986); and COX-4, a crucial 
component  of  the  last  enzyme  in  the  electron  transport  chain  (cytochrome  c  oxidase, 
complex IV), located within the inner mitochondrial membrane (Bottinger et al., 2013).  
 
Primary antibodies were sourced from a variety of different manufacturers and utilized at 
manufacturers’ recommended concentrations (see Appendix Tables APP2. a. and APP2. b., 
pages  216-220).  Antibodies  to  multiple  cellular  comppnents  were  utilized  as  a  positive 
control  to  ensure  the  accuracy  of  subcellular  fractionation  and  as  the  results  below 
illustrated,  mitochondrial  markers  were  enriched  in  mitochondrial  sub-fractions, 
demonstrating that the purity and accuracy of mitochondrial isolation was satisfactory (see 
Figure R1.1).	 ﾠ  Hepatic Mitochondrial Renin-Angiotensin Systems 
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Figure  R1.1.  Representative  Western  blot  of  sub-fractionated  rat  liver  demonstrates 
effective enrichment of known mitochondrial proteins in mitochondrial sub-fractions (H-
Homogenate; C-Cytosol; MS-Microsomes; L–Lysosomes; CM-Crude Mitochondria; PM-
Pure Mitochondria; MAM-Mitochondrial Associated Membranes; SS-Size Standards). 
 
 
R1.3.a.ii. Investigation of RAS components in cellular sub-fractions 
Once the composition of preparations had been confirmed utilising the above described 
technique, the various cellular fractions were stained for RAS components. Primary RAS 
antibodies  were  sourced  from  a  variety  of  different  manufacturers  and  utilized  at 
manufacturers’ recommended concentrations. Initially, antibodies from one manufacturer 
(Santa Cruz Biotechnology; Dallas, Texas, USA) were utilised to assess for the presence of 
RAS components in the various cellular compartments, including mitochondria. With this 
approach,  Western  blots  revealed  RAS  components,  including  renin,  AT1R,  AT2R  and 
angiotensin,  within  multiple  sub-cellular  compartments,  including  sub-fractionated 
mitochondrial compartments in both rat liver tissue and HepG2 cells (see Figures R1.2 & 
R1.3). However, ACE staining (both C-terminal and N-terminal antibodies) was absent from 
all  mitochondrial  sub-fractions  in  both  rat  liver  tissue  and  HepG2  cells,  at  its  normal 
molecular weight of 170-180kDa. Enrichment of a 55 kDa molecule, when stained with an 
ACE  C-terminal  antibody,  was  discovered  within  sub-fractionated  mitochondrial 
compartments, potentially representing a novel, truncated, mitochondrial-specific form of 
ACE;  possibly  similar  to  the  truncated  mitochondrial  form  of  renin  described  by 
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Clausmeyer et al (1999 and 2000). All findings were confirmed in at least three independent 
preparations. 
 
Figure R1.2. Representative Western blot of sub-fractionated rat liver tissue demonstrates 
staining  for  renin,  angiotensin  and  AT1R  (rabbit  polyclonal  antibody)  in  a  pure 
mitochondrial  sub-fraction,  renin,  AT1R  and  AT2R  staining  in  a  crude  mitochondrial 
fraction and AT1R in a mitochondrial-associated membranes sub-fraction when Santa Cruz 
Biotechnology (Dallas, Texas, USA) antibodies are utilised. No consistent staining was seen 
for ACE (C-terminal) in either crude or pure mitochondrial fractions at its usual size of 180 
kDa (H-Homogenate; N-Nucleus; C-Cytosol; MS-Microsomes; L–Lysosomes; CM-Crude 
Mitochondria; PM-Pure Mitochondria; MAM-Mitochondrial Associated Membranes). 
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Figure R1.3. Representative Western blot of sub-fractionated HepG2 cells demonstrates 
renin,  angiotensin,  AT1R  (rabbit  polyclonal)  and  AT2R  staining  in  crude  and  pure 
mitochondrial  sub-fractions,  when  Santa  Cruz  Biotechnology  (Dallas,  Texas,  USA) 
antibodies are utilised. No consistent staining was seen for ACE (C-terminal) in either crude 
or pure mitochondrial fractions (H-Homogenate; N-Nucleus; CM-Crude Mitochondria; PM-
Pure Mitochondria). 
 
 
R1.3. a.iii. Controls: Comparison of antibodies from different manufacturers 
To assess the validity of an approach that utilises only one antibody, two antibodies were 
employed on a single, whole PVDF membrane (to assess non-specific bands, rather than just 
focussing on the molecular weight of interest) to compare results for each RAS component. 
As demonstrated below, inconsistent results were found following comparison (see Figures 
R1.4-R1.12).  
 
Renin Western blots yielded very different results between the two antibodies utilised, with 
one  preparation  suggesting  renin  within  a  pure  mitochondrial  fraction,  and  one 
demonstrating  a  lack  of  mitochondrial  renin.  Similarly,  AT1R  blots  demonstrated 
contrasting results when two preparations from the same manufacturer were utilised, with 
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one antibody demonstrating AT1R staining in CM, PM and MAM fractions, and another 
showing weak CM staining and no staining in PM or MAM fractions. However, AT2R 
antibody use demonstrated the most consistent results, with both preparations demonstrating 
a CM band but no staining in PM or MAM fractions.  
 
Ang antibodies from different manufacturers also demonstrated inconsistent results when 
applied  to  the  same  preparation;  however,  due  to  close  molecular  similarities  between 
angiotensins and angiotensinogen, both antibodies are described by the manufacturers as 
binding  to  multiple  angiotensin  proteins  including  angiotensinogen,  angiotensinogen 
precursor, ang I, ang II and ang III, potentially explaining the presence of multiple bands at 
various molecular weights. 
 
As with the other RAS components, two initial ACE antibodies from the same manufacturer 
(one to the C-terminal and one to the N-terminal of the ACE molecule) were utilised to 
compare their similarity. Both antibodies demonstrated consistent staining at 170-195 kDa 
(usual  ACE  molecular  weight)  in  homogenate  and  nuclear  fractions.  However,  the  C-
terminal  antibody  also  demonstrated  an  enriched  55  kDa  band  in  crude  and  pure 
mitochondria,  and  mitochondrial-associated  membrane  sub-fractions.  Two  further  ACE 
antibodies were therefore employed to further investigate this finding, with a C-terminal 
antibody from an alternate manufacturer delivering similar results with a 170 kDa molecule 
stained in the homogenate and nuclear fractions and a 55 kDa band in the CM fraction; 
whereas, an N-terminal antibody from an alternate manufacturer demonstrated multiple non-
specific bands only. 
 
Thus,  most  antibodies  demonstrated  multiple  non-specific  bands,  casting  doubt  as  to 
whether  the  bands  representative  of  the  sought  molecular  sizes  actually  represented  the 
target  molecule.  Similarly,  antibodies  from  different  manufacturers,  or  of  different 
preparations from the same manufacturer, tended to yield different results, and such lack of 
antibody  specificity  casts  doubt  on  the  validity  of  previously  published  findings  and 
demonstrates the limitations of such molecular techniques. Hepatic Mitochondrial Renin-Angiotensin Systems 
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Renin Preparations 
 
Figure  R1.4.  Representative  whole  Western  blots  of  sub-fractionated  rat  liver  tissue 
demonstrate inconsistent results when the same preparation was stained with renin antibody 
from different manufacturers (Santa Cruz Biotechnology (38-46 kDa) (Dallas, Texas, USA) 
and Atlas Antibodies (40 kDa) (Stockholm, Sweden)). The Santa Cruz antibodies suggest 
the presence of renin within a pure mitochondrial fraction, whereas the Atlas Antibodies 
preparation demonstrates a lack of renin staining within mitochondrial fractions and a large 
amount of non-specific bands at multiple molecular weights (H-Homogenate; N-Nucleus; 
C-Cytosol;  MS-Microsomes;  L–Lysosomes;  CM-Crude  Mitochondria;  PM-Pure 
Mitochondria; MAM-Mitochondrial Associated Membranes). 
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ACE Preparations 
 
Figure R1.5. Representative Western blot of sub-fractionated rat liver tissue demonstrates 
consistent ACE staining at 180 kDa in the homogenate and nuclear fractions when an ACE 
(C-terminal) Santa Cruz Biotechnology (Dallas, Texas, USA) antibody was utilised. An 
enriched  55  kDa  band  in  crude  and  pure  mitochondria,  and  mitochondrial-associated 
membrane  sub-fractions  is  also  identified  (H-Homogenate;  N-Nucleus;  C-Cytosol;  MS-
Microsomes;  L–Lysosomes;  CM-Crude  Mitochondria;  PM-Pure  Mitochondria;  MAM-
Mitochondrial Associated Membranes). 
 
 
Figure R1.6. Repeat Western blot, utilising the same preparations and technique, but an 
enriched sub-fraction of rat liver tissue, again demonstrates ACE staining at both 180 kDa 
and 55 kDa in a crude mitochondrial sub-fraction when an ACE (C-terminal) Santa Cruz 
Biotechnology Dallas, Texas, USA) antibody was employed (H-Homogenate; CM-Crude 
Mitochondria). 
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Figure  R1.7.  Representative  Western  blot  of  sub-cellular  fractions  from  HepG2  cells 
demonstrates ACE staining in the homogenate at 180 kDa and at 55 kDa in both crude and 
pure  mitochondrial  sub-fractions  when  an  ACE  (C-terminal)  Santa  Cruz  Biotechnology 
(Dallas,  Texas,  USA)  antibody  was  used  (H-Homogenate;  N-Nucleus;  CM-Crude 
Mitochondria; PM-Pure Mitochondria). 
 
 
 
Figure R1.8. Representative whole Western blot of sub-cellular fractions of rat liver tissue 
demonstrates consistent ACE staining at 195 kDa in the homogenate and nuclear fractions, 
but  a  less  convincing  55  kDa  band  in  mitochondrial  sub-fractions  when  an  ACE  (N-
terminal)  Santa  Cruz  Biotechnology  (Dallas,  Texas,  USA)  antibody  was  utilised  (H-
Homogenate;  N-Nucleus;  C-Cytosol;  MS-Microsomes;  L–Lysosomes;  CM-Crude 
Mitochondria; PM-Pure Mitochondria; MAM-Mitochondrial Associated Membranes). 
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Figure  R1.9.  Representative  whole  Western  blots  of  sub-fractionated  rat  liver  tissue 
demonstrate inconsistent results when the same preparation was stained with ACE antibody 
from different manufacturers (Millipore (170-180 kDa) (Billerica, MA, USA) and Abcam 
(170 kDa) (Cambridge, UK)). The C-terminal Abcam antibody delivers similar results to the 
Santa Cruz C-terminal antibody, with staining for 170 kDa ACE in the homogenate and 
nuclear sub-fraction and 55 kDa staining in a crude mitochondrial fraction. The Millipore 
9B9 clone antibody is directed to the N-terminal and provides a result with multiple non-
specific bands at various molecular weights (H-Homogenate; N-Nucleus; C-Cytosol; MS-
Microsomes;  L–Lysosomes;  CM-Crude  Mitochondria;  PM-Pure  Mitochondria;  MAM-
Mitochondrial Associated Membranes). 
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Angiotensin Preparations 
 
Figure  R1.10.  Representative  whole  Western  blots  of  sub-fractionated  rat  liver  tissue 
demonstrate inconsistent results when the same preparation was stained with angiotensin 
antibody from different manufacturers (Santa Cruz Biotechnology (Dallas, Texas, USA) and 
LS  Bio  (Seattle,  WA,  USA)).  Due  to  the  nature  of  the  close  molecular  structure  of 
angiotensins and angiotensinogen, both antibodies are described by the manufacturers as 
binding  to  multiple  angiotensin  proteins  including  angiotensinogen,  angiotensinogen 
precursor, ang I, ang II and ang III; it may therefore be in keeping that multiple bands at 
various  molecular  weights  are  identified.  The  Santa  Cruz  antibody  datasheet 
(http://datasheets.scbt.com/sc-7419.pdf))  describes  an  angiotensin  of  60  kDa  molecular 
weight stained with their antibody; whereas, the LSBio data sheet is less specific, describing 
instead that multiple molecular weights may be identified with the use of their antibody 
(http://www.lsbio.com/Documents/PDF/Antibodies/51294) (H-Homogenate; N-Nucleus; C-
Cytosol;  MS-Microsomes;  L–Lysosomes;  CM-Crude  Mitochondria;  PM-Pure 
Mitochondria; MAM-Mitochondrial Associated Membranes). 
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AT1R Preparations 
Figure  R1.11.  Representative  whole  Western  blots  of  sub-fractionated  rat  liver  tissue 
demonstrate inconsistent results when the same preparation was stained with different AT1R 
antibody  preparations  from  the  same  manufacturer  (Santa  Cruz  Biotechnology,  Dallas, 
Texas, USA). The rabbit polyclonal antibody (43 kDa) demonstrates AT1R staining in CM, 
PM  and  MAM  fractions;  whereas,  the  goat  polyclonal  AT1R  antibody  (40  kDa) 
demonstrates weak CM staining and no staining in PM or MAM fractions. Minimal other 
bands are identified, particularly with the rabbit polyclonal antibody (H-Homogenate; N-
Nucleus; C-Cytosol; MS-Microsomes; L–Lysosomes; CM-Crude Mitochondria; PM-Pure 
Mitochondria; MAM-Mitochondrial Associated Membranes).   
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AT2R Preparations 
Figure  R1.12.  Representative  whole  Western  blots  of  sub-fractionated  rat  liver  tissue 
demonstrate consistent results when the same preparation was stained with AT2R antibody 
from  different  manufacturers  (Abcam  (44  kDa)  (Cambridge,  UK)  and  Santa  Cruz 
Biotechnology (44 kDa) (Dallas, Texas, USA)). Both antibodies demonstrate a weak CM 
band but no staining in PM or MAM fractions (H-Homogenate; N-Nucleus; C-Cytosol; MS-
Microsomes;  L–Lysosomes;  CM-Crude  Mitochondria;  PM-Pure  Mitochondria;  MAM-
Mitochondrial Associated Membranes). 
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R1.3. b. Immunofluorecence & Confocal Microscopy 
 
R1.3. b.i. Controls: Immunofluorescence of known cellular proteins  
Clear, specific immunofluorescence of both mitochondria and nuclei was observed utilising 
antibodies to ATP5b and Hoechst 33258 respectively, demonstrating that cellular fixation 
and processing was sufficient to allow immunofluorescence without destroying intracellular 
proteins (see Figure R1.13). 
 
Santa Cruz Biotechnology primary RAS antibodies were utilised to provide consistency 
with Western blot results. Primary and secondary antibodies were utilized at manufacturers 
recommended concentrations (see Appendix Tables APP2.a. and APP2.b., pages 216-220). 
 
 
 
Figure R1.13. The use of Hoechst 33258 antibody (blue immunofluorescence) and ATP5b 
primary  antibody  with  Cy2  green  secondary  antibody  demonstrates  clear  blue  nuclear 
immunofluorescence  and  clear  green  mitochondrial  immunofluorescence  within  HepG2 
cells, thus demonstrating the maintenance of structural integrity of mitochondrial proteins, 
with this processing and fixation technique. 
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R1.3. b.ii. Immunofluorescence of intra-cellular RAS components 
Immunofluorescence of RAS components was performed in conjunction with ATP5b and 
Hoechst 33258 to observe for the presence of RAS components and any co-localisation with 
mitochondrial (ATP5b) or nuclear (DNA) contents. A fluorescent signal following labelling 
was  present  for  all  classical  RAS  components  (e.g.  renin,  ACE,  ang,  AT1R  and  AT2R) 
within HepG2 cells (see Figures R1.14-R1.18). Further, renin, ang and ACE appeared to co-
localise  with  mitochondria,  although  there  was  no  obvious  co-localisation  within 
mitochondria when antibodies to AT1R and AT2R were utilised. The presence of minimal 
non-specific  immunofluorescence  was  confirmed  by  performing  negative  controls  with 
primary antibody and secondary antibody alone (see Figures R1.19-R1.20). 
 
However, the staining identified with these antibodies and this technique could be described 
as relatively non-specific, having no particular pattern of staining. This may suggest that 
significant non-specific primary antibody binding is present, a hypothesis that concurs with 
the fact that multiple non-specific bands were seen when these antibodies were utilised for 
Western  blotting  of  sub-fractionated  rat  liver  tissue.  Alternatively,  these  findings  may 
simply reflect the fact that many of the RAS components under investigation are ubiquitous 
throughout multiple cellular compartments.  
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Figure  R1.14.  Image  of  representative  staining  with  renin  primary  antibody  and 
AlexaFluor®  secondary  antibody  (red  immunofluorescence),  in  conjunction  with  ATP5b 
(green immunofluorescence) and Hoechst 33258 (blue immunofluorescence) demonstrates 
renin within HepG2 cells, where it co-localises with both nuclei and mitochondria. 
 
 
Figure  R1.15.  Image  of  representative  staining  with  ACE  primary  antibody  and 
AlexaFluor®  secondary  antibody  (red  immunofluorescence),  in  conjunction  with  ATP5b 
(green  immunofluorescence)  and  Hoechst  33258  (blue  immunofluorescence)  staining, 
demonstrates ubiquitous ACE immunofluorescence within nuclei and some co-localisation 
with mitochondria. ACE is also demonstrated at the periphery of the cell. 
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Figure  R1.16.  Image  of  representative  staining  with  angiotensin  primary  antibody  and 
AlexaFluor®  secondary  antibody  (red  immunofluorescence),  in  conjunction  with  ATP5b 
(green  immunofluorescence)  and  Hoechst  33258  (blue  immunofluorescence)  staining, 
demonstrates  ubiquitous  angiotensin  immunofluorescence  within  HepG2  cells,  with  co-
localisation in both nuclei and mitochondria. 
 
Figure  R1.17.  Image  of  representative  staining  with  AT1R  primary  antibody  and 
AlexaFluor®  secondary  antibody  (red  immunofluorescence),  in  conjunction  with  ATP5b 
(green  immunofluorescence)  and  Hoechst  33258  (blue  immunofluorescence)  staining, 
demonstrates  AT1R  immunofluorescence  largely  within  the  nuclei  of  HepG2  cells,  with 
minimal co-localisation within the mitochondria. 
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Figure  R1.18.  Image  of  representative  staining  with  AT2R  primary  antibody  and 
AlexaFluor®  secondary  antibody  (red  immunofluorescence),  in  conjunction  with  ATP5b 
(green immunofluorescence) and Hoechst 33258 (blue immunofluorescence) staining, again 
demonstrates AT2R immunofluorescence within the nuclei of HepG2 cells, with minimal 
co-localisation with mitochondria. 
 
Figure R1.19. Representative negative control image utilising ACE primary antibody alone 
and  Hoechst  33258  (blue  immunofluorescence)  demonstrates  minimal  non-specific  red 
immunofluorescence.  Similar  results  were  demonstrated  when  other  RAS  component 
primary antibodies were utilised. 
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Figure  R1.20.  Representative  negative  control  image  utilising  AlexaFluor®  secondary 
antibody alone and Hoechst 33258 (blue immunofluorescence) demonstrates minimal non-
specific  secondary  antibody  binding  and  red  immunofluorescence.  Similar  results  were 
demonstrated when other secondary antibodies were utilised. 
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R1.3. c. Immunogold Labelling & Electron Microscopy 
 
 
R1.3. c.i. Electron microscopy of RAS components in HepG2 cells 
 
Using immunogold labeling and electron microscop1, ACE was shown to be associated with 
the mitochondria of HepG2 cells (see Figures R1.21-R1.27). Staining also visible elsewhere 
within the cell might be non-specific, or might simply reflect a ubiquitous distribution for 
ACE. 
 
 
Figure R1.21. Representative control images of HepG2 cells with primary or secondary 
antibody  only,  demonstrate  little  or  no  non-specific  staining  following  electron 
microscopy  (5600-40,000  x  magnification).  Upper  Left  Image:  overall  view  of 
hepatocyte; Upper Right Image: close up of hepatocyte, demonstrating large vacuole 
and  multiple  mitochondria;  Bottom  Images:  closer  inspection  of  mitochondria, 
demonstrating multiple cristae. 
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Figure  R1.22.  Renin  immunogold  labelling  of  HepG2  cells  with  renin  antibody  and 
appropriate  secondary  antibody  demonstrates  minimal  renin  presence  (black  dots)  in 
association  with  mitochondria  (both  images  31,000  x  magnification).  In  fact,  only  one 
immunogold particle is identified within mitochondria and very little staining is identified 
throughout the cell.  
 
 
Figure R1.23. ACE immunogold labelling of HepG2 cells with ACE (C-terminal) antibody 
and  appropriate  secondary  antibody  demonstrates  the  presence  of  ACE  (black  dots)  in 
association with mitochondria (3400-53,000 x magnification). Further staining can also be 
identified throughout the cell, as might be expected from a ubiquitous molecule. Upper Left 
Image: overall view of hepatocytes; Upper Right Image: close up of cell membrane; Bottom 
Images: closer inspection of mitochondria.  
Mitochondria 
Cytoplasm 
Mitochondria  Renin 
Mitochondria 
Cytoplasm 
Cell Membrane 
Mitochondria 
Mitochondria 
Blebbing 
occurring at 
the cell 
membrane Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      116	 ﾠ
 
Figure R1.24. ACE immunogold labelling of HepG2 cells with ACE (C-terminal) antibody 
and  appropriate  secondary  antibody  demonstrates  the  presence  of  ACE  (black  dots)  in 
association with mitochondria (53,000 x magnification). Further staining can be identified 
throughout the cell, as might be expected from a ubiquitous molecule. 
 
   
Figure  R1.25.  Ang  immunogold  labelling  of  HepG2  cells  with  ang  antibody  and 
appropriate secondary antibody demonstrates the presence of ang (black dots) in association 
with mitochondria (31,000 x magnification). Further staining can be identified throughout 
the cell, as might be expected from a ubiquitous molecule.  
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Figure  R1.26.  AT1R  immunogold  labelling  of  HepG2  cells  with  AT1R  antibody  and 
appropriate  secondary  antibody  demonstrates  the  presence  of  AT1R  (black  dots)  in 
association with mitochondria (31,000 x magnification). Further staining can be identified 
throughout the cell, as might be expected from a ubiquitous molecule.  
 
 
 
Figure  R1.27.  AT2R  immunogold  labeling  of  HepG2  cells  with  AT2R  antibody  and 
appropriate  secondary  antibody  demonstrates  the  presence  of  AT2R  (black  dots)  in 
association with mitochondria (31,000 x magnification). Further staining can be identified 
throughout the cell, as might be expected from a ubiquitous molecule.  
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R1.3.c.ii. Electron microscopy of RAS components in rat liver tissue 
 
Using immunogold labeling and electron microscopy, ACE was shown to be associated with 
the  mitochondria  of  rat  liver  tissue  (see  Figures  R1.28-R1.33).  Staining  also  visible 
elsewhere  within  the  cell  might  be  non-specific,  or  might  simply  reflect  a  ubiquitous 
distribution of ACE. 
 
 
 
   
Figure R1.28. Representative control images of rat liver tissue sections with primary or 
secondary antibody only demonstrate little or no non-specific staining following electron 
microscopy (3400-31,000 x magnification). Upper Left Image: overall view of hepatocyte; 
Upper Right Image: close up of nucleus; Bottom Images: closer inspection of mitochondria. 
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Figure R1.29. Renin immunogold labeling of rat liver tissue sections with renin antibody 
and appropriate secondary antibody demonstrates a lack of renin presence in association 
with mitochondria upon electron microscopy (31,000 x magnification). 
 
 
Figure R1.30. Immunogold labelling of rat liver tissue sections with ACE (C-terminal) 
antibody  and  appropriate  secondary  antibody  demonstrates  the  presence  of  ACE  (black 
dots)  in  association  with  mitochondria  upon  electron  microscopy  (31,000-88,000  x 
magnification). Further staining can be identified throughout the cell, as might be expected 
from a ubiquitous molecule. 
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Figure  R1.31.  Immunogold  labeling  of  rat  liver  tissue  sections  with  ang  antibody  and 
appropriate secondary antibody demonstrates the presence of ang (seen here as black dots) 
in  association  with  mitochondria  upon  electron  microscopy  (31,000  x  magnification). 
However, further staining can also be identified throughout the cell, as might be expected 
from a ubiquitous molecule. 
 
 
Figure R1.32. Immunogold labeling of rat liver tissue sections with AT1R antibody and 
appropriate secondary antibody demonstrates the presence of AT1R (seen here as black dots) 
in  association  with  mitochondria  upon  electron  microscopy  (31,000  x  magnification). 
Further staining can also be identified throughout the cell.  
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Figure R1.33. Immunogold labelling of rat liver tissue sections with AT2R antibody and 
appropriate secondary antibody demonstrates the presence of AT2R (seen here as black dots) 
in  association  with  mitochondria  upon  electron  microscopy  (31,000  x  magnification). 
Further staining can also be identified throughout the cell. 
 
 
R1.3.d.  Summary  of  Immmunohistochemical  techniques  for  the 
mitochondrial localization of RAS 
  WB  IF  EM 
Renin  Y  Y  N 
ACE  N  Y  Y 
Ang  Y  Y  Y 
AT1R  Y  N  Y 
AT2R  Y  N  Y 
Table  R1.6.  The  presence  of  RAS  components  within  hepatic  mitochondria  was 
inconsistent, utilising these techniques, with different strategies suggesting different results 
(WB-  Western  Blotting;  IF-  Immunofluorescence;  EM-  Electron  Microscopy).
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R1.4 Discussion 
Taken together, the data presented in this chapter suggest the possibility of certain RAS 
components  being  present  within  mitochondria;  however,  the  results  are  inconsistent 
between  techniques  and  therefore  cannot  provide  unequivocal  evidence  for  a  full 
mitochondrial RAS, due to the inherent limitations of the antibodies and methods. Western 
blotting  demonstrated  renin,  AT1R,  AT2R  and  angiotensin  within  sub-fractionated 
mitochondrial compartments in both rat liver tissue and HepG2 cells; whilst ACE, at its 
usual size of 170-180 kDa was absent from all mitochondrial sub-fractions in both rat liver 
tissue and HepG2 cells. However, further analysis demonstrated an enrichment of a 55 kDa 
molecule, when stained with ACE C-terminal antibodies, from two different manufacturers, 
within sub-fractionated crude mitochondrial compartments; potentially representing a novel, 
mitochondrial-specific  form  of  ACE.  Immunofluorescence  and  confocal  microscopy  of 
HepG2 cells demonstrated the presence of all classical RAS components (e.g. renin, ACE, 
ang, AT1R and AT2R) within HepG2 cells, with renin, ang and ACE co-localising with 
mitochondria.  Immunogold  labelling  and  electron  microscopy  demonstrated  ACE,  ang, 
AT1R and AT2R in association with rat liver mitochondria and mitochondria of the HepG2 
cell line. 
 
The immunohistochemical techniques utilised are reliant upon the accuracy of cell/tissue 
processing,  to  allow  the  structural  integrity  of  the  molecules  under  investigation  (RAS 
components)  to  be  maintained.  They  also  rely  upon  the  specificity  of  the  antibodies 
employed, to eradicate non-specific background staining, thought to result from attraction of 
primary and secondary antibodies to endogenous Fc receptors (Buchwalow et al., 2011). 
The strategies followed here (and within the previous studies describing RAS components 
within mitochondria) incorporated a blocking step (goat serum or bovine serum albumin), 
thought to prevent the hydrophobic interactions between proteins and ionic or electrostatic 
interactions (Buchwalow et al., 2011). However, recent studies suggest that such widely-
utilised protocols are based upon conflicting and outdated reports and may therefore be 
ineffective  (Buchwalow  et  al.,  2011).  The  antibodies  employed  here  demonstrated 
inconsistent  findings  between  Western  blotting,  immunofluorescence  and  electron 
microscopy.  However,  electron  microscopy  results  between  cell-lines  and  tissue  were Hepatic Mitochondrial Renin-Angiotensin Systems 
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consistent both with each other and the findings of other authors, such as Abadir et al (2011) 
and Peters et al (1996). In contrast with the consistency of EM was the presence of multiple 
bands when the same antibodies are utilised for Western blotting and relatively non-specific 
patterns of staining when utilised for immunofluorescence, both of which reinforce the idea 
that non-specific, background staining may be a particular limitation of this technique and 
these antibodies. Further, antibodies from different manufacturers yielded different results 
when utilised for Western blotting, calling into question the conclusions from past studies, 
which relied only upon one antibody. These results therefore cannot confirm the findings of 
Abadir  et  al  (2011),  who  suggested  that  the  AT2R  might  be  located  upon  the  inner 
mitochondrial membrane. Similarly, without a demonstration of their exact site, hypotheses 
regarding  the  potential  functional  role  of  postulated  intra-mitochondrial  RAS  proteins 
become redundant. Alternative techniques will therefore be necessary to provide irrefutable 
proof  that  RAS  components  are  present  within  mitochondria,  given  such  limitations  of 
immunohistochemical techniques. 
 
One consistent finding was the detection of a 55 kDa band when CM preparations were 
stained with an ACE C-terminal, but not an ACE N-terminal antibody; suggesting that if 
this band did represent a mitochondrial form of ACE, it may be proceesed or cleaved to 
remove the N-terminal. Previous studies have suggested that RAS components may require 
significant  processing  to  enter  the  mitochondria  and  a  novel,  truncated  form  of  non-
secretory renin lacking 36 amino acids (including the complete ER signal) has been reported 
to be present within the mitochondria of the rat adrenal gland (Clausmeyer et al., 2000, 
Clausmeyer  et  al.,  1999,  Wanka  et  al.,  2009).  This  55  kDa  molecule  may  potentially 
represent a novel, truncated form of ACE; however, this molecular weight is significantly 
below the usual size of ACE (170-195 kDa) and would necessitate significant cleavage and 
processing of the ACE molecule prior to mitochondrial import, potentially rendering its 
enzymatic  activity  non-functional  and  raising  the  question  of  what  its  function  may 
subsequently be. Further investigation of the nature of this 55 kDa molecule was performed, 
via  isolation  and  characterisation  of  the  molecule  of  interest  (see  Results  2:  Is  there  a 
mitochondrial-specific form of ACE). 
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Abstract 
 
Introduction:  Mitochondrial  RAS  proteins  were  inconsistently  identified  in  initial 
experiments,  results  appearing  dependent  upon  the  investigative  strategy  used  and  the 
antibody employed. Whilst the normal molecular weight of ACE is 180-195 kDa, Western 
blots consistently identified a 55 kDa molecule which stained with an ACE (C-terminal) 
antibody  in  mitochondrial  (particularly  CM)  fractions,  potentially  representing  a  novel, 
specific, truncated, intra-mitochondrial form of ACE. For further investigation the 55 kDa 
band  was  isolated,  purified  and  concentrated  to  allow  proteomic  analysis  by  mass 
spectrometry.  
Methods:  Immunoprecipitation  was  performed  on  rat  liver  crude  mitochondrial  sub-
fractions to isolate and concentrate the 55 kDa form of ACE. Deglycosylation of the band of 
interest was also performed to reduce heterogeneity of mass and charge in the sample and 
facilitate subsequent mass spectrometry via MALDI-TOF.  
Results:  Immunoprecipitation  of  rat  liver  tissue  and  ACE  (C-terminal)  antibody 
demonstrated consistent concentration of a 50 kDa band, whereas deglycosylation of 
this immunoprecipitation eluate demonstrated a subsequent consistent reduction in mass 
to 30 kDa. Database searches following mass spectrometry of 55 kDa, 50 kDa and 30 kDa 
bands demonstrated no results consistent with ACE protein. 
Discussion:  Smaller  ACE  isoforms  than  the  usual  size  of  170-195  kDa  have  been 
previously described, as has a truncated intra-mitochondrial renin protein. Negative mass 
spectrometry results, as presented here, indicate that that the 55 kDa band is most likely to 
represent non-specific binding by the ACE (C-terminal) antibody and although these results 
do  not  completely  exclude  the  presence  of  ACE  in  low  abundance,  they  do  render  the 
presence of ACE in the mitochondria unlikely. 
 
 
 
	 ﾠ  Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      126	 ﾠ
R2.1 Introduction 
Mitochondrial RAS proteins were inconsistently identified in previous experiments, results 
appearing dependent upon the investigative strategy used and the antibody employed (see 
Results  1:  Presence  of  RAS  components  in  hepatic  mitochondria,  pages  94-125).  If  a 
functional, self-sufficient RAS were to exist within mitochondria, it should contain enzymes 
generating ang II, a role mostly fulfilled by ACE, the enzyme directly responsible for the 
generation of ang II from ang I throughout the body.  Whilst the normal molecular weight of 
ACE is 180-195 kDa, initial Western blots consistently identified a 55kDa molecule which 
stained with an ACE (C-terminal) antibody in mitochondrial (particularly CM) fractions. 
This  might  represent  a  finding  of  genuine  biological  significance,  since  shorter  natural 
human  and  rat  ACE  isoforms  exist  [ACE-T,  Uniprot  P47820],  and  a  novel,  specific, 
truncated intra-mitochondrial form of renin has previously been described (Clausmeyer et 
al., 2000, Clausmeyer et al., 1999, Wanka et al., 2009). To confirm the identity of the 55 
kDa  mitochondrial  band,  a  series  of  experiments  were  performed  to  isolate,  purify  and 
concentrate the 55 kDa protein and allow proteomic analysis by mass spectrometry.  
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R2.2 Methods 
Immunoprecipitation (IP) was performed on rat liver crude mitochondrial sub-fractions to 
isolate  and  concentrate  the  55  kDa  form  of  ACE  for  proteomic  analysis  by  mass 
spectrometry  (for  further  information  see  ‘M9.  Mass  Spectrometry’;  page  87).  Each 
immunoprecipitation experiment was performed utilising ACE (C-terminal) antibody (Santa 
Cruz  Biotechnology;  Dallas,  Texas,  USA)  and  the  results  of  immunoprecipitation  were 
assessed  by  Western  blotting  or  direct  silver  staining  of  a  Bis-Tris  gel  following 
electrophoresis. Each experiment was performed at least three times to ensure consistency 
of results and representative images are presented below. 
 
 
R2.2.a. Western blotting & Silver Staining 
Western  blotting  and  silver  staining  utilising  the  end  product  (eluate)  from 
immunoprecipitation of a CM fraction with the ACE (C-terminal) antibody demonstrated 
consistent enrichment of a 50 kDa band, as demonstrated by dense staining and reduced 
non-specific  staining  around  the  band  of  interest  (see  Figure  R2.1).  This  represented  a 
consistent 5 kDa reduction in mass, as compared to staining of the CM fraction with ACE 
C-terminal antibody, which consistently revealed a 55 kDa band, potentially consistent with 
concentration and removal of contaminants (purification). Multiple copies of the 50 kDa 
band  (containing  the  protein  of  interest  bound  to  antibody)  were  excised  from  gels  to 
undergo further processing and proteomic analysis by mass spectrometry (see Figure R2.2).  
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Figure R2.1. Western blot image demonstrating concentration of a 50 kDa band following 
immunoprecipitation of a crude mitochondrial fraction from rat liver tissue utilising ACE 
(C-terminal)  antibody  (IP  eluate).  When  compared  to  the  55  kDa  band  seen  after 
electrophoresis of a CM fraction alone, the concentrated band has reduced mass (50 kDa) 
and reduced non-specific staining (PM- Pure mitochondria; CM- Crude mitochondria; GRP- 
Control utilising antibody to GRP75; Resin- Control utilising resin only and no antibody; IP 
Eluate- Eluate from immunoprecipitation of CM with ACE (C-terminal) antibody). 
 
 
 
 
Figure R2.2. Silver stain images again demonstrate concentration of a 50 kDa band (IP 
Eluate)  following  immunoprecipitation  of  a  crude  mitochondrial  fraction  from  rat  liver 
tissue, utilising ACE (C-terminal) antibody (upper gel). The band is subsequently excised 
for trypsin digestion and proteomic analysis by mass spectrometry (middle gel). Ultimately 
multiple  bands  were  processed  and  excised  to  increase  the  volume  of  protein  for  mass 
spectrometry (lower gel) (CM- Crude mitochondria; SS-Size standards; IP Eluate- Eluate 
from immunoprecipitation of CM fraction with ACE (C-terminal) antibody). 
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R2.2.b Deglycosylation 
Deglycosylation of the IP eluate (of a CM fraction and ACE (C-terminal) antibody) was also 
performed to remove N-linked glycans from the IP eluate under investigation to compare to 
the results following IP alone. This technique reduced the heterogeneity of both mass and 
charge within the sample, thus assisting analysis by mass spectrometry. Western blotting 
and  silver  staining  were  again  subsequently  performed  to  assess  the  effect  of 
deglycosylation and compare to IP alone. Each experiment was performed at least three 
times to ensure consistency of results and representative images are presented below. 
 
 
R2.2.c Mass Spectrometry 
Following electrophoresis, deglycosylation and excision of the bands of interest, gel-pieces 
were delivered for mass spectrometry to be performed by experienced technical staff at one 
of two centres (University College London, UK or Harvard Medical School, Boston, USA 
(see  Methods,  page  87  for  further  information  on  methodology).  Resultant  mass 
spectrometry  data  were  compared  against  a  database  of  known  proteins  including 
UniProtKB/Swiss-Prot,  a  non-redundant  protein  sequence  database  maintained  by  the 
UniProt consortium (www.uniprot.org/). 
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R2.3 Results 
 
R2.3.a. Western Blotting & Silver Staining 
Western  blotting  and  silver  staining,  utilising  the  deglycosylated  IP  eluate  (from 
immunoprecipitation  of  a  rat  liver  CM  fraction  with  ACE  (C-terminal)  antibody) 
demonstrated a consistent reduction in mass from 50 kDa to 30 kDa (see Figures R2.3-2.4). 
Such  a  finding  may  be  consistent  with  deglycosylation  of  a  heavily  glycosylated 
glycoprotein, such as ACE. 
 
   
Figure R2.3. Silver stain images again demonstrated concentration of the 50 kDa band in an 
IP eluate (IP) following immunoprecipitation of a crude mitochondrial fraction from rat 
liver tissue, utilising ACE (C-terminal) antibody. A crude mitochondrial sub-fraction (CM; 
also shown for comparison) demonstrated the previously identified 55 kDa band. When the 
IP eluate underwent deglycosylation (IP Degly), a further 30 kDa band was also seen in 
addition  to  the  50  kDa  band;  however,  when  the  crude  mitochondrial  sub-fraction 
underwent deglycosylation, only the 50 kDa band was seen (SS- Size standards; CM-Crude 
mitochondria; IgG- IgG control (immunoprecipitation of ACE (C-terminal) antibody alone); 
IP- Eluate from immunoprecipitation of CM fraction with ACE (C-terminal) antibody; CM 
Degly-Deglycosylation of crude mitochondrial sub-fraction; IP Degly- Deglycosylation of 
IP eluate). 
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Figure R2.4. Silver stain images again demonstrated concentration of a 30 kDa band (IP 
Degly)  when  the  IP  eluate  was  deglycosylated  and  the  50  kDa  band  (IP)  following 
immunoprecipitation alone (upper gel). Both band sizes (50 kDa and 30 kDa) were carefully 
excised  for  proteomic  analysis  by  mass  spectrometry  (lower  gel)  (IP-Eluate  from 
immunoprecipitation with ACE (C-terminal antibody); IP Degly-Deglycosylation of eluate 
from immunoprecipitation). 
 
 
R2.3.b Mass Spectrometry 
Results are presented depending upon the site of analysis. UCL results were analysed 
via the Protein Lynx Global Server (PLGS) (Waters; Milford, MA, USA) and a ‘PLGS 
score’ assigned based upon a computer software algorithm that utilised filtering and 
scoring  routines  to  analyse  all  available  mass  spectrometry  data  and  statistically 
measure peptide  assignment accuracy as well as minimising the occurrence of false 
positive results (scores greater than 78 are significant (p<0.05)). Harvard results were 
analysed by Seaquest (Thermo Scientific; Waltham, MA, USA), a mass spectrometry 
data analysis programme that assigns scores such as ‘XCorr’, a cross-correlation score 
derived  from  the  database  search,  which  is  used  to  produce  the  final  ranking  of 
candidate peptides in the search (values above 2 represent a good correlation); ‘Delta 
correlation score’ (dCn), a score computed by the Seaquest algorithm, which represents 
an assessment of the distance between the best database search hit and the second best 
(the closer to 1, the more positive the result); and ‘Ions’, which is an assessment of how 
many experimental ions matched with theoretical ions for the peptide under analysis 
(>70 % represents a positive result). 
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Samples sent for mass spectrometry analysis include:  
i)  a 55 kDa band following electrophoresis of a rat liver crude mitochondrial sub-
fraction (CM) stained with ACE (C-terminal antibody);  
ii)  a 50 kDa band following immunoprecipitation of a CM sub-fraction with ACE 
(C-terminal antibody) (IP); and  
iii)  a 30 kDa band following deglycosylation of a 50 kDa IP eluate (IP Degly). 
 
i. Rat liver crude mitochondrial sub-fraction (CM 55 kDa band) 
Database searches following mass spectrometry of the 55 kDa band derived from crude 
mitochondrial  sub-fraction  incubation  with  ACE  (C-terminal)  antibody  demonstrated  no 
results consistent with ACE protein (see Figure R2.5 and Appendix 3, page 221 for full 
results). Proteins identified included keratin and dermicidin (likely human contaminants), as 
well as reagents used during experimentation, such as trypsin (for in-gel protein digestion) 
and enolase (protein used to standardise mass spectrometry performance). Actual rat liver 
mitochondrial proteins with similar molecular weight, which could give rise to the non-
specific binding of the antibody might include the pyruvate kinase isozymes M1 and M2, 
and  tubulin  alpha  8  chain,  which  has  previously  been  shown  to  be  associated  with 
mitochondria. 
 
Figure  R2.5.  Representative  mass  spectra  results,  following  analysis  of  a  gel  piece 
containing a 55 kDa band derived from a crude mitochondrial sub-fraction of rat liver tissue, 
demonstrate no findings consistent with ACE.  Hepatic Mitochondrial Renin-Angiotensin Systems 
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ii. Immunoprecipitation eluate (IP 50 kDa band) 
Database  searches  following  mass  spectrometry  of  the  50  kDa  band  derived  from  the 
immunoprecipitation eluate (of crude mitochondrial sub-fraction incubation with ACE (C-
terminal) antibody) similarly demonstrated contaminants and experimental reagents but no 
results consistent with ACE protein (see Figure R2.6 and Appendix 3, page 221). Two gel-
pieces analysed at University College London identified a weak correlation (PLGS scores 
76  and  63)  of  the  50  kDa  band  with  an  unknown  rat  protein  of  molecular  weight 
approximately 46 kDa. 
 
 
Figure R2.6. Representative mass spectra results after analysis of a gel piece containing a 
50 kDa band derived from an immunoprecipitation eluate of a rat liver crude mitochondrial 
sub-fraction demonstrated no findings consistent with ACE. 
 
iii. Deglycosylated immunoprecipitation eluate (IP Degly 30kDa band) 
Database  searches  following  mass  spectrometry  of  the  30  kDa  band  derived  from 
deglycosylation of the immunoprecipitation eluate of a crude mitochondrial sub-fraction 
incubated  with  ACE  (C-terminal)  antibody  demonstrated  contaminants  (enolase)  but  no 
results consistent with ACE protein (see Appendix 3, page 221, for full results).  
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R2.4 Discussion 
	 ﾠ
Immunoprecipitation of rat liver tissue and ACE (C-terminal) antibody demonstrated 
consistent  concentration  of  a  50  kDa  band,  whereas  deglycosylation  of  this 
immunoprecipitation eluate demonstrated a consistent reduction in mass from 50 kDa to 
30 kDa. Database searches following mass spectrometry of 55 kDa (from CM sub-fraction), 
50 kDa (from IP eluate) and 30 kDa (from deglycosylated IP eluate) bands demonstrated no 
results consistent with ACE protein. Proteins consistently identified included contaminants 
(e.g. keratin and dermicidin), and experimental reagents (e.g. enolase). The results therefore 
indicate that the 55 kDa band is most likely to represent non-specific binding by the ACE 
(C-terminal) antibody and although these results do not completely exclude the presence of 
ACE in low abundance, they do render the presence of ACE in the mitochondria unlikely. 
 
Smaller ACE molecules than the usual size of 170-195 kDa have been previously described 
with  at  least  four  isoforms  identified  in  rats  (intracellular  130  and  68  kDa  forms  and 
secretory 130 and 60 kDa (Camargo de Andrade et al., 2006). Truncated intra-mitochondrial 
renin proteins have also been previously described (Wanka et al., 2009, Clausmeyer et al., 
2000, Clausmeyer et al., 1999), reinforcing the idea that a truncated mitochondrial ACE 
protein  is  possible.  However,  the  truncated  renin  described  lacks  a  small  portion  of  its 
overall structure (representing its ER targeting sequence); whereas, a molecular weight of 
30-55 kDa is significantly below the usual size of ACE and would necessitate considerable 
cleavage and processing of the ACE molecule prior to mitochondrial import, potentially 
rendering its enzymatic activity non-functional and raising the question of what its function 
may subsequently be. Positive mass spectrometry results here would have suggested a role 
for  a  truncated  intra-mitochondrial  ACE  and  would  therefore  imply  the  existence  of  a 
mitochondrial RAS where nuclear genome-derived RAS components are formed within the 
cytoplasm, subsequently undergoing significant post-translational processing and cleavage 
prior to mitochondrial import, where intra-mitochondrial conversion of ang I to ang II may 
take  place.  Negative  mass  spectrometry  results,  as  presented  here,  do  not  completely 
exclude the presence of a mitochondrial RAS, but would suggest that if such a system 
existed, intra-mitochondrial ang I to II conversion would occur via the enzymatic action of 
non-ACE, alternate, previously undescribed enzymes.     Hepatic Mitochondrial Renin-Angiotensin Systems 
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Abstract 
 
Introduction:  Earlier  results  suggest  that  mitochondria  may  contain  classical  RAS 
components, although a mitochondrial-specific form of ACE is unlikely to exist. If such a 
hepatic intra-mitochondrial RAS were to exist, its function remains unknown. To further 
investigate the potential functions of a mitochondrial RAS, a series of experiments were 
performed to assess the effects of stimulating or antagonising the renin-angiotensin system. 
Methods: Functional fluorescence microscopy was used to measure real-time, dynamic, 
live-cell (HeLa and HepG2) alterations in multiple, crucial intracellular processes (including 
mitochondrial  membrane  potential,  intracellular  calcium  concentration  and  NADH 
concentration)  following  addition  of  various  stimulatory  (ang  II)  and  inhibitory  factors 
(Losartan (AT1R antagonist), PD123319 (AT2R antagonist) (at both 1 mM and 1 µM), as 
well  as  substrates  known  to  alter  mitochondrial  metabolism  in  a  predictable  fashion 
(including rotenone (inhibitor of complex I & II), FCCP (uncoupling agent) and oligomycin 
(inhibitor of ATP synthase)). Real-time, dynamic alterations in oxygen consumption were 
also assessed via a Clark electrode in response to angiotensin II and its receptor antagonists, 
as well as established mitochondrial substrates. 
Results: Functional fluorescence microscopy data demonstrated accurate use of positive 
controls with FCCP decreasing mitochondrial membrane potential, intracellular calcium and 
intracellular  NADH;  and  rotenone  resulting  in  significant  decreases  in  mitochondrial 
membrane  potential  and  intracellular  calcium,  associated  with  an  increase  in  NADH 
concentration. However, ang II, losartan and PD123319 addition led to inconsistent results 
without biological plausibility in both HeLa and HepG2 cells. 
The addition of reagents to live HepG2 cells demonstrated consistent oxygen consumption 
results: ang II had no significant effect upon cellular oxygen consumption at 1 µM or 1 mM; 
whereas, both Losartan and PD123319 had no effect at 1 µM concentration but led to a 
significant increase in cellular oxygen consumption at 1 mM concentration. When added to 
live HeLa cells, ang II led to a significant decrease in cellular oxygen consumption at 1 µM 
concentration;  whereas,  both  Losartan  and  PD123319  had  no  significant  effect  at  a 
concentration of 1 µM, but led to a significant increase in cellular oxygen consumption at 1 
mM concentration.  Hepatic Mitochondrial Renin-Angiotensin Systems 
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Discussion: It can be hypothesized that the HepG2 results presented may be inconsistent 
due to the dual presence of cell membrane and mitochondrial membrane receptors; however, 
results derived from HeLa cells should represent effects at the mitochondrial membrane 
only (as HeLa cells contain no plasma membrane ang receptors). Thus, addition of ang II 
may lead to a decrease in cellular oxygen consumption, a result that would be consistent 
with previously described studies but this effect is likely to be non-specific in that it can be 
prevented by both AT1 and AT2 receptor inhibitors. Further, the physiological intracellular 
concentration of ang II is likely to be in the picomolar range, in accordance with the sub-
nanomolar affinity of angiotensin receptors on the cell surface, and the supra-physiological 
reagent concentrations utilised here may therefore result in non-endogenous effects. 
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R3.1 Introduction 
Previous Western blot, immunohistochemistry and electron microscopy results suggested 
that  mitochondria  may  contain  classical  RAS  components,  although  a  mitochondrial-
specific form of ACE is unlikely to exist. Specifically, Western blotting demonstrated renin, 
AT1R, AT2R and angiotensin within sub-fractionated mitochondrial compartments in both 
rat  liver  tissue  and  HepG2  cells;  whilst  ACE  was  absent  from  all  mitochondrial  sub-
fractions  in  both  rat  liver  tissue  and  HepG2  cells  at  its  usual  size  of  170-180  kDa. 
Immunofluorescence and confocal microscopy of HepG2 cells demonstrated the presence of 
renin,  ang  and  ACE  within  mitochondria,  whilst  immunogold  labeling  and  electron 
microscopy demonstrated ACE in association with rat liver mitochondria and mitochondria 
of the HepG2 cell line. However, mass spectrometry results indicated that a truncated ACE 
of 55 kDa molecular weight was not present within mitochondria. 
 
If a hepatic intra-mitochondrial RAS were to exist, its function remains unknown. Abadir et 
al (2011) suggest that activation of a mitochondrial RAS is coupled to mitochondrial nitric 
oxide  production  and  can  modulate  cellular  respiration,  whilst  intracrine  hepatic  RAS 
activation may be pro-inflammatory and pro-fibrotic, contributing to the pathogenesis of 
chronic liver disease and liver fibrosis/cirrhosis (Grace et al., 2012). To further investigate 
the potential functions of a mitochondrial RAS, a series of experiments were performed to 
assess the mitochondrial effects of stimulating or antagonising the renin-angiotensin system. 
A variety of crucial mitochondrial functions were therefore assessed, including: 
i.  NADH concentration: NADH is an energy-rich molecule produced within the 
mitochondrial matrix via the Krebs cycle. The redox energy from such molecules 
is transferred to oxygen in several steps via the electron transport chain within 
the inner mitochondrial membrane. 
ii.  Mitochondrial  membrane  potential  (ΔΨm;  for  further  information  see  ‘M1. 
Materials’; page 61): The redox action of NADH allows the generation of energy 
utilised to pump protons into the mitochondrial intermembrane space, forming an 
electrochemical proton gradient or mitochondrial membrane potential. Protons 
can only subsequently re-enter the mitochondrial matrix via the ATP synthase 
complex, where their potential energy is employed to drive the generation of Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      139	 ﾠ
chemical energy in the form of ATP. Thus the maintenance and stability of this 
membrane potential remains crucial for fundamental mitochondrial function and 
a significant loss of ΔΨm renders the cell depleted of energy with subsequent 
cell death.  
iii.  Oxygen consumption: Mitochondria utilise oxygen to produce ATP and the rate 
of  oxygen  consumption  is  therefore  a  valuable  tool  in  the  assessment  of 
mitochondrial  function  as  it  directly  reflects  the  efficiency  of  oxidative 
phosphorylation. 
iv.  Intracellular calcium concentration (for further information see ‘M1. Materials’; 
page 61): Free intracellular calcium concentrations are vital for the regulation of 
an array of cellular reactions and signal transduction; and mitochondria can have 
significant effects on calcium levels via interaction with endoplasmic reticulum 
(ER), the most significant site of intracellular calcium storage. 
As in previous experiments, the HepG2 cell line and rat liver tissue were utilised. HeLa 
cells, which lack plasma membrane angiotensin receptors [personal communication: Peter 
Varnai (Semmelweis Medical School, Budapest, Hungary)] were also used, as any cellular 
metabolic alteration identified following the introduction of RAS components must occur 
secondary to direct mitochondrial or non-specific action only, and not via plasma membrane 
angiotensin receptors. 
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R3.2 Methods 
 
R3.2.a. Functional Fluorescence Microscopy 
Functional fluorescence microscopy refers to the process of imaging live cells on a confocal 
microscope, following the addition of fluorescent molecules. It is used to measure real-time, 
dynamic alterations in multiple intracellular processes, in response to various stimulatory or 
inhibitory factors. The intensity of fluorescence dynamically alters as the metabolic process 
under examination changes, allowing quantitative study of cellular pathways within live 
cells.  
 
The actual mitochondrial membrane potential of hepatocytes has been estimated as -154.3 
mV in young Fischer rats (Hagen et al., 1997); however, functional fluorescence 
microscopy allows quantitative assessment of changes in mitochondrial membrane potential 
(as well as other parameters), in response to various internal and external factors, in a 
consistent and reproducible manner (see Figures R3.1-R3.2 and ‘M1. Materials’; page 61). 
Here, changes in mitochondrial membrane potential (TMRM; excitation at 500 nm), 
intracellular calcium concentration (Fluo 4; excitation at 488 nm) and NADH concentration 
(auto-fluorescence; excitation at 364 nm) were assessed in response to ang II agonism and 
antagonism (Losartan, AT1R antagonist and PD123319, AT2R antagonist), and to well-
established substrates that alter mitochondrial metabolism in a predictable fashion, including 
rotenone (inhibitor of electron transport chain complex I & II) and FCCP (uncoupling 
agent). Histamine was also added as a positive control, as binding to Histamine receptors on 
the plasma membrane should cause a cytosolic, and subsequent, mitochondrial Ca
2+ signal. 
 
Live cells were allowed to equilibrate for at least five minutes within the microscope, on a 
heated stage at 38 °C. Cellular fluorescence was constantly measured during the experiment, 
utilsiing statistical software pre-installed on the microscope, and the initial fluorescence at 
the commencement of the experiment was arbitrarily set to a relative fluorescence value of 
1. Relative changes in fluorescence were subsequently assessed as reagents were added to 
the  live  cells  (with  relative  fluorescence  increasing  >1  for  brighter  fluorescence  and 
decreasing <1 for a reduction in fluorescence, as compared to the original fluorescence at 
the commencement of the experiment). Relative fluorescence was measured for at least two Hepatic Mitochondrial Renin-Angiotensin Systems 
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minutes before and after addition of each of the various reagents. Each experiment was 
carried out at least five times and a mean of the alteration in relative fluorescence for all 
experiments calculated and presented below. Statistically significant alterations in mean 
relative fluorescence, before and after addition of various substrates, were assessed by two-
tailed t-test; and a probability value of less than 5 % (p< 0.05) was considered significant.  
 
Figure R3.1. Representative image of a decrease in mitochondrial membrane potential, seen 
as a decrease in relative fluorescence (due to pre-incubation with TMRM) between left and 
right images. The change occurred following addition of ang II (1mM) and these example 
images demonstrate that alterations in relative fluorescence can be visibly observed with the 
naked eye, as well as formally quantified. 
 
 
Figure R3.2. Representative image grid demonstrating relative increases and decreases in 
red fluorescence (mitochondrial membrane potential) in live HeLa cells over time (approx.7 
minutes), following addition of various substrates (a red square in the top right hand corner 
of an image demonstrates that a new reagent has been added). The grid of images is read 
from left to right and a new image is captured every seven seconds. 
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R3.2.b. Oxygen Consumption 
Real-time, dynamic alterations in oxygen consumption were assessed via a Clark electrode 
(see Figure 3.14 and ‘M10. Oxygen Consumption’; page 92), in both HepG2 and HeLa 
cells, in response to angiotensin II and to its receptor antagonists (Losartan and PD123319). 
Well-established substrates that alter mitochondrial metabolism in a predictable fashion, 
including oligomycin (inhibitor of ATP synthase) and FCCP (uncoupling agent) were 
utilised as positive controls (for further information see ‘M1. b. Reagents’; page 61). 
Two million live cells (HepG2 or HeLa) were allowed to equilibrate within the chamber of 
the Clark electrode at 38 °C and oxygen consumption set to 100 % after an equilibration 
period of at least five minutes. The rate of oxygen consumption was subsequently measured 
for two minutes and a basal rate of oxygen consumption measured and set arbitrarily to 100 
%.  Thus,  any  subsequent  change  in  the  rate  of  oxygen  consumption  per  minute  was 
expressed as a percentage change from 100 % (e.g. -0.02 equals decrease in rate of oxygen 
consumption of 2 % per minute from pre-set level of 100 %). A substrate was subsequently 
added via the designated hole in the lid of the apparatus chamber and the rate of oxygen 
consumption again measured for two minutes. The rate of oxygen consumption naturally 
reduces  over  time  in  cells  examined  in  this  fashion  and  each  separate  set  of  cells  was 
therefore replaced after ten minutes to allow for this. Each experiment was performed five 
times and the mean of the results presented below. Statistically significant alterations in 
mean rates of oxygen consumption, following addition of various substrates, were assessed 
by  two-tailed  t-test;  and  a  probability  value  of  less  than  5  %  (p<0.05)  was  considered 
significant.  Hepatic Mitochondrial Renin-Angiotensin Systems 
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Figure R3.14. An image of the computer software utilised to measure oxygen consumption 
demonstratedd  how  alterations  in  the  rate  of  oxygen  consumption  were  calculated.  The 
initial level is arbitrarily set to 100 % after cellular equilibration (for at least five minutes) 
and  the  steepness  of  the  rate  of  decline  was  measured  following  addition  of  various 
reagents. Oxygen consumption was assessed for at least two minutes prior to and following 
the addition of each reagent (O
2CR- Rate of oxygen consumption). 
 
 
 
 
 
 
   
!""#$%&'%(')*+,*&-'
./0)'1')*+,*&-'2'
./0)'1')*+,*&-'/'
2334'
5+6*7#&*'./0)'Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      144	 ﾠ
R3.3 Results 
 
R3.3. a. Functional Fluorescence Microscopy 
 
R3.3. a.i HepG2 Cells (see Figures R3.3-3.6) 
The addition of FCCP to live HepG2 cells led to predictable and significant decreases in 
intracellular  calcium,  NADH  and  mitochondrial  membrane  potential.  Ang  II  addition 
produced  a  significant  decrease  in  NADH  concentration  and  a  significant  increase  in 
mitochondrial  membrane  potential,  with  no  significant  effect  noted  upon  intracellular 
calcium.  Losartan  addition  significantly  decreased  intracellular  NADH  and  significantly 
increased  intracellular  calcium  levels;  whereas,  PD123319  treatment  had  no  significant 
effects.  
 
Figure R3.3. The addition of FCCP (uncoupling agent; concentration 1 µM) to live HepG2 
cells led to predictable and significant decreases in concentrations of intracellular calcium 
(Fluo-4; p= 0.000) and NADH (p= 0.000), as well as a significant decrease in mitochondrial 
membrane potential (TMRM; p= 0.006). Each time point represents 7 seconds and each 
experiment was performed 6 times with the mean presented here. 
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Figure R3.4. The addition of angiotensin II (concentration 1 µM) to live HepG2 cells led to 
a significant decrease in concentrations of NADH (p= 0.020) and a significant increase in 
mitochondrial  membrane  potential  (TMRM;  p=  0.036).  There  was  no  effect  upon 
intracellular calcium (Fluo-4; p= 0.223). Each time point represents 7 seconds and each 
experiment was performed 6 times with the mean presented here. 
 
Figure  R3.5.  The  addition  of  Losartan  (AT1R  antagonist;  concentration  1  µM)  to  live 
HepG2  cells  led  to  a  significant  decrease  in  intracellular  NADH  (p=  0.000),  and  a 
significant increase in intracellular calcium levels (Fluo-4; p= 0.000). No significant effect 
was  seen  upon  mitochondrial  membrane  potential  (TMRM;  p=  0.927).  Each  time  point 
represents 7 seconds and each experiment was performed 6 times with the mean presented 
here. 
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Figure R3.6. The addition of PD123319 (AT2R antagonist; concentration 1 µM) to live 
HepG2 cells had no significant effects upon intracellular calcium concentration (Fluo-4; p= 
0.734), NADH concentration (p= 0.431) or mitochondrial membrane potential (TMRM; p= 
0.918. Each time point represents 7 seconds and each experiment was performed 6 times 
with the mean presented here. 
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R3.3. a.ii HeLa Cells (see Figures R3.7-3.13) 
HeLa cells have no plasma membrane angiotensin receptors [personal communication: Peter 
Varnai  (Semmelweis  Medical  School,  Budapest,  Hungary)]  and  therefore  any  cellular 
metabolic alteration following the introduction of RAS components must occur secondary to 
direct mitochondrial or non-specific action only, and not via plasma angiotensin receptors. 
The  addition  of  angiotensin  II  to  live  HeLa  cells  led  to  a  significant  decrease  in 
mitochondrial  membrane  potential,  intracellular  calcium  concentration  and  NADH 
concentration. Losartan addition conversely produced a significant decrease in intracellular 
calcium concentration and a significant increase in mitochondrial membrane potential, and 
PD123319  resulted  in  significant  decreases  in  mitochondrial  membrane  potential, 
intracellular calcium concentration and NADH concentration.  
Control reagents had predictable effects, with histamine causing no effects apart from a brief 
calcium surge (calcium spike); and FCCP leading to a significant decrease in mitochondrial 
membrane  potential,  intracellular  calcium  and  intracellular  NADH.  Rotenone  addition 
resulted in a significant decrease in mitochondrial membrane potential, and intracellular 
calcium, associated with an increase in NADH concentration; and when HeLa cells were 
pre-treated with rotenone prior to ang II addition, ang II led to an additional increase in 
mitochondrial  depolarization  and  NADH  levels,  super-imposed  upon  rotenone  effects, 
suggesting that the mechanism of ang II action was separate to that of rotenone (therefore 
not occurring via complex I). 
 
 
 
   Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      148	 ﾠ
	 ﾠ
Figure R3.7. The addition of Histamine (concentration 1 µM) to live HeLa cells led to a 
predictable and swift increase in intracellular calcium levels (calcium spike) (Fluo-4) but no 
longer-term  effects  upon  intracellular  calcium  levels  (Fluo-4;  p=  0.349),  mitochondrial 
membrane potential (TMRM; p= 0.524), or NADH concentration (p= 0.194). Each time 
point  represents  7  seconds  and  each  experiment  was  performed  6  times  with  the  mean 
presented here. 
	 ﾠ
Figure R3.8. The addition of FCCP (uncoupling agent; concentration 1 µM) to live HeLa 
cells led to a predictable and significant decrease in concentrations of intracellular calcium 
(Fluo-4; p= 0.002) and NADH (p= 0.000), as well as a significant decrease in mitochondrial 
membrane potential (TMRM; p= 0.000). Each time point represents 7 seconds and each 
experiment was performed 6 times with the mean presented here. 
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Figure R3.9. The addition of rotenone (inhibitor of electron transport chain complex I & II; 
concentration  1  µm)  to  live  hela  cells  led  to  a  predictable  and  significant  decrease  in 
mitochondrial membrane potential (TMRM; p= 0.000), and intracellular calcium (Fluo-4; 
p= 0.000), associated with an increase in NADH concentration (p= 0.000). Each time point 
represents 7 seconds and each experiment was performed 6 times with the mean presented 
here. 
 
Figure R3.10. The addition of angiotensin II (concentration 1 µM) to live HeLa cells led to 
a  significant  decrease  in  mitochondrial  membrane  potential  (TMRM;  p=  0.000), 
intracellular calcium concentration (Fluo-4; p= 0.011) and NADH (p= 0.000) concentration.  
Each time point represents 7 seconds and each experiment was performed 6 times with the 
mean presented here. 
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Figure R3.11. The addition of Losartan (AT1R antagonist; concentration 1 µM) to live 
HeLa cells led to a significant decrease in intracellular calcium concentration (Fluo-4; p= 
0.000) and a significant increase in mitochondrial membrane potential (TMRM; p= 0.005) 
with no significant effect upon NADH concentration (p= 0.140). Each time point represents 
7 seconds and each experiment was performed 6 times with the mean presented here. 
 
Figure R3.12. The addition of PD123319 (AT2R antagonist; concentration 1 µM) to live 
HeLa cells led to significant decreases in mitochondrial membrane potential (TMRM; p= 
0.000), intracellular calcium concentration (Fluo-4; p= 0.000) and NADH concentration (p= 
0.000). Each time point represents 7 seconds and each experiment was performed 6 times 
with the mean presented here. 
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Figure  3.13.a.  and  3.13.b.  Addition  of  ang  II  to  HeLa  cells  pre-treated  with  rotenone 
demonstrated  additional  mitochondrial  depolarization  (a.  Upper  image)  and  NADH 
elevation (b. Lower image), super-imposed upon the effects occurring secondary to rotenone 
(w rotenone- Pre-treated with rotenone; w/o rotenone- Not pre-treated with rotenone). 
	 ﾠ 	 ﾠHepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      152	 ﾠ
 
Reagent  Cell-Line  NADH  Calcium  Mitochondrial 
Membrane 
Potential 
Ang II (1 µm)         
  HepG2  Decrease  Nil  Increase 
  HeLa  Decrease  Decrease  Decrease 
Losartan (1 µm) 
       
  HepG2  Decrease  Increase  Nil 
  HeLa  Nil  Decrease  Increase 
PD123319 (1 µm)   
     
  HepG2  Nil  Nil  Nil 
  HeLa  Decrease  Decrease  Decrease 
Table R3.3. A summary of data derived from the addition of ang II or RAS antagonists 
during fluorescence microscopy experimentation in live HepG2 and HeLa cells. 
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R3.3.b Oxygen Consumption 
 
R3.3. b.i. HepG2 Cells (see Figures R3.15-R3.18) 
These  experiments  demonstrated  that  there  was  no  effect  upon  mitochondrial  oxygen 
consumption, as measured by Clark electrode, of adding angiotensin II (1 µM or 1 mM) to 
live HepG2 cells. Similarly, there was no effect upon adding RAS antagonists at 1 µM; 
however, when the concentration was increased to 1 mM, an increase in the rate of oxygen 
consumption was seen following addition of both Losartan and PD123319; however, such a 
concentration is significantly higher than the concentratyions that would be found in vivo.  
Table R3.1. Mean rates of oxygen consumption measured at baseline and after addition of 
each reagent in live HepG2 cells. Rates of oxygen consumption are expressed as a change in 
oxygen consumption per minute, as compared to 100 % (e.g. -0.02 arbitrary units (AU) 
equals decrease in rate of oxygen consumption of 2 % per minute from baseline rate of 
oxygen consumption). Significant changes in rate of oxygen consumption are highlighted in 
red (p< 0.05). 
  n  Mean Basal Rate 
(AU) 
Rate After 
Reagent (AU) 
Mean Change in 
Rate (AU) 
p 
Ang II (1µM)  11  -0.230  -0.204  -0.016  0.062 
Ang II (1mM) 
 
13  -0.251  -0.249  -0.003  0.502 
Losartan (1µM)  8  -0.072  -0.064  -0.002  0.375 
Losartan (1mM) 
 
6  -0.137  -0.179  0.042  0.029 
PD123319 (1µM)  8  -0.072  -0.079  0.002  0.533 
PD123319 (1mM)  6  -0.137  -0.174  0.037  0.019 Hepatic Mitochondrial Renin-Angiotensin Systems 
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Figure R3.15. The addition of angiotensin II to live HepG2 cells, at a concentration of 1 
µM, had no significant effect upon cellular oxygen consumption (p= 0.062). Substrates with 
known mitochondrial effects (histamine- no effect; (p= 0.307) oligomycin (complex I&II 
inhibitor)- significant decrease (p= 0.001); FCCP (uncoupling agent)- significant increase 
(p= 0.000)) were included as positive and negative controls (Ang II- Angiotensin II; O
2C- Change 
in Oxygen consumption; AU- Arbitrary units). 
	 ﾠ
	 ﾠ
Figure R3.16. The addition of angiotensin II to live HepG2 cells, at a concentration of 1 
mM, had no significant effect upon cellular oxygen consumption (p= 0.502). Substrates with 
known mitochondrial effects (oligomycin (complex I&II inhibitor)- significant decrease (p= 
0.003); FCCP (uncoupling agent)- significant increase (p= 0.002)) were included to act as 
positive controls. 
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Figure  R3.17.  The  addition  of  Losartan  (AT
1R  antagonist)  and  PD123319  (AT
2R 
antagonist) to live HepG2 cells, at a concentration of 1 µM, had no significant effect upon 
cellular  oxygen  consumption  (p=  0.375  and  0.533  respectively).  Substrates  with  known 
mitochondrial effects (oligomycin (complex I&II inhibitor)- significant decrease (p= 0.049); 
FCCP (uncoupling agent)- significant increase (p= 0.001)) were included to act as positive 
controls. 
	 ﾠ
Figure  R3.18.  The  addition  of  Losartan  (AT
1R  antagonist)  and  PD123319  (AT
2R 
antagonist) to live HepG2 cells, at a concentration of 1 mM, led to a significant increase in 
cellular  oxygen  consumption  (p=  0.029  and  0.019  respectively).  Substrates  with  known 
mitochondrial effects (oligomycin (complex I&II inhibitor)- significant decrease (p= 0.002); 
FCCP (uncoupling agent)- no change (p= 0.058)) were included to act as positive controls. 
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R3.3. b.i. HepG2 Cells 
These data demonstrate that a significant decrease in mitochondrial oxygen consumption 
was  seen  upon  addition  of  angiotensin  II  (concentration  1  µM)  to  live  HeLa  cells,  as 
assessed  by  Clark  electrode  (see  Table  R3.2).  There  was  no  effect  upon  adding  RAS 
inhibitors, unless the concentration was increased to 1 mM, at which point an increase in the 
rate of oxygen consumption was seen following addition of both Losartan and PD123319 
(see Figures R3.19-R3.21); an effect that is biologically inconsistent and occurring at only 
extremely high antagonist concentrations. 
 
 
 
 
 
Table R3.2. Mean rates of oxygen consumption measured at baseline and after addition of 
each reagent in live HeLa cells. Rates of oxygen consumption are expressed as a change in 
oxygen consumption per minute, as compared to 100 % (e.g. -0.02 arbitrary units (AU) 
equals decrease in rate of oxygen consumption of 2 % per minute from baseline rate of 
oxygen consumption). Significant changes in rate of oxygen consumption are highlighted in 
red. 
 
  n  Mean Basal Rate 
(AU) 
Rate After 
Reagent (AU) 
Change in Rate 
(AU) 
p 
Ang II (1 µM) 
 
7  -0.485  -0.013  -0.007  0.005 
Losartan (1 µM) 
 
7  -0.039  -0.050  0.004  0.149 
Losartan (1 mM) 
 
6  -0.137  -0.179  0.0412  0.029 
PD123319 (1 µM) 
 
6  -0.039  -0.034  0.003  0.626 
PD123319 (1 mM) 
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Figure R3.19. The addition of angiotensin II to live HeLa cells, at a concentration of 1 µM, 
led  to  a  significant  decrease  in  cellular  oxygen  consumption  (p=0.005).  Substrates  with 
known  mitochondrial  effects  (oligomycin  (complex  I&II  inhibitor)-  significant  decrease 
(p=0.003); FCCP (uncoupling agent)- significant increase (p=0.005)) were included to act as 
positive controls. 
 
 
Figure  R3.20.  The  addition  of  Losartan  (AT
1R  antagonist)  and  PD123319  (AT
2R 
antagonist) to live HeLa cells, at a concentration of 1 µM, had no significant effect upon 
cellular  oxygen  consumption  (p=0.149  and  0.626  respectively).  Substrates  with  known 
mitochondrial effects (oligomycin (complex I&II inhibitor)- significant decrease (p=0.000); 
FCCP (uncoupling agent)- significant increase (p=0.006)) were included to act as positive 
controls. 
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Figure  R3.21.  The  addition  of  Losartan  (AT
1R  antagonist)  and  PD123319  (AT
2R 
antagonist) to live HeLa cells, at a concentration of 1 mM, led to a significant increase in 
cellular  oxygen  consumption  (p=0.029  and  0.019  respectively).  Substrates  with  known 
mitochondrial effects (oligomycin (complex I&II inhibitor)- significant decrease (p=0.002); 
FCCP  (uncoupling  agent)-  non-significant  increase  (p=0.058))  were  included  to  act  as 
positive controls. 
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Reagent  Cell-Line  Concentration 
of Reagent 
Rate of Oxygen 
Consumption 
Ang II  HepG2  1 µM  Nil 
    1 mM  Nil 
  HeLa  1 µM  Decrease 
    1 mM  N/A 
       
Losartan  HepG2  1 µM  Nil 
    1 mM  Increase 
  HeLa  1 µM  Nil 
    1 mM  Increase 
       
PD123319  HepG2  1 µM  Nil 
    1 mM  Increase 
  HeLa  1 µM  Nil 
    1 mM  Increase 
 
 
Table R3.4. A summary of data derived from the addition of ang II or RAS antagonists 
during oxygen consumption experiments in live HepG2 and HeLa cells. 
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R3.4 Discussion 
These  functional  fluorescence  microscopy  results  demonstrate  accurate  positive  controls 
with the use of histamine resulting in no effects apart from a brief intracellular calcium 
surge (calcium spike); FCCP leading to significant decreases in mitochondrial membrane 
potential,  intracellular  calcium  and  intracellular  NADH;  and  rotenone  resulting  in 
significant  decreases  in  mitochondrial  membrane  potential,  and  intracellular  calcium, 
associated with an increase in NADH concentration (see Table R3.3). These control data 
indicate that the functional fluorescence technique described is an accurate assessment of 
mitochondrial function in these cell-lines. When the same technique was used and ang II or 
its  antagonists  were  applied  to  live  HepG2  or  HeLa  cells,  inconsistent  results  were 
demonstrated. Ang II (concentration 1 µM) added to live HepG2 cells caused a significant 
decrease  in  NADH  concentration  and  a  significant  increase  in  mitochondrial  membrane 
potential; Losartan (AT1R antagonist; concentration 1 µM) led to a significant decrease in 
intracellular NADH and a significant increase in intracellular calcium levels; and PD123319 
(AT2R antagonist; concentration 1 µM) had no significant effects. In HeLa cells, ang II 
(concentration 1 µM) led to a significant decrease in mitochondrial membrane potential, 
intracellular calcium concentration and NADH concentration; Losartan (AT1R antagonist; 
concentration 1 µM) led to a significant decrease in intracellular calcium concentration and 
a  significant  increase  in  mitochondrial  membrane  potential;  and  PD123319  (AT2R 
antagonist; concentration 1 µM) led to a significant decrease in mitochondrial membrane 
potential, intracellular calcium concentration and NADH concentration.  
 
Published studies suggest that the addition of ang II might be expected to depolarize the 
mitochondrial  membrane  potential  (Doughan  et  al.,  2008),  and  decrease  oxygen 
consumption via AT1-receptor dependent action (Cassis et al., 2002). Further, ang II might 
be expected to reduce NADH levels via the activation of plasma membrane-bound NADH-
/NADPH-oxidases, contributing to decreased mitochondrial membrane potential and oxygen 
consumption, as well as increased production of reactive oxygen species and superoxides, 
effects that are antagonized by AT1R inhibitors and less so by AT2R inhibitors (Zhang et al., 
1999a).  Ang  II  has  also  been  shown  to  increase  intracellular  calcium  concentration, 
similarly via action at the AT1 receptor (Greco et al., 2002, Nitschke et al., 2000).  Hepatic Mitochondrial Renin-Angiotensin Systems 
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The non-consistent results seen in these experiments with HepG2 cells could be ascribed to 
confusing dual effects of both cell membrane and intra-cellular or mitochondrial (if they 
exist) angiotensin receptors in HepG2 cells. However, HeLa cell results should represent 
true  mitochondrial  effects  of  reagent  addition,  without  the  compromising  effects  of  cell 
membrane receptors (as they contain no cell-membrane ang receptors), suggesting that the 
addition  of  ang  II  leads  to  a  significant  decrease  in  mitochondrial  membrane  potential, 
intracellular calcium concentration and NADH concentration via an intracellular mechanism 
(rather than acting via cell membrane receptors), with NADH and mitochondrial membrane 
potential effects antagonised by the AT1R antagonist Losartan and AT2R antagonists having 
no effect. These effects are potentially compatible with two hypotheses: ang II might inhibit 
complex  I,  thus  reducing  NADH  consumption  and  depolarising  the  mitochondrial 
membrane; or ang II may stimulate mitochondrial metabolism via a non-Ca
2+ dependent 
mechanism. In order to test whether the effect of ang II occurs via increased NADH from 
the Krebs cycle, I pre-treated HeLa cells were pre-treated with rotenone (complex I inhibitor 
i.e. inhibitor of NADH consumption) to demonstrate that ang II led to further elevations of 
NADH, even following rotenone application, suggesting a separate mechanism of action. 
Furthermore,  ang  II  increased  mitochondrial  depolarisation  even  in  the  presence  of 
rotenone, potentially indicating a direct effect upon ATP synthase. 
 
Another potential strategy to investigate such RAS effects upon mitochondria would be to 
add reagents to isolated mitochondria; however, such techniques have recently fallen out of 
favour.  Isolation  of  pure  mitochondria  exposes  the  mitochondria  to  non-physiological 
oxygen conditions and removes cellular regulatory systems, thus, all results are assessed 
outside the context of the mitochondrion’s normal functioning conditions. Further, although 
the intracellular concentrations of ang II are yet to be reported, tissue ang II levels are likely 
to  vary  from  picomolar  to  the  low  nanomolar  range  (depending  upon  tissue  type  and 
conditions), and the physiological concentrations of intracellular ang II are likely to occur in 
the picomolar range, in accordance with the sub-nanomolar affinity of angiotensin receptors 
on the cell surface. In contrast, isolated mitochondria are inevitably exposed to substrate 
concentrations far higher than that found in the endogenous cellular microenvironment in 
vivo.  To  provide  the  most  robust  evidence  for  a  functioning  mitochondrial  RAS,  a 
combination of data from isolated mitochondria and intact cells, in conjunction with both in 
vivo and in vitro techniques is likely to be required. Hepatic Mitochondrial Renin-Angiotensin Systems 
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Abadir et al (2011) suggested that functional AT2Rs are present on inner mitochondrial 
membranes (co-localising with ang II) of rat heart and liver, where they lead to modulation 
of respiration via coupling to mitochondrial nitric oxide production. However, the AT2R 
(although highly expressed in the foetus) has low expression levels in normal adults and its 
precise  role  remains  open  for  clarification.  The  AT2R  may  be  involved  in  signaling 
pathways such as activation of protein phosphatases and the bradykinin/nitric oxide/cyclic 
guanosine 3’,5’-monophosphate pathway, as well as stimulation of phospholipase A2, but its 
only true established function is vasodilation, although it may be involved in cardiovascular 
remodeling and inflammation. Similarly, it may also be involved in apoptotic cell death, 
thereby playing a role in developmental biology; however, mice lacking the gene encoding 
the AT2R develop normally and have a normal blood pressure (although they display an 
increased response to the addition of ang II) (Hein et al., 1995), potentially suggesting that it 
may not play a crucial role in mitochondria or elsewhere. Abadir’s group also utilised only 
one antibody for their immunofluorescence results and provided no examination of antibody 
specificity: their results should therefore be interpreted with this in mind. Further, the study 
utilised  only  CGP  42112  for  AT2R  agonism,  a  compound  that  has  been  reported  to 
antagonise  the  AT1R  as  well  as  agonise  the  AT2R,  and  a  functional  assessment  of 
endogenous ATR ligands was not undertaken.  
In contrast to these functional immunofluorescence data, the addition of various reagents to 
live  HepG2  cells  demonstrated  consistent  oxygen  consumption  results:  ang  II  had  no 
significant  effect  upon  cellular  oxygen  consumption  at  1  µM  or  1  mM;  whereas,  both 
Losartan  (AT
1R  antagonist)  and  PD123319  (AT
2R  antagonist)  had  no  effect  at  1  µM 
concentration but led to a significant increase in cellular oxygen consumption at a high 1 
mM  concentration  (see  Table  R3.4).  When  added  to  live  HeLa  cells,  ang  II  led  to  a 
significant decrease in cellular oxygen consumption at 1 µM concentration; whereas, both 
Losartan and PD123319 had no significant effect at a concentration of 1 µM, but led to a 
significant increase in cellular oxygen consumption at 1 mM concentration. As previously 
discussed, the HepG2 cell results may be confused by the dual presence of cell membrane 
and mitochondrial membrane receptors; whereas, results derived from HeLa cells should 
represent effects at the mitochondria only. Thus, addition of ang II may lead to a decrease in 
cellular oxygen consumption, a result that would be consistent with previously described 
studies; however, this effect appears to be antagonised by both AT1and AT2 receptors, a Hepatic Mitochondrial Renin-Angiotensin Systems 
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finding which would appear to be biologically inconsistent. Further, as previously discussed, 
the physiological intracellular concentration of ang II is likely to be in the picomolar range, 
in accordance with the sub-nanomolar affinity of angiotensin receptors on the cell surface, 
and the supra-physiological reagent concentrations utilised here may therefore result in non-
endogenous effects. 
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DISCUSSION 
 
 
 
 Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      165	 ﾠ
D1. Conclusions 
The existence of an intracellular RAS has now been extensively investigated and its putative 
actions have been reported to include mitochondrial dysfunction in the form of increased 
ROS production, decreased mitochondrial respiratory control and decreased mitochondrial 
membrane potential (Li et al., 2014, Mariappan et al., 2012, Doughan et al., 2008). RAS 
inhibition  subsequently  improves  ATP  production  and  overall  mitochondrial  function 
(Sumbalova  et  al.,  2010,  Taskin  et  al.,  2014).  Such  effects  upon  mitochondria  may,  of 
course, be mediated indirectly via cell-surface receptors and second messenging systems, or 
alternate endocrine, paracrine or autocrine actions. Published data had suggested that an 
intra-mitochondrial RAS might be responsible (Abadir et al., 2011); however, a paucity of 
data and the fact that many of the studies to date, particularly those reliant upon single 
antibodies, remain significantly flawed from a methodological point of view, thus raised the 
question  of  whether  the  conclusions  from  such  studies  are  valid.  To  explore  this  issue 
further,  a  variety  of  techniques  were  utilised  in  hepatic  cells  and  tissue.  Two  major 
hypotheses were proposed at the commencement of the study: 
 
1.  RAS components can be found within mitochondria (mRAS) derived from rat liver 
tissue and a liver cell-line, utilizing Western blotting, confocal microscopy and 
electron microscopy techniques. 
The studies performed for this thesis initially suggested the presence of renin, AT1R, AT2R 
and angiotensin within sub-fractionated mitochondrial compartments in both rat liver tissue 
and HepG2 cells on Western blotting; renin, ang and ACE co-localising with mitochondria 
in HepG2 cells on immunofluorescence and confocal microscopy; and ACE, ang, AT1R and 
AT2R in association with mitochondria of rat liver and the HepG2 cell line on immunogold 
labeling and electron microscopy. However, findings were inconsistent between techniques 
and tissue/cell-lines, in keeping with a recent American study (Benicky et al., 2012) which 
reported that six commercially-available antibodies against AT1R (including the sc-1173 
AT1R antibody (Santa Cruz Biotechnology, Dallas, Texas, USA) utilised for this thesis) lack 
specificity. The authors demonstrated that each AT1R antibody (utilised for Western blotting 
and immunocytochemistry) yielded multiple prominent immunoreactive bands and that the 
immunostaining patterns were different for each antibody tested. Further, although each 
antibody did identify a 43 kDa band (target size of AT1R), the same bands were seen in Hepatic Mitochondrial Renin-Angiotensin Systems 
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AT1R  knockout  mice  and  rat  hypothalamic  4B  cells  not  expressing  AT1  receptors.  The 
authors subsequently concluded that none of the tested antibodies met sufficient criteria to 
be considered specific and suggested that radioligand binding might be the only reliable 
approach for the assessment of AT1R physiology.  
 
Initial Western blots also identified a previously unexpected but prominent 55 kDa band, 
when immunostaining a crude mitochondrial fraction with ACE C-terminal antibody. Thus, 
the original experimental plan was altered to attempt analysis of the prominent band and in 
particular to assess whether it represented a novel, mitochondrial-specific form of ACE. 
However,  multiple  subsequent  fruitless  attempts  to  identify  an  underlying  protein 
demonstrated that these Western blot findings most likely represent non-specific antibody 
binding only. The majority of studies investigating the presence of an intra-mitochondrial 
RAS have relied upon the findings of one antibody, and these studies must now be reviewed 
in the light of these recent findings.  
 
Abadir  et  al  (2011)  suggested  that  AT2Rs  are  located  upon  the  inner  mitochondrial 
membrane of rat heart and liver, where they co-localise with endogenous ang II to modulate 
cellular respiration via mitochondrial nitric oxide production, based upon the use of a single 
antibody. Similarly, Peters et al (1996), who identified renin and ACE in intramitochondrial 
dense  bodies  of  the  rat  adrenal  zona  glomerulosa  and  cortex  after  nephrectomy  and 
hemodialysis  but  relied  upon  single  antibodies  and  provided  no  assessment  of  antibody 
sensitivity.  Close  inspection  of  EM  images  provided  by  Peters  et  al  show  a  scattered 
distribution  of  immunogold  labeling  around  mitochondria,  consistent  with  non-specific 
binding. Further, the work of Wanka et al (2009) identified the presence of mitochondrial 
renin, again reliant upon the use of a single antibody. Indeed, the only intra-mitochondrial 
RAS study to date to utilize radio-labeled ligands demonstrated the presence of a truncated 
prorenin  that  was  imported  into  mitochondria  in  adrenal  zona  glomerulosa  cells 
endogenously (Clausmeyer et al., 1999). However, this study utilised a laboratory-created 
construct and therefore does not necessarily reflect a phenomenon that occurs endogenously.  
 
Thus, such qualitative techniques (e.g. Western blotting, immunofluorescence and electron 
microscopy) contain inherent limitations in that they rely upon the limited specificity of 
antibodies to definitively prove the existence of intra-mitochondrial RAS components. Hepatic Mitochondrial Renin-Angiotensin Systems 
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2.  Addition of RAS components to liver cells adversely affects a variety of hepatic 
mitochondrial functions (as assessed via measurement of oxygen consumption and 
dynamic  fluorescence  microscopy);  whereas,  RAS  antagonism  leads  to 
improvements in hepatic mitochondrial function. 
Functional experimentation performed for this thesis, via addition of ang II to live HepG2 
cells, demonstrated a significant decrease in NADH concentration and a significant increase 
in  mitochondrial  membrane  potential.  Conversely,  the  addition  of  Losartan  (AT1R 
antagonist) significantly decreased intracellular NADH and increased intracellular calcium 
levels.  The  use  of  ang  II  in  HeLa  cells,  however,  led  to  a  significant  decrease  in 
mitochondrial  membrane  potential,  intracellular  calcium  concentration  and  NADH 
concentration, whilst the addition of Losartan led to a significant decrease in intracellular 
calcium  concentration  and  a  significant  increase  in  mitochondrial  membrane  potential. 
Exposure to PD123319, a selective, non-peptide AT2 receptor antagonist led to a significant 
decrease  in  mitochondrial  membrane  potential,  intracellular  calcium  concentration  and 
NADH concentration. The clear inconsistencies within this data suggest that such functional 
experimentation, particularly when used at such significantly supra-physiological levels (1 
µM – 1 mM), is incapable of separating effects secondary to RAS receptor-ligand binding at 
the cell-surface, intracellularly or, specifically, intra-mitochondrially. Such data therefore 
suggests that the effect of ang II on liver mitochondria is unlikely to be direct, and that any 
positive associations discovered to date are likely to be secondary to methodological flaws. 
Such findings do not exclude ang II effects upon mitochondrial function, but suggest that 
any action is likely to occur via one of several intracellular pathways, such as Ca
2+ signaling 
via  the  AT1R/G-protein/IP3  system,  regulation  of  gene  expression  or  mitochondrial 
biogenesis pathways. 
 
This thesis contains unbiased analyses of all known classical RAS components, as well as a 
targeted evaluation of the presence of ACE via mass spectrometry. The results, as presented 
here, provide no evidence for the idea of a complete, functioning hepatic mitochondrial 
RAS of the type postulated by other authors. It remains possible, if unlikely, however, that 
RAS  components  may  be  imported  into  mitochondria  for  a  specific  function  in  certain 
tissues under certain specific conditions.  Perhaps more likely is that the observed effects of 
ang  II  on  mitochondrial  function  (in  certain  tissues)  occurs  via  its  well-established  and Hepatic Mitochondrial Renin-Angiotensin Systems 
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ubiquitous intracrine actions upon the nucleus (Erdmann et al., 1996, Huang et al., 2003, 
Robertson and Khairallah, 1971b), albeit that the specific mechanisms and consequences of 
such actions require further elucidation (Re and Cook, 2010). Another possibility remains 
the  theory  of  endosomal  escape,  whereby  the  ligand  (in  this  case  ang  II)  leaks  from 
endosomes following receptor-ligand internalisation, becoming free within the cytoplasm to 
act upon organelles, including mitochondria, and leading to intracrine effects (Cho et al., 
2003), a mechanism that forms the basis of many mammalian DNA transfection strategies. 
Angiotensin  receptor  (AT1R  or  AT2R)  antagonists  may  therefore  protect  from  such 
intracrine or mitochondrial ang II action by preventing receptor-ligand endocytosis, and 
subsequent  endosomal  escape,  rather  than  via  local  receptor  blockade  of  putative 
mitochondrial  or  other  such  functional  intracellular  receptors.  Furthermore,  there  is  no 
evidence  to  prove  the  existence  of  intra-mitochondrial  ang  II  production,  a  necessary 
requirement for an intrinsic mitochondrial RAS. 
 
 
Taken together, therefore, these data exclude the presence of a complete, functioning RAS 
within  hepatic  mitochondria,  as  well  as  the  direct  action  of  intracrine  ang  II  upon 
mitochondria.  If  an  intrinsic,  functional  hepatic  mitochondrial  RAS  were  to  exist,  its 
regulation, roles and actions remain unknown, and the role of ACE2 and the Mas receptor 
remain similarly unknown. Challenges exist in the examination of the presence of such an 
intracrine/intracellular system, particularly given the limitations of immunohistochemical 
techniques,  and  following  such  negative  experimentation,  as  presented  here,  it  must  be 
asked whether further experimentation is indeed required to investigate the presence of a 
hepatic  mitochondrial  RAS.  Repeating  the  experiments  presented  here  upon  isolated 
mitochondria would be unlikely to yield novel results, although the further study of both 
isolated  mitochondria  and  intact  cells,  in  conjunction  with  both  in  vivo  and  in  vitro 
techniques, might be advantageous. In particular, the development of functional strategies 
that can distinguish intracellular ang II’s effects on cytoplasmic, nuclear or mitochondrial 
receptors and those from extracellular ang II (via cell surface receptors) may help provide 
further evidence. To this end, the creation of cell-permeable angiotensin probes would aid in 
the delineation of the site of action of ang II, as would the generation of transgenic animals 
expressing intracellular ang II proteins, and strategies, such as high-affinity radio-ligand Hepatic Mitochondrial Renin-Angiotensin Systems 
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binding  assays,  aimed  at  identifying  those  molecules  endogenously  bound  to  ang  II 
intracellularly (Redding et al., 2010). 
Further functional strategies would include pre-treatment of tissues and cell-lines with ang II 
or  inhibitors,  to  assess  effects  upon  metabolic  rate  and  the  utilisation  of  SiRNA  (small 
interfering  ribonucleic  acid),  cDNA  constructs  and  tissue  from  knock-out  models  to 
investigate the functional effects of under- and over-expression of various RAS components. 
Functional  assessments  could  also  be  extended  to  include  OXPHOS  (oxidative 
phosphorylation) measurements (via a Seahorse plate reader (Seahorse Bioscience, North 
Billerica, MA, USA)), confocal microscopic assessment of cellular ATP levels (via FRET 
(Fluorescence  Resonance  Energy  Transfer)-based  fluorescent  probes  targeted  to  the 
cytoplasm  or  mitochondrial  matrix)  and  mitochondrial  ROS  production  (via  fluorescent 
probes DHEt (Dihydroethidium) and mitoSox (Molecular probes, Invitrogen, Carlsbad, CA, 
USA)), as well as measurement of mitochondrial DNA content (via real-time quantitative 
polymerase chain reaction).  
 
If such assessment of hepatic tissue provides no definitive evidence for the presence of 
mitochondrial RAS, the exploration of alternate cell and tissue types could be attempted as 
differential expression of RAS components in various tissues has already been observed 
(e.g. human liver and aorta predominantly express AT1 receptor mRNA, whilst human right 
atrium contains both AT1 and AT2 receptor mRNAs). The presence of such mitochondrial 
RAS components may be limited to certain tissues and conditions, particularly to the adrenal 
cortex following nephrectomy (Rong et al., 1994, Peters et al., 1996) and may not be present 
within hepatocytes at all. Future experimentation could therefore be expanded initially to 
renal  and  adrenal  tissues,  and  assessment  of  novel  and  alternate  peptides  of  the  RAS, 
including AT4R, BK1R, BK2R, & ACE2, could also take place. Hepatic Mitochondrial Renin-Angiotensin Systems 
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D2. Hepatocellular RAS 
If  we  thus  exclude  the  presence  of  a  complete  and  functional  intra-mitochondrial  RAS 
within hepatocytes, we can clarify, to some extent, a mechanism of action for hepatic RAS. 
Although all classical RAS components (renin, angiotensinogen, ACE, ang II, AT1R and 
AT2R) have been identified in rat and human liver (Paizis et al., 2002, Paizis et al., 2005), 
hepatic  RAS  appears  to  predominantly  act  via  ang  II  binding  to  extracellular  AT1Rs. 
Hepatocyte ang II exposure leads to a decrease in surface ang II receptors, consistent with 
swift endocytosis and internalisation of the receptor-ligand complex (a process that could be 
reliant upon cysteine residues) (Jimenez et al., 1999). Such internalisation leads to inhibition 
of  cyclic  adenosine  monophosphate  (cAMP)  production  and  increases  in  intracellular 
inositol  4,5-bisphosphate  (IP2),  inositol  1,4,5-trisphosphate  (IP3)  generation  and  calcium 
concentration,  suggesting  that  these  second  messenger  systems  are  crucial  to  the 
downstream  intracellular  function  of  ang  II  (Jimenez  et  al.,  1999).  Such  intracellular 
calcium mobilisation following calcium release from ER stores (Spat and Hunyady, 2004) 
results  in  activation  of  the  Krebs  cycle  and  oxidative  phosphorylation;  although  over-
stimulation of the system may result in adverse effects including mitochondrial calcium 
overload,  mitochondrial  membrane  depolarisation  and  reduced  efficiency  of  ATP 
production (Mizuno et al., 1988, Fournier et al., 2012, Yogev and Pines, 2011).  
 
Other  AT1R-dependant  second  messaging  systems  activated  include  ROS,  MAPK,  P13-
kinase, PKC and NF-κB signal pathways (Zhao et al., 2013, Karimian et al., 2012), all of 
which may have effects upon mitochondrial physiology or pathophysiology (Hunyady and 
Catt, 2006, Re et al., 1981), as well as resulting in induction of C-reactive protein (CRP) and 
its related signal pathway expression (in vitro and in vivo), ROS production (Zhao et al., 
2013)  and  protection  against  bile-salt  induced  apoptosis,  via  inhibition  of  ER  stress 
(Karimian et al., 2012).  
 
The addition of exogenous ang II also increases hepatocellular collagen expression, via an 
AT1R-NADPH oxidase-mediated pathway (Bataller et al., 2003c), contributing to hepatic 
fibrosis (Bataller et al., 2000, Hirose et al., 2007, Kim et al., 2008, Ibanez et al., 2007, Ueki 
et al., 2006, Yang et al., 2005, Tuncer et al., 2003, Bataller et al., 2005, Colmenero et al., 
2009, Debernardi-Venon et al., 2007, Sookoian et al., 2005, Terui et al., 2002, Yoshiji et al., Hepatic Mitochondrial Renin-Angiotensin Systems 
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2005, Yoshiji et al., 2006, Yokohama et al., 2006) and has pro-mitotic and pro–proliferative 
effects,  possibly  via  an  autocrine/paracrine  AT1R-PDGF  pathway  (Cook  et  al.,  2001).  
Antagonism of hepatic ACE or AT1R, however, enhances NRF-1 and PGCV-1 mRNA, 
resulting  in  attenuation  of  age-related  mitochondrial  DNA  decrease,  improved 
mitochondrial function and lower oxidant production (de Cavanagh et al., 2008b). 
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APP1. Experimental Working Solutions 
 
APP1. a. Krebs-Ringer Buffer (KRB)  
KRB is a buffer solution utilised for maintenance of osmotic balance and pH within cells, as 
well as providing access to water and inorganic ions. 1 L of KRB is made up by dissolving 
the following in 1 L of distilled water at pH 7.4 and storing at 4 ˚C (see Table APP1. a.). 
Ion/Reagent  Molecular 
Weight 
Final 
Concentration 
NaCl  58.44  125 mM 
KCl  74.55  5 mM 
Na3PO4.12H2O  380.12  1 mM 
MgSO4.7H2O  246.48  1 mM 
Glucose  180.16  5 mM 
HEPES  
(Organic chemical 
 buffer) 
238.3  20 mM 
Table APP1. a. The ingredients for KRB Solution 
 
 
APP1. b. Phosphate-Buffered Saline (PBS) (Invitrogen (Cat. No. 20012-068)); Carlsbad, 
CA, USA) 
PBS is an isotonic water-based salt solution, which has many uses as a physiological buffer 
as its phosphate groups aid in the maintenance of a constant pH of 7.2. It contains the 
following within distilled water (see Table APP1. b.). Hepatic Mitochondrial Renin-Angiotensin Systems 
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Ion/Reagent  Molecular 
Weight 
Final 
Concentration 
KH2PO4  136  1.54 mM 
NaCl  58  155.17 mM 
Na2HPO4-7H2O  268  2.71 mM 
Table APP1. b. The ingredients for Phosphate-Buffered Saline 
 
 
APP1. c. Solution A (For Mitochondrial Isolation via Differential Centrifugation see ‘M3. 
Cellular Sub-Fractionation & Mitochondrial Isolation’; page 70) 
Solution A is a mitochondrial buffer that is utilised to suspend the fragmented cells during 
differential centrifugation. The following reagents can be dissolved in distilled water at pH 
7.4 to make up 500ml of solution, which should be subsequently stored at 4 ˚C (see Table 
APP1. c.). 
Ion/Reagent  Molecular 
Weight 
Final 
Concentration 
Mannitol  182.17  250 mM 
EGTA 
(Ethylene  Glycol  (Bis(β-
Aminoethylether)-
N,N,N,-Tetraacetic Acid 
380.4  0.5 mM 
HEPES 
(Organic chemical buffer) 
238.3  5 mM 
Table APP1. c. The ingredients for Solution A. 
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APP1. d. Solution B & Percoll (For Mitochondrial Isolation via Differential Centrifugation 
see ‘M3. Cellular Sub-Fractionation & Mitochondrial Isolation’; page 70). 
Solution B is a similar mitochondrial buffer that is utilised to suspend the fragmented cells 
while Percoll density gradient separation occurs. The following reagents can be dissolved in 
distilled water to make up 100 ml of solution at pH 7.4, which should be subsequently 
stored at 4 
oC (see Table APP1. d.).  
 
Percoll consists of colloidal silica particles coated with polyvinylpyrrolidone and has a low 
viscosity and osmolarity with no toxicity, and is therefore well-suited for density gradient 
separation  experiments.  When  required,  Solution  B  is  added  to  Percoll  to  make  a  final 
solution of 70%/30% (vol/vol) solution. 
Ion/Reagent  Molecular 
Weight 
Final 
Concentration 
Mannitol  182.17  225 mM 
EGTA 
(Ethylene  Glycol  (Bis(β-
Aminoethylether)-
N,N,N,-Tetraacetic Acid 
380.4  5 mM 
HEPES 
(Organic chemical buffer) 
238.3  25 mM 
Table APP1. d. The ingredients for Solution B. 
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APP2. Antibodies 
 
APP2. a. Primary Antibodies 
Primary antibodies were sourced from a variety of different manufacturers and utilized at 
manufacturer’s recommended concentrations (see Table APP2. a.). 
 
Antibody  Manufacturer  Catalogue 
Number 
Antibody Type  Molecular 
Weight 
Dilution 
RAS Components           
           
           
Renin (B-12)  Santa-Cruz 
Biotechnology 
(Dallas, Texas, USA) 
 
sc-133145  Mouse 
Monoclonal IgG1 
38-46 kDa  1:100 
Renin Antibody  Atlas Antibodies 
(Stockholm, Sweden) 
 
HPA005131  Rabbit Polyclonal 
IgG 
40kDa  1:250 to 1:500 
ACE (C-20)  Santa Cruz 
Biotechnology 
(Dallas, Texas, USA) 
 
sc-12187  Goat Polyclonal 
IgG 
195 kDa  1:100 
ACE (N-20)  Santa Cruz 
Biotechnology 
(Dallas, Texas, USA) 
 
sc-12184  Goat Polyclonal 
IgG 
195kDa  1:200 
ACE 
(C-Terminal) 
Abcam (Cambridge, 
UK) 
 
ab39172  Rabbit Polyclonal 
IgG 
170kDa  1:1000 
ACE (Clone 9B9)  Millipore  
(Billerica, MA, USA) 
 
MAB4051  Mouse 
Monoclonal 
170-180kDa  1:100 
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Antibody  (Seattle, WA, USA) 
 
Angiotensin (N-10) 
Antibody 
Santa Cruz 
Biotechnology 
(Dallas, Texas, USA) 
 
sc-7419  Goat Polyclonal 
IgG 
60kDa  1:200 
AT1R (N-10) 
Antibody 
Santa Cruz 
Biotechnology 
(Dallas, Texas, USA) 
 
sc-1173  Rabbit Polyclonal 
IgG 
43kDa  1:200 
AT1R Antibody  Santa Cruz 
Biotechnology 
(Dallas, Texas, USA) 
 
sc-20255  Goat Polyclonal 
IgG 
40kDa  1:200 
AT2R  Abcam  
(Cambridge, UK) 
 
ab19134-50  Rabbit Polyclonal  44 kDa  1:200 
AT2R (C-18) 
Antibody 
Santa Cruz 
Biotechnology 
(Dallas, Texas, USA) 
sc-7420  Goat Polyclonal 
IgG 
44kDa  1:200 
           
Standard Cellular 
Components 
         
           
Cox-4  Cell Signalling 
Technology 
(Danvers, MA, USA) 
 
#4844  Polyclonal Rabbit  17kDa  1:1000 
VDAC (Anti-Porin 
31HL) Antibody 
Calbiochem  
(Merck Group, 
Darmstadt, Germany) 
 
529534  Mouse IgG  20-30kDa  1:500 
Grp75  Santa Cruz  sc-1058  Goat Polyclonal 
IgG 
75 kDa  1:200 Hepatic Mitochondrial Renin-Angiotensin Systems 
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Biotechnology 
(Dallas, Texas, USA) 
 
ATP5b  Abcam  
(Cambridge, UK) 
 
ab37922  Chicken 
Polyclonal 
57kDa  1:2000 
ATP5b [3D5]  Abcam 
 (Cambridge, UK) 
 
ab14730  Mouse monoclonal  52kDa  1:200 
Hoescht 33258  Life Technologies 
(Paisley, UK) 
H3569  Nucleic acid stain  Binds to DNA  1:1000 
Table APP2. a. Primary antibodies utilised for experimentation  
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APP2. b. Secondary Antibodies 
Secondary antibodies were sourced from a variety of different manufacturers and utilized at 
multiple different concentrations to investigate the optimum working conditions (see Table 
APP2. b.). 
Antibody  Manufacturer  Catalogue 
Number 
Optimal 
Dilution 
       
Rabbit Anti-Goat IgG 
(Fc), Peroxidase 
Conjugated 
Thermo Scientific 
(Waltham, MA, USA) 
 
#31433  1:200 
Cy2 Green 
Conjugated 
Affinipure Donkey 
Anti-Chicken 
Jackson 
Immunoresearch 
(West Grove, PA, 
USA) 
 
82544  1:50 
AlexaFluor® 594 
Donkey Anti-Goat 
IgG 
 
Invitrogen 
(Carlsbad, CA, USA) 
 
A-11058  1:200 
Alexa Fluor® 488 
donkey anti-mouse 
IgG 
 
Invitrogen 
(Carlsbad, CA, USA) 
 
A-21202  1:200 
Alexa Fluor® 488 
donkey anti-goat IgG 
 
Invitrogen 
(Carlsbad, CA, USA) 
 
A-11055  1:200 
Alexa Fluor® 594 
donkey anti-mouse 
IgG 
 
Invitrogen 
(Carlsbad, CA, USA) 
 
A-21203  1:200 
Alexa Fluor® 594 
donkey anti-rabbit 
IgG 
 
Invitrogen 
(Carlsbad, CA, USA) 
 
A-21207  1:200 Hepatic Mitochondrial Renin-Angiotensin Systems 
 
	 ﾠ
    James R A Skipworth      220	 ﾠ
Alexa Fluor® 647 
donkey anti-mouse 
IgG 
 
Invitrogen 
(Carlsbad, CA, USA) 
 
A-31571  1:200 
Alexa Fluor® 647 
donkey anti-goat IgG 
 
Invitrogen 
(Carlsbad, CA, USA) 
 
A-21447  1:200 
Table APP2. b. Secondary antibodies utilized for experimentation 
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APP3. Complete Mass Spectrometry Results 
                                                                                                                                           
Table APP3. a.  A table of database search results, following mass spectrometry performed 
at University College London, demonstrated no findings consistent with ACE, but multiple 
contaminants  (keratin,  dermicidin)  and  experimental  reagents  (trypsin,  enolase)  (mW- 
Molecular weight; Da- Daltons; PLGS Score- Protein Lynx Global Server Score). 
 
 
	 ﾠ  
 
  Description  mW (Da)  PLGS Score  Coverage (%) 
Q6IG03 
K2C73 RAT Keratin type II cytoskeletal 73 OS Rattus norvegicus GN 
Krt73 PE 1 SV 1  60349  284.036  36.528 
Q6IMF3 
K2C1 RAT Keratin type II cytoskeletal 1 OS Rattus norvegicus GN 
Krt1 PE 2 SV 1  64790  505.1323  29.44 
Q68FR8 
TBA3 RAT Tubulin alpha 3 chain OS Rattus norvegicus GN Tuba3a 
PE 2 SV 1  49927  497.5478  40.4444 
Q4FZU2 
K2C6A RAT Keratin type II cytoskeletal 6A OS Rattus norvegicus GN 
Krt6a PE 1 SV 1  59212  211.974  33.8768 
Q6IG01 
K2C1B RAT Keratin type II cytoskeletal 1b OS Rattus norvegicus GN 
Krt77 PE 2 SV 1  57219  252.1117  27.9383 
P11980 
KPYM RAT Pyruvate kinase isozymes M1 M2 OS Rattus norvegicus 
GN Pkm2 PE 1 SV 3  57780  179.5759  28.4369 
P00924 
ENO1 YEAST Enolase 1 OS Saccharomyces cerevisiae GN ENO1 PE 1 
SV 2  46773  297.3125  37.2998 
Q6AY56 
TBA8 RAT Tubulin alpha 8 chain OS Rattus norvegicus GN Tuba8 PE 
2 SV 1  50005  318.9343  23.3853 
P07323 
ENOG RAT Gamma enolase OS Rattus norvegicus GN Eno2 PE 1 SV 2 
  47110  296.8302  29.4931 
P85108 
TBB2A RAT Tubulin beta 2A chain OS Rattus norvegicus GN Tubb2a 
PE 1 SV 1  49874  256.935  33.2584 
Q6P9T8 
TBB2C RAT Tubulin beta 2C chain OS Rattus norvegicus GN Tubb2c 
PE 1 SV 1  49769  244.966  25.618 
Q6AYZ1 
TBA1C RAT Tubulin alpha 1C chain OS Rattus norvegicus GN Tuba1c 
PE 1 SV 1  49905  373.2762  26.9488 
Q6P9V9 
TBA1B RAT Tubulin alpha 1B chain OS Rattus norvegicus GN Tuba1b 
PE 1 SV 1  50119  429.9057  21.286 
P04764 
ENOA RAT Alpha enolase OS Rattus norvegicus GN Eno1 PE 1 SV 4 
  47098  322.2678  19.1244 
P69897 
TBB5 RAT Tubulin beta 5 chain OS Rattus norvegicus GN Tubb5 PE 1 
SV 1  49638  293.6011  21.1712 
P15429 
ENOB RAT Beta enolase OS Rattus norvegicus GN Eno3 PE 1 SV 3 
  46984  272.7215  21.659 
Q3KRE8 
TBB2B RAT Tubulin beta 2B chain OS Rattus norvegicus GN Tubb2b 
PE 1 SV 1  49920  247.7995  11.4607 Hepatic Mitochondrial Renin-Angiotensin Systems 
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Gel Piece 
Accession  Description 
mW 
(Da) 
PLGS 
Score 
Coverage  
(%) 
1 
P70610 
DOC2B RAT Double C2 like domain 
containing protein beta OS Rattus 
norvegicus GN Doc2b PE 1 SV 2  45812  76.1767  2.1845 
2 
P70610 
DOC2B RAT Double C2 like domain 
containing protein beta OS Rattus 
norvegicus GN Doc2b PE 1 SV 2  45812  63.0816  2.1845 
Table APP3.2. Two gel pieces analysed at University College London demonstrated no 
significant correlations and no findings consistent with ACE  (mW- Molecular weight; Da- 
Daltons; PLGS Score- Protein Lynx Global Server Score). 
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Description  dCn  Ions  XCorr 
URIC_RAT Uricase OS=Rattus norvegicus GN=Uox PE=1 
SV=3 
0.3522  16/20  3.1180 
ACTA_RAT Actin, aortic smooth muscle OS=Rattus 
norvegicus GN=Acta2 PE=1 SV=1 
0.1048  28/60  4.0710 
ANXA1_RAT Annexin A1 OS=Rattus norvegicus 
GN=Anxa1 PE=1 SV=2 
0.3589  21/26  5.0531 
ACTB_RAT Actin, cytoplasmic 1 OS=Rattus norvegicus 
GN=Actb PE=1 SV=1 
0.2091  27/68  4.1511 
ANXA2_RAT Annexin A2 OS=Rattus norvegicus 
GN=Anxa2 PE=1 SV=2 
0.2074  35/68  5.2817 
RLA0_RAT 60S acidic ribosomal protein P0 OS=Rattus 
norvegicus GN=Rplp0 PE=1 SV=2  
0.4936  20/32  5.1187 
1433Z_RAT 14-3-3 protein zeta/delta OS=Rattus norvegicus 
GN=Ywhaz PE=1 SV=1  
0.3792  22/26  5.0860 
ENOA_RAT Alpha-enolase OS=Rattus norvegicus 
GN=Eno1 PE=1 SV=4  
0.5344  22/34  4.5639 
Table APP3.3.  A table of database search results, following mass spectrometry performed 
at  Harvard  Medical  School  demonstrated  no  findings  consistent  with  ACE  (dCn-  Delta 
correlation score; XCorr- Cross correlation score). 
 